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Abstract 
 
Immunotherapeutic approaches to target antigens associated with metastasis could provide a 
valuable means of targeting metastatic cells specifically. Metastasis Associated Antigen (MTA1) 
is one such relatively novel antigen, which has been associated with aggressive tumours, and 
shown to be over expressed in breast, oesophageal, colorectal, gastric and pancreatic cancer, 
amongst others. Various studies have indicated that MTA1 is essential for the transformation of 
cells and hence targeting it is unlikely to generate antigen loss variants. This study proposed to 
investigate MTA1 as a potential target for immunotherapy in a murine tumour model. We have 
shown that murine MTA1 (mMTA1) mRNA is highly expressed in most of the tumour cell lines 
as compared to normal tissues, which express mMTA1 at very low levels. Furthermore, to rule 
out any post-transcriptional modifications, MTA1 protein levels were also confirmed by western 
blotting. It was observed that most of the cell lines expressed MTA1 at high levels, whereas no 
protein expression was detected in the normal tissues by western blotting. Next, we decided to 
identify MHC class I and II restricted immunogenic peptides from murine and human MTA1 
gene for syngeneic and transgenic mice respectively. Three MHC class I immunogenic peptides 
for Balb/c mice and two for C57BL/6 syngeneic mice were identified but none of those peptides 
were found to be naturally processed. Similarly, HLA-A2 and HLA-DR4 restricted 
immunogenic peptides were also identified using transgenic mice, but proved to be not 
endogenously processed. We hypothesised that, MTA1 being a ubiquitously expressed self-
antigen, central and peripheral tolerance mechanisms might have a vital role in non-availability 
of high affinity T cell repertoire against MTA1 and therefore peptide vaccination might be 
unable to break tolerance to mMTA1 on its own. Hence we decided to investigate more potent 
strategies such as DNA vaccination, viral vaccination and xenogeneic vaccination to overcome 
this issue.  
Syngeneic or xenogeneic plasmid DNA vaccination was unable to generate an immune response 
to MTA1 in a mouse tumour model, even in combination with low dose cyclophosphamide for 
regulatory T cell depletion. Finally, semliki forest virus particles encoding for MTA1 did suggest 
weak immune reactivity against MTA1, as seen by delay in tumour growth in immunised 
animals. Further work will have to be done to optimise vaccination protocol to generate immune 
reaction against MTA1 and other such ‘self-antigens’.  Moreover, recent studies have suggested 
a presence of Treg repertoire against such SEREX defined self-antigens and immunisation with 
such antigens may actually be immunosuppressive. Such a possibility might exist for MTA1 and 
needs to be investigated. 
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Abbreviations 
 
ADCC Antibody dependant cellular cytotoxicity 
ALL Acute lymphatic leukaemia  
AML Acute Myeloid Leukaemia 
APC Antigen Presenting Cells 
Bgal Beta-galactosidase 
CEA Carcino-embryonic antigen 
CIITA MHC class II transactivator 
CML Chronic Myeloid Leukaemia 
CNS Central Nervous system 
CPM 
CT 
Cyclophosphamide 
Cancer Testis 
CTL    Cytotoxic T Lymphocytes 
DC Dendritic Cell 
DNA Deoxyribonucleic Acid 
DNA Deoxyribonucleic Acid 
DTH Delayed type II hypersensitivity 
EBV Epstein Barr Virus 
EGF Epidermal growth factor 
ELISA     Enzyme-Linked Immunosorbent Assay 
ER Endoplasmic reticulum 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GM-CSF Granulocyte macrophage colony stimulating factor 
HDAC Histone deacetylase complex 
HLA Human Leukocyte Antigen 
HPV Human Papilloma Virus     
HSC Haematopoietic stem cells 
HSP Heat shock proteins 
hTERT human Telomerase reverse transcriptase  
HTLV Human T cell leukemia virus 
ICAM   Intercellular cell adhesion molecule 
IDO Indoleamine 2,3-Dioxygenase 
IFN Interferon 
IGF Insulin like growth factor 
IL Interleukin 
KIR Killer immunoglobulin-like receptors 
LPS    Lipopolysacchride 
MHC Major Histocompatibility Complex 
mRNA Messanger RNA 
MTA Metastasis Associated Antigen 
NK Natural Killer Cells 
NuRD Nucleosome remodelin 
PDGF Platelet-derived growth factor 
PPAR Pathogen pattern recognition receptors 
PSA Prostate specific antigen 
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PSMA Prostate membrane specific antigen 
Rb Retinoblastoma 
RNA   Ribonucleic Acid 
ROS Reactive oxygen species 
RT-PCR                       Reverse Transcription-Polymerase Chain Reaction 
SEREX Serologic Analysis of Recombinant cDNA expression  libraries 
SFV Semliki forest virus 
TAM Tumour associated macrophages 
TAM Tumour associated macrophages 
TAP    Transporter Associated Protein 
TCR      T cell Receptor 
Th Helper T cells 
TLR Toll like receptors 
TNF      Tumour Necrosis Factor 
TRAIL TNF-related apoptosis-inducing ligand 
TSG Tumour suppressor gene 
VEGF Vascular Endothelial growth factor 
WHO World Health Organisation 
 
 3
List of figures 
 
Figure 1.1:- Cell cycle  
Figure 1.2:- Multistep progression of tumours in colon carcinoma  
Figure 1.3:- Different levels of cell cycle being affected by oncogenic mutations 
Figure 1.4:- Development of the immune system cells from common progenitor cells 
arising from the bone marrow.  
Figure 1.5:-Distribution of MHC genes in humans and mice  
Figure 1.6:- MHC class I molecule structure as determined by x-ray crystallography 
Figure 1.7:- MHC class II molecule structure as determined by x-ray crystallography 
Figure 1.8:- Schematic diagram of MHC class I antigen processing 
Figure 1.9:- Schematic diagram of MHC class II antigen processing 
Figure 1.10:- Development of the lymphoid progenitor cell into SP T cells in the thymus  
 
Figure 3.1:- Expression of MTA1 in colon carcinoma and patient matched normal colon 
tissue 
Figure 3.2:- Expression of MTA1 in gastric carcinoma and patient matched normal gastric tissue 
Figure 3.3:- Expression of MTA1 in breast carcinoma and patient matched normal breast 
tissue 
Figure 3.4:- Agarose gel electrophoresis of mGAPDH and mMTA1 following RT- PCR 
Figure 3.5:- Real time PCR analysis of mouse MTA1 in mouse tumour cell lines and 
normal mouse tissues 
Figure 3.6:- Western Blot of murine tumour cell lines, normal tissues and human tumour cell lines. 
Figure 3.7:- Immunofluorescence assay for localisation of MTA1 in BHK cells after 
transfection with pSMART2b/mMTA1 
 
Figure 4.1:- SFV structure 
Figure 4.2:- Agarose gel electrophoresis of full length mMTA1 following RT- PCR from mouse 
 testis for 40 cycles 
Figure 4.3:- Agarose gel electrophoresis after double digestion of TOPO-Blunt clones 
with mMTA1 insertion. 
Figure 4.4:- Agarose gel electrophoresis of TOPO-Blunt/mMTA1 clones after BamHI-AgeI double  
digest  
Figure 4.5:- HindIII-XbaI double digest of TOPO-Blunt/mMTA1 and pcDNA3  
Figure 4.6:- Western-blot of 293 cells after transfection with pcDNA3/mMTA1 or 
pcDNA3/hMTA1 expression vectors and α-tubulin western blot as a control  
Figure 4.7:- Double digest of TOPO-Blunt/mMTA1 and pSMART2b vector with BamHI 
and NsiI 
Figure 4.8:- BamHI-NsiI double digest of pSMART2b/mMTA1  
Figure 4.9:- Wester-blot of BHK cells 48 after transfection with pSMART2b/mMTA1 or hMTA1 
Figure 4.10:- Xgal assay BHK cells 24 hours after infection with SFV-bgal vector generated using 
original protocol and modified protocol 
Figure 4.11:- Xgal assay 24 hour post-infection of dendritic cells with SFV/B-gal. 
Figure 4.12:- Immunohistochemisty staining of BHK cells 48 hour post infection of 
 SFV/mMTA1 
 
 4
Figure 5.1:- Schematic diagram of interaction of DC with CD4+ and CD8+ T cells to 
initiate an immune response. 
Figure 5.2:- Direct and Reverse Immunology approaches for epitope identification  
Figure 5.3: - FACS analysis of the T2 binding assay for human MTA1 peptides for HLA-
A201 molecules 
Figure 5.4:- Fluorescence Ratio (FR) of human MTA1 peptides at various concentrations 
in T2 binding assay. 
Figure 5.5:- Cytotoxicity assay using T cells generated from HHD II mice immunised with 
hMTA1 peptides 22(A) and 57(B) 
Figure 5.6:- Cytotoxicity assay using T cells generated from HHD II mice immunised 
with plasmid encoding p53 followed by a 5 day in vitro re-stimulation with p53 149 
peptide 
Figure 5.7:- Cytotoxicity assay against EL4/HHD II cells pulsed with MTA1 peptides after 3 
immunisations with MTA1 DNA and in vitro re-stimulation with MTA1 22(A) and 57(B) 
 peptides. 
Figure 5.8:- Optimisation of immunisation protocol in Balb/c mice with TPH peptide.  
Figure 5.9:- Cytoxicity assays for MTA1 peptides mMTA1 622 (a), 208(b) and 168 (c) in 
syngeneic Balb/c mice. 
Figure 5.10:- Cytotoxicity assays for murine MTA1 peptides 436 (A), 148 (B), 551 (C) 
and 298 (D) 
Figure 5.11:- Proliferation results of MTA1 497 (A) and 550 (B) peptides in HLA-DR1 
(A and B) & HLA-DR4 (C and D) transgenic mice. 
Figure 5.12:- Proliferation assay to evaluate natural processing of MTA1 487 (A) and 
MTA1 550 (B) peptides. 
Figure 5.13:- Proliferation (A) and cytotoxicity assay (B) after intramuscular 
immunisation of HLA-DR4 and HLA-0201 transgenic mice with pcDNA3/hMTA1. 
 
Figure 6.1:- Tumour Challenge experiment following gene gun immunisation in balb/c mice 
(A) Tumour growth rate (B) Survival Curve. 
Figure 6.2:- Tumour Challenge experiment following syngeneic and xenogeneic MTA1 
gene gun immunisation in balb/c mice. (A) Tumour growth rate (B) Survival Curve. 
Figure 6.3:- Intramuscular syngeneic and xenogeneic MTA1 immunisation followed by tumour  
challenge and monitoring for tumour growth (A) and percent survival (B). 
Figure 6.4:- FACS staining for CD25+ cells after isolation of CD4+ T cells from naïve 
and cyclophosphamide administered mice. 
Figure 6.5:- Combination of cyclophosphamide (CPM) and gene-gun immunisation. 
Figure 6.6:- Cytotoxicity assay using CTLs generated from SFV-Bgal immunised mice. 
Figure 6.7:- Comparison of SFV-bgal with Adeno-bgal and DISC-bgal vectors at 1x106 
pfu for their ability to generate Bgal specific CTLs. 
Figure 6.8:- Tumour protection (A) and therapy (B) studies using SFV-Bgal. 
Figure 6.9:- Delayed CL-25 tumour development following SFV-mMTA1/hMTA1 
vaccination. 
 5
List of Tables 
 
Table 1.1:- Growth factors and Growth factor receptors implicated in cancer development 
Table 1.2:- Tumour Suppressor genes involved in cancer 
Table 1.3:-Classification of Tumour Antigens 
Table 1.4:- Examples of different Types of Cancer Vaccines used in clinical trials 
Table 2.1:- Cell Lines and their descriptions 
Table 2.2:- Primers used for PCR, Cloning and sequencing of murine and human MTA1 
Table 2.3:- Forward and Reverse primer sequences of primers used for RT-Q-PCR 
Table 2.4:- Peptides selected using SYFPEITHI to test for cytotoxicity 
Table 2.5:- HLA-DR1/DR4 restricted peptides derived from MTA1 used in proliferation 
assays 
Table 3.1:- Colon Carcinoma sample information and their relative MTA1 expression 
Table 3.2:- Gastric Carcinoma sample information and their relative MTA1 express 
Table 3.3:- Breast Carcinoma information and their relative MTA1 express 
Table 4.1:- Advantages and Disadvantages of DNA vaccines  
Table 4.2:- Characteristics of Different viral vectors (Adapted from Bonnet et al., 2000) 
Table 5.1:- Results of T2 biding assay of human MTA1 peptides 
Table 5.2:-Summary of the peptides tested and their immunogenicity 
 
 6
Chapter 1                                                                                                                                                   Introduction   
1.1 Cancer 
Cancer is a disease of varied spectrum and stages and can be defined as “uncontrolled cellular 
proliferation which at its advanced stages spreads to distant organs of the body”. According to 
the latest figures of World Health Organisation (http://www.who.int/cancer/en/), cancer is the 
second largest cause of mortality in the world; approximately 11 million new cases are diagnosed 
every year and 7 million deaths a year are cancer related. Various etiologies, such as 
environmental, biological and chemical agents, have been implicated in cancer causation. 
Smoking is a very well known risk factor for cancer. Inhalation of minerals such as asbestos and 
silica during mining also presents a serious risk of mesothelioma, either on its own or 
synergistically with smoking (Kurihara & Wada, 2004). Similarly, exposure to the ultra-violet 
radiation of sunlight is the main risk factor for melanoma, the commonest type of skin cancer 
(Ivry et al., 2006). Experimental and epidemiological studies have also associated various 
chemicals to cancer and epidemiological studies have linked obesity to cancers such as 
adenocarcinoma of the oesophagus, colon cancer, breast cancer, endometrial cancer and renal 
carcinoma (Calle & Kaaks, 2004). Studies have also suggested an association between obesity 
and pancreatic, liver and gall bladder cancer (Calle & Kaaks, 2004). Among biological agents, 
several viruses have been shown to be directly and indirectly responsible for cancer. Epstein Barr 
virus has been linked to at least four different types of human cancer, including Burkitt’s 
lymphoma and nasopharyngeal carcinoma. Similarly, Hepatitis B virus is shown to cause 
hepatocellular carcinoma (zur Hausen, 1991). Pathological examination of more than 98% 
cervical cancers show infection by human papilloma virus and thus provides a very strong 
evidence of this virus involvement in the disease process. Apart from these, cells can also 
acquire spontaneous DNA damage during normal cell division, leading to cancer. 
 
1.1.2 Cell Cycle and Cancer 
The human body consists of approximately 1015 cells and each cell of the body has to faithfully 
duplicate its genomic contents before dividing. Existence of haematopoietic stem cells (HSC), 
which have the capability of self-renewal and multi-lineage differentiation potential, is well 
known now. Recently, tissue specific stem cells have also been identified, which can divide and 
repopulate the mature organs (Huntly & Gilliland, 2005). Thus, approximately 1012 divisions in 
the stem cell compartment alone occurs daily (Bertram, 2000). Each cell cycle consists of four 
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 main stages G1,S, G2 and M (Fig 1.1). 
 
Figure 1.1:- Cell cycle (Taken from www.cancerline.com) 
 
Various proteins control these cell cycle stages and to ensure efficient cell division, cells have 
evolved cell cycle check points to ascertain the integrity of the DNA and DNA mutations and 
chromosomal abnormalities are identified and repaired at these check points. If the DNA damage 
incurred by the cell is irreparable, the complex pathway of programmed cell death (apoptosis) is 
activated, thus ensuring that the damaged DNA is not duplicated and the mutation does not 
become fixed. Apoptosis, a programmed cell death mechanism, has evolved to induce cell 
suicide in cells and occurs via either extrinsic or intrinsic pathways. Extrinsic pathway is 
activated in response to engagement of death receptors on the cell surface i.e binding of Fas 
ligand and tumour necrosis factor (TNF) to their respective receptors. Intrinsic apoptotic 
pathway is activated in response to various intracellular and extracellular stresses such as DNA 
damage, growth-factor withdrawal and hypoxia. Both these distinct pathways, through complex 
cascade reactions, lead to activation of caspases, which exist in normal cells as pro-caspase 
precursors. Effector caspases on activation cleave other substrates in the cell which in turn cause 
several biochemical and morphological changes in the cell, eventually leading to cell death 
(Okada & Mak, 2004). One of the several genes involved in this complex process is p53, also 
known as the ‘guardian of the genome’. Considering the complex machinery operating in the cell 
to prevent DNA damage and division, it is not surprising that most of the mutations observed in 
the cancer cell occur in the proteins controlling these cell cycle pathways and check-points.  
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1.1.3 Cancer-A multistep process 
In spite of the numerous cell divisions taking place throughout life, the occurance of a cancer cell 
is still a relatively rare event. This is due to the fact that a single cell has to acquire multiple 
mutations to attain the cancerous phenotype. In fact, it is estimated that in humans, 5-6 mutations 
are required by the cell to become cancerous. Each of these mutations provides the cells with a 
selective advantage and endows them with properties such as independence of growth factors, 
non-responsiveness to growth inhibitory signals, infinite replicative potential, resistance to 
apoptosis, angiogenic potential and ability to metastasise; which are the essential hallmarks of 
cancerous cell (Fig 1.2) (Bertram, 2000). However, this is not strictly true as evident by certain 
childhood cancers, such as retinoblastoma (Rb), where in most cases, loss or mutation of both 
alleles of the Rb gene can cause cancer. Any DNA damage, which goes undetected by the 
cellular machinery becomes fixed and is passed on to daughter cells, which has to then acquire 
further mutations.   
 
Figure 1.2:- Multistep progression of tumours  
in colon carcinoma (Taken from Knudson, 
2001) 
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Thus, cancer cell acquire sequential mutations, each providing them with a selective advantage 
over other cells in a ‘Darwinian’ evolution manner, helping them to overcome the natural 
defenses protecting against cancer.  
 
1.1.4 Oncogenes and Tumour Suppressor Genes 
 
Almost all the agents implicated as a cause of cancer, lead to mutations in the genes controlling 
the cell cycle or cause disruption of these pathways or in case of viruses, can introduce 
oncogenes in the cell genome i.e. E6/E7 by human papilloma virus. Most of these genetic 
changes have been discovered in genes that are classified into either oncogenes or tumour 
suppressor genes. 
 
1.1.4.1 Oncogenes 
Initially, viruses were implicated as the causative agents for cancer and they were discovered to 
carry certain genetic sequences, ‘oncogenes’ which result in transformation of infected cells. 
Indeed, viruses such as Epstein-Barr virus, hepatitis B virus, human papilloma virus etc. have 
been implicated as causative agents for cancer (zur Hausen, 1991). Oncogenes carried by these 
viruses can integrate into the human genome and lead to uncontrolled cell proliferation. 
However, it was later identified that normal cells also contain these genes, known as ‘proto-
oncogenes’. Proto-oncogenes encode for proteins which are involved in pathways of growth 
regulating signal transduction and hence any disruption of this cellular signaling could lead to 
cancer. Various genetic events such as chromosomal translocations, gene amplification and point 
mutations can lead to oncogenic activation. One of the most commonly known chromosomal 
abnormalities is the translocation between chromosomes 9 and 22, which juxtaposes the ABL 
(tyrosine kinase) and BCR (break point cluster region), giving rise to Philadelphia chromosome 
and this abnormality is seen in 90% of the CML patients (Ren, 2005).  
Proteins encoded by oncogenes include growth factors, growth factor receptors, cytoplasmic 
protein tyrosine kinases, signal pathway transduction mediators and transcription factors (Table 
1) (Fig 1.3)(Peters and Vousden, 1997). 
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Figure1.3 Different levels of cell cycle being affected by oncogenic mutations (modified 
from www.nature.com/nature/journal/v411/n6839/images/) 
 Growth factors mediate cellular signaling by binding to their receptors on cell surface and can 
initiate cell differentiation, migration and activation of cell multiplication. Growth factors of the 
fibroblast growth factor, epidermal growth factor, platelet derived growth factor, WNT family, 
transforming growth factor β (TGFβ), insulin like growth factors and hepatocyte growth factors 
have been shown to be involved in cellular transformation (Table 1) (Peters and Vousden, 1997). 
Growth factors, such as vascular endothelial growth factor (VEGF) can induce endothelial cell 
proliferation and chemotaxis, thereby promoting angiogenesis of tumour cells (Folkman, 1995). 
Moreover, they may also be involved in extracellular matrix degradation and facilitate invasion 
and metastasis (Radinsky, 1991). Apart from the growth factors secreted by the tumour cells, 
stromal cells also support the tumour growth by secreting other factors, although their role is not 
fully understood. 
Growth factor receptors can be mutated or present in high amounts leading to their constitutive 
activation in the absence of or low amounts of growth factors. EGF receptors, angiogenic 
receptors, PDGF receptors, IGF receptor and neurotropin receptor family are some of the 
receptor families implicated in cancer. EGF receptor is one of the most well studied receptor and 
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is found to be frequently altered in certain types of tumours such as glioblastomas. Mutations in 
the growth factor receptors can lead to a constitutively activated receptor, without a need for 
ligand binding. Furthermore, over-expression of normal human EGF receptors is also sufficient 
for transformation of fibroblasts in vitro (Velu et al., 1987). EGF receptor downregulation by 
anti sense RNA is able to reverse the transformed phenotype of the human epidermoid carcinoma 
cell line (Moroni et al., 1992). 
Table 1.1:- Growth factors and Growth factor receptors implicated in cancer development 
 
Growth Factors Growth Factor Receptors 
Fibroblast growth factor family ERBB2/3/4 
Epidermal growth factor family (EGF) Epidermal growth factor receptor  
Platelet-derived growth factor family (PDGF) PDGF α and β receptors 
WNT family Stem cell factor receptor (KIT) 
Transforming growth factor beta family Colony stimulating factor-1 receptor (FMS) 
Hepatocyte growth factor Hepatocyte growth factor receptor 
Insulin-like growth factors (IGF) Insulin-like growth factors I receptor 
 Neurotrophin receptor family 
 Angiogenic receptors 
 Erythropoietin receptor 
 Thrombopoietin receptor 
Protein tyrosine kinases are responsible for cell growth and differentiation, cell motility and 
secretion. Receptor tyrosine kinases are associated with growth factors. Of the seven different 
classes of cytoplasmic tyrosine kinases, members of the SRC, FPS and ABL families have so far 
demonstrated oncogenic potential. Many of the cytoplasmic tyrosine kinases can be activated by 
different growth factors such as PDGF, GM-CSF and IL-3. However, overexpression of 
oncogenic kinases generates signals which are sufficient for cell growth without the need for 
either a growth factor or receptor.  These oncoproteins can have multiple roles in cell mitosis; 
activation at the receptor level, phosphorylation of the membrane docking proteins as well as 
direct interaction with signalling proteins (Peters and Vousden, 1997).  
Downstream effectors of the growth factors include the signal transduction molecules of the 
RAS/RAF/ERK families, which are mutated in a number of tumours. Mutant version of the 
normal H-RAS was the first oncogene to be identified (Parada et al., 1982). It is now well known 
that RAS oncogene regulates multiple pathways in the cells and constitutive activation of this H-
RAS can deregulate the JNK and/or ERK pathways, giving rise to biochemical and cytoskeletal 
changes in the transformed cells (Peters and Vousden, 1997). Being involved in transcription of 
protein genes, it is not surprising that transcription factors are frequent targets of the mutagenesis 
leading to cancer. Members of FOS, JUN and MYC family are the main transcription factors 
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involved in cancer. These transcription factors regulate gene expression of a number of 
molecules involved in the cell cycle. MYC oncogene is involved in regulation of p53, cyclin A 
and cyclin E among others (Peters and Vousden, 1997). Deregulation of the cyclins promotes 
entry of the cells in the cell cycle and cell division. Similarly, MYB may be involved in blocking 
cell differentiation (Patel, 1993) 
 
1.1.4.2 Tumour Suppressor Genes (TSG) 
Normal genes suffer numerous insults from environmental factors but only a small number of 
these are propagated, eventually leading to cancer (Table 2). Tumour suppressor genes, are 
involved in controlling the growth of cells which have sustained DNA damage. These genes are 
involved in various functions such as DNA repair, inhibition of cell growth, induction of cellular 
senescence, differentiation and death (Jakobisiak et al., 2003). Loss of tumour suppressor gene 
activity due to ‘loss of function’ via mutations predisposes the cells to various kinds of cancers. 
Two of the most important TSG are the retinoblastoma gene (Rb) and p53. Rb gene was the first 
TSG to be discovered (Friend et al., 1986).  
 
Table 1.2:- Tumour Suppressor genes involved in cancer 
Tumour Suppressor Genes Cancers 
Retinoblastoma Tumour suppressor gene (pRB) Retinoblastoma 
p53 Many Cancers 
BRCA1/BRCA2 Breast and Ovarian cancers 
p16INK4a Esophageal squamous cellcarcinoma 
THY1 Nasopharyngeal carcinoma 
Neurofibromatosis type 1 (NF1) Many Cancers 
During the cell cycle, phosphorylation level of Rb is periodically regulated, with 
hypophosphorylated Rb being involved in negative cell growth. Rb mediated cell growth 
suppression is overcome by increased phosphorylation. It was initially identified in pediatric 
tumour retinoblastoma but has since been shown to be mutated in a large number of cancers. Rb 
interacts with a number of proteins in the cell, such as E2F. E2F functions as a transcription 
factor for several molecules involved in cell cycle. Hyper phosphorylation of Rb inhibits the 
interaction between E2F and Rb, resulting in unchecked activity of E2F. Other regulatory 
proteins shown to interact with Rb are cyclins D1, D2, D3, c-MYC, MDM2, c-ABL etc (Peters 
and Vousden, 1997).  
p53 is the most frequently mutated protein in the cancer cells and serves various biological 
functions in the cell, including the maintainance of G1 checkpoint in the cell cycle. Delay in the 
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G1 phase allows the cell to repair the DNA damage, failing of which may lead to p53 mediated 
apoptosis. It is also involved in cellular differentiation, DNA replication and repair. It is known 
as the ‘guardian’ of the genome and the importance of its role is underlined by the fact that p53 
gene is mutated in more than 70% of all cancers (Bertram, 2000). Analyses of these mutations 
have revealed that they are concentrated in specific regions of the gene, known as ‘mutational 
hotspots’, mainly in the DNA/protein interacting region of p53. Thus these mutations disrupt the 
association of p53 with DNA molecules (Bertram, 2000). Interestingly, different environmental 
insults can cause different mutations in p53, although it may lead to the same cancers. For 
example, mutational spectrum of p53 in hepatocellular carcinoma in China is different from 
those in Western countries (Aguilar et al., 1994). Moreover, both mutated and wild-type p53 can 
exist in the same cells and not only does the mutant form have a longer half-life than wild type 
but can also be dominant over wild-type p53. Fortunately, frequent occurrence of certain 
mutations, provides an opportunity to target these mutant p53 expressing cancer cells. 
1.1.5 Cancer Antigens and Their Classification 
Mutated or non-mutated, oncogenes and TSG, can be targeted for therapy and are known as 
tumour antigens. Hundreds of tumour antigens have been identified  in the past 15 years, since 
the identification of first tumour antigen MAGE-1 (van der Bruggen et al., 1991). The 
techniques used to identify these antigens are explained in chapter 5. Different tumour antigens 
have been classified as follows:- 
1. Cancer Testis Antigens: - CT antigens are found to be overexpressed in a number of 
different tumours but amongst normal tissues, they are mainly expressed in testis, ovary 
and rarely in placenta. However, these normal tissues are generally immuno-privileged 
since testis does not express MHC class I molecules and is not a target for CD8+ T cells. 
Expression of these genes in cancers and testis is due to the demethylation of genes 
which are generally transcriptionally silent in the normal tissues. Functions of most of the 
CT antigens are still unknown. These represent attractive targets for immunotherapy due 
to their widespread expression in cancer cells. Indeed, CT antigens are amongst some of 
the most extensively investigated antigens in animal models and clinical trials. MAGE 
was the first antigen to be discovered in this group following which a large number of 
others have been added to the list such as GAGE, BAGE, LAGE and NY-ESO-1 (van der 
Bruggen et al., 1991; Chen et al, 1997; Simpson et al., 2005). 
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2. Differentiation Antigens: - These antigens are generally shared between cancer cells and 
their normal counterparts, and might be specific for a particular lineage of cells or a point 
of differentiation. Melanoma associated antigens are mostly expressed in melanomas and 
normal melanocytes. Some of these antigens are involved in the biosynthesis of the 
pigment melanin. The most well studied antigens from this group are tyrosinase, TRP-1, 
gp100, MART-1, prostate specific antigen (PSA), carcino-embryonic antigen (CEA) and 
prostate membrane specific antigen (PSMA) (Kawakami et al, 1994; Yao and Bachich., 
2006). Since these antigens are also expressed at low levels in normal tissues, targeting 
them involves the risk of autoimmune reactions like vitiligo, as observed in some clinical 
trials (Schreiber et al., 1999; Trefzer et al., 2000). Moreover, being self antigens, 
generating immune response to them will require breaking tolerance to these antigens and 
potent immunisation strategies, as it is generally agreed that only the low avidity T cells 
for these antigens would have escaped the thymic tolerance mechanisms. 
3. Tumour Specific unique antigens: - These represent the most attractive 
immunotherapeutic targets as they are unique to each individual tumour or shared 
between specific tumour types. Bcr/abl is a well recognised antigen in this group, a fusion 
protein which is formed due to translocation between chromosomes 9 and 22 leading to 
chronic myeloid leukaemia (CML) (Ren, 2005). Other unique antigens are generated due 
to point mutations or gene fusions in some of the essential oncogenes or tumour 
suppressor genes such as k-ras, β-catenin, CDK4 and p53 (Yang & Cristofanilli, 2006; 
Ruiz-Godoy et al, 2006). Some research groups consider tumour specific antigens as the 
best option for therapy as they represent the most immunogenic epitopes. Tailor-made 
individualised therapies are seriously being considered as an option by certain 
immunologists and this group of antigens is their priority targets. 
4. Over-expressed self antigens: - These antigens are widely expressed in normal tissues 
are over-expressed in wide range of tumours as well. Unfortunately, most of the tumour 
antigens identified till date belong to this group, and represents the most challenging 
aspect of cancer immunotherapy. Like differentiation antigens, tolerance to these antigens 
seems to be the biggest concern as well as the challenge of finding the “narrow 
therapeutic window” between immunity and autoimmunity. However, recent evidence 
suggests that normal tissues are more robust in dealing with immune responses than their 
cancerous counterparts and/or the level of antigen expression in them is below the 
threshold of T cell recognition and activation (Hodge et al, 2003). Their ubiquitous 
expression suggests an essential role for them in cell growth and proliferation, which 
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reduces the possibility of generating antigen loss variants while targeting these antigens. 
Amongst the interesting antigens in this group are survivin, p53 and hTERT. Metastasis 
Associated antigen 1 (MTA1) also belongs to this category of antigens (Toh et al, 1995). 
5. Viral antigens: - Viral infections are responsible for a number of human cancers such as 
Epstein Barr virus (EBV) for Burkitt’s lymphoma, hepatitis B virus for hepatic 
carcinoma, human papilloma virus (HPV) for cervical cancer and human T cell leukemia 
virus (HTLV) for adult T cell leukemia (zur Hausen, 1991). Although prevention of these 
viral infections offers the most promising chance of decreasing these cancer incidences, 
for established cases, therapeutic vaccination might also hold potential. Tissues infected 
with virus would generally also express viral antigens offering the T cells an opportunity 
to recognise and destroy them. Moreover, viral antigens are highly immunogenic as the 
immune system has not encountered them previously and has evolved to clear microbial 
infections. Several clinical trials have been undertaken to target these viral antigens. For 
example, the antigens E6 and E7 of the HPV have been the focus of clinical trials for 
cervical cancer and have generated encouraging results (Govan, 2005). 
6. Post-translationally modified antigens: - Altered glycosylation appears to be a constant 
phenomenon associated with oncogenic transformation in essentially all types of 
naturally occurring human cancers. Most of the biochemical or, more recently, 
immunological methods used to identify tumour-associated antigens have resulted in the 
isolation of glycolipids or glycoproteins (mucins) with altered glycosylation patterns 
(Taylor-Papadimitriou & Epenetos, 1994). Mucins are large (> 200 kDa) glycoproteins 
with a high carbohydrate content. They are expressed by a variety of normal and 
malignant epithelial cells. 
7. Oncofetal antigens: - The oncofoetal antigens are “self” proteins normally expressed 
during foetal development and then undetectable or at low levels in normal healthy adult 
tissues. On the other hand these antigens have been detected in the sera of patients with 
gynaecological cancer. Carcinoembryonic antigen (CEA) is one of the first known 
tumour markers. Since then, many more have been described, but CEA remains alone or 
in combination with others the most commonly used biomarker for cancer progression. 
CEA is not organ specific and abnormal values may be found in a wide range of 
carcinomas (Ballesta et al, 1995). One of the most useful applications of this marker is in 
post surgical prognosis in the treatment of neoplasms. Any elevation of this marker after 
conventional treatment of neoplasms has been correlated with a recurrence of cancer 
(Holubec et al, 2000). 
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Table 1.3 Classification of Tumour Antigens 
Group Tumour Antigens Cancer expressing the antigen 
Cancer Testis MAGE1-3 and -12, BAGE,  
GAGE, HAGE, NY-ESO-1 
Melanoma, breast Head/neck,  
bladder, gastric and lung 
Differentiation antigens Tyrosinase, gp-100, TRP-1  
and -2, MART-1 
Melanoma 
Tumour Specific 
Antigens 
p53 (mutated) 
Ras (mutated) 
CDK4 
Caspase-8 
b-catenin 
BCR/ABL 
Breast, colon, other cancers 
CML, ALL, AML,  
Melanoma 
Head/neck 
Melanoma 
CML 
Over-expressed/ Mutated 
antigens 
HER-2/neu 
MUC-1 
 
p53 (non-mutated) 
WT-1  
Proteinase-3, 
PAP, PSA, PSMA 
Breast, ovary, lung 
Breast, adenocarcinoma colorectal,  
lung, bladder, head/neck 
Pancreatic, colon, lung 
CML 
Prostate 
Viral antigens EBV 
HCV 
HPV 
Burkitt’s lymphoma, Hepatocellular 
 carcinoma 
Cervical and penile cancer 
Post-translationally 
modified antigens 
Mucin Oesophageal, pancreatic cancers 
Onco-foetal antigens CEA 
 
α-Fetoprotein 
5T4 
Onco-trophoblast glycoprotein
Colon, breast, pancreatic caner 
Liver cancer 
Many carcinomas 
Many carcinomas 
Idiotype antigens Ig Idiotype B-cell NHL, MM 
 
8. Idiotypic antigens: - B cell lymphoma arises as a clonal event. Specific immunoglobulins 
(Ig) are generated by a unique combination of gene segments during B cell differentiation 
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and these are expressed throughout the development of the tumour. The Ig idiotypic 
determinants comes from a unique heavy (VH) and light (VL) chains and provide a 
unique tumour associated antigen to target for immunotherapy against lymphoma. 
1.1.6 Cancer Stem Cells 
In recent years, the concept of cancer stem cells has gained widespread acceptance. Stem cells 
were first identified in haematological malignancies but since then they have also been isolated 
from CNS, breast and prostate cancers (Collins et al., 2005; Huntly & Gilliland, 2005). Cancer 
stem cells are defined as cells with self-renewal capability and multi-lineage differentiation 
potential and are similar in nature to normal tissue stem cells. Current evidence from studies in 
animal models also suggests that tumours arise from a single cancer stem cell and transplantation 
of even a single cancer stem cell can lead to tumour formation (Polyak and Hahn, 2006).  
 
Several hypothesis regarding the origin and the role of cancer stem cells have been suggested. 
One possibility is that these stem cells are the primary cells in which cancer initiation occurs. 
Tissue stem cells persist throughout adult life and undergo frequent cell divisions making them 
more susceptible to accumulate the required number of genetic hits (Polyak & Hahn, 2006). 
Stem cells form a tiny compartment of the normal tissues and most cancers consist of 
heterozygously differentiated cells. It is possible that initial mutations affecting genetic 
instability occur in the tissue stem cells followed by accumulation of more genetic mutations in 
the more differentiated cells arising from such stem cells. Fusion of stem cells with other cells 
which have accumulated additional mutations might also be responsible for providing these cells 
an immortalized phenotype with tumour forming potential (Bjerkvig et al., 2005). Lastly, cancer 
stem cells might represent the dedifferentiated cells of the tumour. Thus, tumour cells sustaining 
genetic alterations affecting their differentiation process might cause the cell to be de-
differentiated and mimic stem cell behavior (Polyak & Hahn, 2006).  
 
The increased interest in these stem cells has arisen due to their importance in cancer therapy. 
Inability to target these stem cells might be one of the reasons for the failure of chemotherapeutic 
drugs. Most chemotherapy drugs target rapidly dividing cells and may not affect the slow 
growing stem cells, which in future can repopulate tumours. However, this does not apply to all 
the cancers as certain chemotherapy drugs provide a distinct therapeutic affect, especially in 
hematopoietic malignancies, which arise from such stem cells. Further research will be needed to 
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determine the real extent of cancer stem cell involvement in tumour growth and resistance to 
therapy. 
 
1.1.7 Conventional Modalities of Treatment and their Limitations 
Various methods of treatment are currently used for the treatment of cancer. 
 (i) Surgery: - Surgical removal of the cancerous tissue is probably the most favoured treatment 
as it causes the least damage to the surrounding normal tissue and have the least side effects. 
With modern surgical techniques, it is possible to remove tumours from almost any part of the 
body. However, it can only be applied in initial stages of cancer as once the cancer cells have 
metastasised, removal of primary tumour is generally palliative. Surgery can be used in 
combination with either chemotherapy or radiotherapy to initially decrease the tumour burden. 
(ii) Chemotherapy: - Chemotherapy is essentially treating cancer with cytotoxic drugs, which act 
on the rapidly dividing cells, and inhibits their proliferation or kills them. Although reasonably 
successful, chemotherapy has been associated with severe adverse effects and superseding their 
benefits. There are over 50 chemotherapeutic drugs; while some are given alone, most of them 
are given in combinations. Methotrexate is one of the main drugs used for treatment of acute 
lymphatic leukaemia (ALL) as well as certain lymphomas, osteosarcoma and choriocarcinoma 
(Chabner & Roberts, 2005). Similarly vincristine, a vinca alkaloid which inhibits microtubule 
polymerisation and cell division, is used in a combination regime for treatment of ALL, 
hodgkin’s and non-hodgkin’s lymphoma (Moxley et al, 1967). Chemotherapy is generally used 
at high doses in combination regimes to prevent the generation of resistant cells to one drug, 
which can also increase adverse effects. Usually chemotherapeutic drugs are administered at 
intervals of 3 weeks to allow the hematological cells of the bone marrow to proliferate and re-
constitute the immune cells, thereby decreasing the likelihood of infections. However, 
chemotherapy is most effective only on the well perfused and rapidly proliferating cells, a 
drawback which allows the tumour cells distant to the blood supply to escape their cytotoxic 
effects and repopulate. 
(iii) Radiotherapy: - Cancerous tissues are targeted by ionizing radiation, which is usually 
administered in small doses of 1.8-2.0 Gray and is given on the weekdays for 5-7 weeks (Kim 
and Tannock, 2005). No therapy is given on the weekends to allow the normal tissues of the 
body to recover from sub-lethal irradiation. This ionizing radiation causes lethal damage to the 
DNA of the tumour cells and thereby causing their death. However, radiotherapy is most 
effective on well-oxygenated cancerous cells and thus is unable to kill the hypoxic tumour cells 
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allowing their re-population. There is also increasing evidence that in some cases radiotherapy 
and chemotherapy regimes actually lead to increase in the growth rate of the tumour (Kim & 
Tannock, 2005). 
(iv) Hormonal therapy: - Cancers such as breast and prostate are dependent on the hormones 
produced by the body and can be controlled by hormonal therapy. Prostate cancers are usually 
dependent on testosterone, and hence therapies aimed to reduce serum testosterone levels have 
been used in the past with reasonable success. However, many of these cancers will eventually 
become resistant and these therapies are not suitable for hormone refractory tumours and for 
advanced cancers (Denmeade & Isaacs, 2002).  
Thus, in spite of the various advances in the diagnosis and treatment of cancer, the conventional 
modalities of treatment have been unable to significantly decrease the mortality rate in patients 
diagnosed with advanced disease. This has resulted in a renewed interest in the field of 
immunotherapy i.e. activating the immune system of the body to fight against cancer cells. 
 
1.2 Immune System and Cancer 
The immune system consists of various cells which have evolved to protect us against dangerous 
pathogens and microbes. However, its role in cancer prevention was realised when an increase in 
cancer development was observed in immuno-deficient animals and transplant patients on 
immunosuppressive therapy (Dunn et al, 2004). It was argued that the observed increase was due 
to the inability of the body to combat the oncogenic viruses, which are the real cause of these 
cancers. However, this argument has been countered by several lines of evidence in the recent 
years. Firstly, significant increase in the spontaneous tumour development has been shown in the 
various animal models with no apparent viral etiology (Dunn et al, 2004). Secondly, various 
tumour antigens have been identified using SEREX technique (Serological Analysis of antigens 
by recombinant expression cloning), whereby antibodies from serum of cancer patients is used to 
screen the cDNA library from the testis or cancer cells, which provide conclusive evidence of 
immune reactivity against cancer (Li et al, 2005). Lastly, immune cell infiltration has been 
observed in many human and murine tumours and the prognosis correlated with their numbers 
and activity (Dunn et al, 2004).  Thus, it is clear from these findings that the immune system has 
the ability to react against the tumour cells. 
 
How then does the tumour develop despite the presence of the active immune system and can it 
be activated to identify the presence of transformed cells and eliminate them?  The following 
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sections describe the development of the immune system, the cells involved in immunity and 
their mechanism of action to deal with cancer, including the mechanisms evolved by the cancer 
cells to evade the immune system. Moreover, evidence of immune system’s role in shaping the 
phenotype of the tumour cells will also be discussed, termed as ‘immunoediting’.  
 
 Immune System Development 
All cells of the immune system develop from the pluripotent stem cells in the bone marrow; 
differentiate into common myeloid and lymphoid progenitors. Further development of the 
myeloid progenitors gives rise to cells of the innate immune system such as eosinophils, 
neutrophils, basophils, macrophages and dendritic cells, whereas lymphoid progenitors 
differentiate into cells of the adaptive immune system, B lymphocyte and T lymphocyte 
(Janeway et al, 2001) (Fig 1.4).  
 
1.2.1 Innate Immune System 
Innate immune system provides the first line of defence against the pathogens. It is characterised 
by non-specific response, no immunological memory and it is constitutively present in the body, 
in contrast to adaptive immune cells, which require some time to be mobilised and are antigen 
specific. 
The immune system has evolved to protect living organisms against various microbes and 
infectious agents. This is achieved by recognition of the pathogens through various receptors 
present on the surface of the immune cells. Cells of the innate immune system detect the 
presence of a microbe in the body through a limited number of germline encoded receptors 
known as pathogen pattern recognition receptors (PPAR) (Janeway et al, 2001). These receptors 
are specialised to recognise the conserved molecules present in different bacteria, viruses and 
other pathogens.  Activation of these receptors on the surface of the antigen presenting cells such 
as dendritic cells and macrophages can lead to either phagocytosis of the pathogens and 
activation of other cells of the innate and adaptive system. Toll Like receptors (TLR) are one of 
the major pattern recognition receptors and are responsible for activation of antigen presenting 
cells and subsequent activation of the adaptive immune system.  
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Figure 1.4:- Development of the immune system cells from common progenitor cells 
arising from the bone marrow (Taken from Janeway et al, 2001). 
 
(a) Neutrophils 
Neutrophils form the majority of white blood cells in our body, as they might have evolved to 
provide the first line of defence against most commonly occurring viral infections and other 
pathogens. They are the chief mediators of inflammation, they are considered as pro-tumour due 
to their role in chronic inflammation, which may lead to cancer development (De Larco et al., 
2004). Neutrophils produce cytotoxic mediators and cytokines such as reactive oxygen species 
(ROS), Interferons, TNF-α, IL-1β, proteases and membrane perforating agents (Di Carlo et al., 
2001). Neutrophils can recruit APC to site of tissue damage, influence their differentiation, and 
can also drive the proliferation of T and B cells (Nathan, 2006). Although neutrophilic ROS can 
suppress T cell and macrophage function, they can also lyse tumour cells (Di Carlo et al., 2001). 
Inspite of their limited ability to secrete cytokines, the fact that these cells form up to 70% of 
total leukocytes suggests that they can form a reckoning force to mediate tumour cell destruction.  
 
(b) Eosinophils 
Eosinophils are considered as the main mediators of allergic reactions due to release of cationic 
proteins by them during asthma, but they are also known to interact with T cells and DC and lead 
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to Th2 polarisation of immune response (Odemuyiwa et al., 2004). Eosinophil infiltrates have 
been observed in a number of different tumours, however, their role in cancer is still debatable. 
Earlier studies indicated that eosinophil infiltrates in tumour cells correlated with a good 
prognosis (Iwasaki et al., 1986). However, a recent study demonstrates that they are responsible 
for producing Indoleamine 2,3-Dioxygenase (IDO) enzyme, which has been implicated as one of 
the tumour escape mechanism (Odemuyiwa et al., 2004). 
 
(c) Macrophages 
Macrophages are tissue resident antigen presenting cells derived from monocytes. Apart from 
phagocytosis of dead/dying or infected cells and their debris, they are also involved in antibody 
mediated cellular cytotoxicity (ADCC). Although some animal models have demonstrated anti-
tumour activity of the macrophages, most studies seem to suggest that tumour cells can 
manipulate tumour associated macrophages (TAM) for their own benefit. Initial studies reported 
macrophage associated tumour cell killing through secretion of cytotoxic cytokines likeTMFα 
and IL-1, reactive oxygen intermediates, proteases and nitric oxide. Macrophages also recruit 
secondary inflammatory cells, like neutrophils, to tumour site and are involved in antigen 
dependent cellular cytotoxicity (ADCC) of tumour cells (Foss, 2002). TAM have been shown to 
be manipulated for tumour invasion, growth, metastasis, angiogenesis and immuno suppression. 
In different areas of the tumour such as the stroma, perivascular sites and hypoxic/necrotic areas 
macrophages may be educated by their microenvironments to perform different functions (Lewis 
& Pollard, 2006). Supporting this hypothesis, macrophages derived from healthy tissues are 
capable of lysing tumour cells, whereas the ones isolated from tumours are unable to do so 
(Lewis & Pollard, 2006). 
 
(d) Mast Cells 
Mast cell accumulation at the edge of the tumours was observed in a number of studies and their 
degranulation is often associated with later stages of tumour proliferation (Cawley & Hoch-
Ligeti, 1961; Hartveit et al., 1984). A significant increase in tumour growth rate in mast cell 
deficient mice and their ability to produce TNF-α suggests that they might have some anti-
tumour function (Dimitriadou & Koutsilieris, 1997). On the contrary, mast cells can also 
promote tumour angiogenesis through release of mediators such as heparin, bFGF, TGFβ, 
proteases and histamine (Dimitriadou & Koutsilieris, 1997). 
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(e) Natural Killer Cells 
Natural killer (NK) cells consist of large granular lymphocytes and are considered as one of the 
most important defence mechanism of immunosurveillance against virally infected cells and 
tumour cells. Being an innate “immune” cell, the NK cell does not require prior priming and 
expansion, and does not kill in an antigen specific manner. NK cells are capable of detecting 
virally infected or tumour cells which have down-regulated their MHC class I molecules and 
mediating their killing (‘Missing Self” hypothesis) (Kumar & McNerney, 2005). On the other 
hand, they maintain a status of self-tolerance towards the normal cells of the body owing to the 
fact that almost all nucleated cells of the body express MHC class I molecules. This property of 
the NK cells is due to the presence of inhibitory receptors on their surface, which belong to two 
families, immunoglobulin like receptors and C-type lectin-like receptors. Killer 
immunoglobulin-like receptors (KIR) belong to the previous category and specifically recognise 
HLA-A, HLA-B and HLA-C alleles (Papamichail et al., 2004). Apart from the inhibitory 
receptors, NK cells also express an activating receptor, NKG2D, which recognises the human 
non-classical MHC molecules MIC-A and MIC-B. MIC molecules are stress inducible molecules 
that are frequently expressed by the transformed cells (Papamichail et al., 2004). NK cells can 
not only kill transformed cells through granzyme-perforin and apoptosis inducing receptors 
(FasL, TNF and TNF related apoptosis inducing ligand [TRAIL]), but they can also secrete huge 
quantities of cytokines such as IFN-γ, TNF-α, IL-10 and GM-CSF (Lehmann et al., 2001; Mori 
et al., 1997; Takeda et al., 2005). Thus, these cells might also play an important role in directing 
the immune response and in the process establish an important link between the innate and the 
adaptive immune response. Indeed, it has been observed that NK cells and DC might be involved 
in a complex crosstalk to enhance the immune reaction (Zitvogel, 2002; Fernandez et al., 1999). 
Contrary to NK cell’s established role in immunosurveillance, NKT cells have recently 
generated very conflicting results. NKT cells express markers of both NK and T cells and are 
marked by production of large quantities of cytokines, mainly IL-13. Several studies have 
established their role as immunosuppressive cells and down regulators of immunosurveillance 
(Terabe et al., 2000; Moodycliffe et al., 2000). However, other studies have argued that they are 
actually responsible for rejection of tumours (Cui et al., 1997; Godfrey et al., 2000; Crowe et al., 
2002). 
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(f) Antigen Presenting Cells 
 
Cells such as macrophages, B cells and dendritic cells (DC) have been endowed with specialised 
functions of antigen capture and presentation to the other immune cells in order to initiate an 
immune response against these antigens. Although B cells and macrophages are competent 
antigen presenters, dendritic cells are the most potent and important APC in the body. DC are 
located at the sites of antigen entry in the body and are efficient in antigen capture, processing 
and presenting it to T cells along with co-stimulatory molecules (Itano & Jenkins, 2003).  Thus, 
it is not surprising that a lot of research has been devoted to unraveling the different subsets and 
the roles of these cells in various microbial infections and cancer. 
 
DC, along with other APCs possess evolutionarily conserved sets of receptors known as pattern 
recognition receptors (PRRs), which are involved in cell activation. PRR also include molecules 
mediating opsonisation, endocytosis, activation of complement and coagulation cascades, 
activation of inflammatory signaling pathways and/or induction of apoptosis (Kapsenberg, 
2003). One of the most important PRRs are the toll like receptors (TLR), of which ten different 
subtypes in humans and nine in mice have been identified. These TLR are specialised in 
recognition of pathogen associated molecular patterns (PAMP), which are shared by various 
microbes and pathogens. Different TLR receptors have different microbial ligands and can 
induce different intracellular signalling pathways. Various PAMP recognised by TLR include 
lipopolysaccharide (TLR4), bacterial lipoproteins and lipoteichoic acids (TLR2), flagellin 
(TLR5), unmethylated CpG DNA of bacterial and viral origin (TLR9), double stranded RNA 
(TLR3) and single stranded viral RNA (TLR7) (Iwasaki & Medzhitov, 2004). Thus, TLRs 
1,2,4,5, and 6 bind to bacterial products whereas TLRs 3, 7 and 9 are involved in viral pattern 
recognition. Apart from these microbial products, DC can also be activated by inflammation and 
stress induced tissue factors such as inflammatory cytokines, eicosanoids, heat shock proteins 
(HSPs), extracellular matrix components, cell-surface bound molecules and necrotic cell lipids 
(Gallucci et al., 1999). Initial environmental factors during DC activation, through different 
receptors, can later dictate their ability in directing polarisation of the immune response.  
 
Dendritic cells constitute about 0.3% of the entire circulating blood-leukocyte population and 
also reside in various tissues of the body in an immature state (Dallal & Lotze, 2000). On being 
activated in the periphery, DC engulfs the antigens released by the damaged or infected cells, 
through several mechanisms including macropinocytosis and receptor mediated endocytosis via 
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mannose and Fc receptors. After antigen uptake these DC migrate to the neighboring lymph node 
and on route they mature and process the captured protein antigens into peptides. These peptides 
are bound to the MHC molecules and are presented to naïve T cells in the lymph node. On 
maturation, the phagocytic ability of DC decreases considerably, and is replaced by enhanced 
expression of MHC and co-stimulatory molecules on their surface for optimum antigen 
presentation. Maturation state of the DC is highly important in generating stable T cell synapse 
and their activation (Benvenuti et al., 2004). Immature DC are unable to form long-lasting 
interaction with naïve T cells, which could lead to T cell anergy (Benvenuti et al., 2004). 
Usually, captured antigen is delivered to the MHC class II compartments where it is processed 
and presented on the cell surface through MHC class II receptors and serves to elicit CD4+ T cell 
responses. However, DC can also present exogenous antigens on MHC class I molecules by 
directing exogenous antigens to the endoplasmic reticulum through ‘cross-priming’. Thus, DC 
can also present antigens to the CD8+ T cells and lead to their activation. Even a single peptide-
MHC complex can be recognised by the T cells on the APC surface (Krogsgaard & Davis, 
2005). Moreover, DC have also been shown to interact and activate other innate cells of the body 
such as natural killer (NK), natural killer T lymphocytes (NKT) cells and B cells (Fernandez et 
al., 1999). Hence, antigen presentation by the DC can lead to activation of both innate and 
adaptive immune responses. 
 
Optimal activation of T cells by the DC requires two signals. Signal one is provided by the 
ligation of the T cell receptor (TCR) to the MHC-peptide complex on the surface of the DC. 
Along with this, co-stimulatory signals (signal 2) are vital, as signal 1 in absence of signal 2 can 
lead to T cell anergy. Signal 2 is provided by activation of CD28 molecules on T cells by binding 
of CD80 and CD86 molecules on the APC. Recently, it has been suggested that a third signal in 
the form of cytokines secreted by DC is also required for polarisation of the T cell response 
(Kapsenberg, 2003). Cytokines such as IL-12, IL-23, IL-27 and type I interferons are considered 
as Th1 polarising whereas IL-10, TGF-β and monocyte chemotactic protein 1 (MCP1) are Th2 
polarising. Various subsets of DCs have been discovered in humans and mice, and it is unclear at 
the moment whether different subsets of DC possess different capability in generating immune 
response and tolerance (Shortman & Liu, 2002). 
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1.2.2 Adaptive Immune System 
Unlike innate system, cells of the adaptive immune system use highly diverse and stringently 
selected somatically generated antigen-specific receptors. Adaptive immune reaction is mediated 
by either humoral (antibody) mediated or cell mediated mechanisms. Although both types of 
immune response have an essential role in immune recognition and elimination, cell-mediated 
response is considered as the chief architect of immune responses against cancer.  
 
1.2.2.1 Humoral immune response and Cancer 
 
Antigen recognition receptor on the B cells is called Immunoglobulin receptor and consists of 
two heavy and two light chains. These heavy and light chains are arranged in a Y shape and are 
bound to each other by disulphide bonds. Both the chains contain a hyper variable region and a 
constant region. Different combinations of the light and heavy chains, combined with the 
diversity of the hyper variable regions, due to somatic rearrangement of the segments forming 
these regions, generate a highly diverse set of receptors (Janeway, 2001).  
 
Identification of numerous tumour antigens through SEREX (Serological analysis of tumour 
antigens by recombinant cDNA expression cloning) suggests that the immune system is quite 
capable of mounting an antibody response to most tumour antigens. In contrast to the CD8+ T 
cells, self reactive CD4+ and B cells may not be subjected to intense scrutiny and deletion during 
development and hence they are easily reactivated against cancer cells. Depending on the 
environment at the initial DC activation, they can direct the ensuing immune response to a Th2 
response, which mainly leads to antibody production. However, a Th2 response has traditionally 
been considered as detrimental to effective anti-tumour immune response (Kao et al., 2006; 
Osawa et al., 2006). It has been suggested that a proper Th1/Th2 balance in the favour of a Th1 
is essential for tumour rejection. In fact, tumour cells might themselves skew the immune system 
towards a predominant humoral response to avoid CTL generation (Kao et al., 2006). 
Furthermore, several studies have shown that rejection of tumour cells does not require B cells 
(Lindencrona et al., 2004). 
 
Contrary to the above studies, several other tumour models have demonstrated an effector role of 
antibodies in mediating tumour rejection (Renard et al., 2003; Simon et al., 2002). Antibodies 
alone or in a combination with Th1 response are also capable of mounting tumour rejection. In 
fact, several monoclonal antibodies have already been approved for the treatment of various 
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cancer and several others are in clinical trials. Moreover, tumour cells often down regulate MHC 
class I molecules to evade CTL response, and in such cases antibodies might be the appropriate 
therapeutic option. Thus, effective tumour rejection might require activation of multiple arms of 
the immune system such as CD4+, CD8+ and B cells. 
 
1.2.2.2 Cell mediated immune response and Cancer 
The T cell receptor (TCR) is generated in a similar manner to receptors expressed on B cells, 
however, there are certain crucial differences. T cell receptors consist of a heterodimer formed 
by a single α and β chain or γ and δ chain which are linked by disulphide bond. Unlike B cell 
receptors which can be secreted as antibodies, T cell receptors are membrane bound (Janeway, 
2001). Both the α and β chains consist of the variable domains formed by the somatic 
rearrangement of the genes forming these segments, thus generating a highly diverse set of 
receptors enabling each T cell with a unique specificity. However, this is not strictly true in all 
instances, as explained later. These highly diverse repertoires of receptors enable the cells of the 
adaptive system to react specifically against different pathogens. 
 
Although the majority of the T cells in the body bear αβ TCR, less than 5% of them have γδ 
TCR. These γδ T cells arise from a common progenitor as αβ T cells, but have a distinct role in 
the body. They are found mostly in the gastrointestinal mucosa and are adapted to identify 
antigens such as mycobacterial ligands and heat shock proteins (Chen & Letvin, 2003). 
Moreover, they can identify antigens presented by non classical MHC molecules (Spada et al., 
2000). Function of γδ T cells is not entirely clear at the moment, although several groups have 
suggested that certain subtypes of these cells are capable of generating an adaptive immunity and 
might have an important role in some cancers (Chen & Letvin, 2003). 
 
(a) Major Histocompatibility Complex and its polymorphism 
 
Tissue grafting experiments suggested the existence of genes controlling graft acceptance and 
rejection. The genetic complex devoted to this function was named as major histocompatibility 
complex (MHC) in mice and human leukocyte antigen region (HLA) in humans (Fig 1.5). The 
genes encoded by the MHC are involved in processing of proteins into peptides, their transport 
and their presentation on the surface of cells for recognition by T cells. T cells only recognise 
peptides when they are presented to them as a complex with the MHC molecules on the surface 
of cells. 
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The murine MHC is located on chromosome 17 and that of humans on chromosome 6 (Klein, 
1979; Erlich et al., 1983). Two of the major complexes encoded by MHC are the MHC class I 
and class II molecules, which present peptides to CD8+ and CD4+ T cells respectively. MHC 
class I molecule is heterodimer, made up of highly polymorphic integral membrane glycosylated 
α chain which is non-covalently associated with β-2 microglobulin (β2m) (Rajagopal et al., 
2004). Interestingly, gene coding for β2m is located on chromosome 15, separate from rest of 
MHC genes. The α chain is folded into three domains α1, α2 and α3. Folding of the α1 and α2 
domain creates a groove, which is the site where the peptides are bound to the MHC molecules 
and are displayed on the surface (Fig 1.6) (Janeway et al, 2001). MHC class II molecules are 
heterodimer molecules consisting of a non-covalently linked, trans-membrane glycoprotein α and 
β chain. Each chain is folded into two domains. The α1 and β1 domains form the groove for the 
peptide binding and unlike MHC class I molecule, it is open at both ends thereby allowing 
binding of longer peptides (Fig 1.7). 
 
Figure 1.5:-Distribution of MHC genes in humans and mice (Taken from Janeway et al, 2001). 
 
Because antigen recognition by T cells critically depends on peptide presentation by MHC 
molecules, they are polygenic and highly polymorphic, providing a broad range of peptide 
binding molecules. In fact, MHC molecules are the most polymorphic genes in the human body. 
Several genes encode for MHC class I and II molecules and every individual possess a set of 
MHC molecules with different range of peptide binding specificities (Janeway et al, 2001). In 
the MHC complex there are three MHC genes for class I called HLA-A, B and C; and 3 pairs of 
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MHC class II α and β genes called HLA-DR, DP and DQ (Fig 1.5). Moreover the DR region 
contains an extra β chain which can pair with DR α chain, thus generating two different DR 
molecules. At each gene locus, there are considerable variants which can give rise to different 
alleles and there are more than 200 different MHC class I and II alleles. Moreover, expression of 
MHC alleles is co-dominant, so each individual expresses six sets of MHC class I and eight 
types of MHC class II molecules. Each allele differs from the other by up to 20 amino acids 
which are concentrated in the peptide binding groove of the MHC molecule. This provides the 
diversity to the MHC molecule to bind to numerous peptides with different specificities and 
affinities. This is helpful in predicting the peptides from an antigen which are likely to bind to a 
given MHC molecule with high affinity and could be used as peptide vaccines. Importantly, 
MHC class I molecules are expressed by all nucleated cells of the body except testis, whereas 
MHC class II molecules are normally expressed by only professional antigen presenting cells 
(DC, B cells and macrophages). 
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Figure 1.6:- MHC class I molecule structure as determined by x-ray crystallography 
(Taken from Janeway, 2001; Fremont et al, 1992) 
 
Apart from the MHC class I and class II molecules, the MHC also encodes for other proteins 
such as LMP 2/7, TAP, Tapasin, HLA-DM and HLA-DO, which are required for the antigen 
processing and presentation. On exposing cells to IFN-γ, which would be produced in viral 
infections, there is a marked increase in transcription of MHC class I and β2m genes along with 
proteasome, tapasin and TAP genes (Khan et al., 2001). Similarly MHC class II genes are also 
regulated by IFN-γ via production of a transcriptional activator known as MHC class II 
transactivator (CIITA) (Boss, 1997). This positive regulation of these MHC class I and II genes 
is essential for the immune cells to cope with increased antigen processing during any pathogenic 
infections. 
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Figure 1.7:- MHC class II molecule structure as determined by x-ray crystallography 
(Taken from  Janeway et al, 2001; Dessen et al, 1997). 
 
(b) Antigen Processing 
As discussed previously, T cells can only be activated when they bind to peptide-MHC 
complexes on the surface of APC. CD4+ T cells bind to peptides presented in complex with 
MHC class II molecules, whereas CD8+ T cells recognise the peptides in complex with MHC 
class I molecules. MHC class I molecules are expressed by all nucleated cells of the body, 
whereas MHC class II molecules are expressed only on the surface of certain specialized antigen 
presenting cells like B cells, macrophages and dendritic cells. So how are these MHC peptide 
complexes formed and displayed on the surface of the cells?  
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MHC class I antigen processing 
 
All proteins produced by the cell have to be degraded by various mechanisms once their function 
is completed. Initially recognition of the proteins to be degraded is required and the most 
common and clearly understood mechanism is by poly-ubiquitinylation, where enzymes such as 
E1, E2 and E3 activate ubiquitin molecules and covalently link them to the lysine residues of the 
proteins to be degraded. This tagging of the proteins allows the cytosolic proteasomes to 
distinguish the proteins to be degraded and is likely to be involved in the unfolding of the 
proteins. The proteasomes mediate the degradation of the majority of cytosolic proteins. Without 
proteasomal degradation, the MHC I molecules remain starved in the endoplasmic reticulum 
(ER) and are themselves eventually degraded (Pamer & Cresswell, 1998).  Moreover, in the 
absence of the peptides, MHC class I molecules can assemble but are unstable at body 
temperature and recycled rapidly (Ljunggren et al., 1990). 
 
Proteasomes are multicatalytic units, composed of approximately 28 subunits arranged in four 
stacked rings of 7 subunits each and consisting of a hollow core lined with the proteolytic 
subunits. Eukaryotic proteasomes contain 3 Interferon-γ inducible units, two of which are 
encoded by the MHC complex, LMP 2 and LMP 7. Usually, cells express constitutive 
proteasomes and exposure to IFN-γ causes LMP 2 and 7 to replace two β subunits. The third 
subunit recently identified, MECL-1 replaces proteasome subunit Z. This proteasome with IFN-γ 
inducible subunits is known as ‘Immunoproteasome’ and is found to be constitutively expressed 
in antigen presenting cells (Janeway et al, 2001). Expression of these subunits alters the 
specificity of the proteasome. Specifically, LMP-2 and LMP-7 expression enhances the cleavage 
after hydrophobic and basic amino acids whereas cleavage after acidic residues is inhibited. This 
proteasomal machinery generates numerous peptides, the majority of which are believed to be 
degraded in the cytosol and only a few survive to become ligands for MHC class I. Although the 
majority of the class I peptides are generated from the endogenous antigens, it has been shown 
that often antigens acquired from extracellular spaces are also displayed on MHC class I surface; 
a process known as ‘Cross Priming’ (Rock et al., 1990; Kovacsovics-Bankowski & Rock, 1995). 
The precise mechanism of this process is unknown although occasional rupture of the 
phagosome carrying the antigen might be responsible for release of the antigen into the cytosol. 
 
Peptides resulting from proteasome cleavage are transported to the ER through certain 
chaperones like heat shock proteins (HSP) and are translocated across the ER membrane through 
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the means of a heterodimer TAP, consisting of two subunits TAP.1 and TAP.2, encoded by 
genes within the MHC (Fig 1.8). Numerous studies have confirmed the requirement of both 
subunits of TAP to be expressed for efficient translocation of the peptides. Also, TAP is able to 
translocate longer peptides into the ER, where NH2 terminal trimming is thought to occur by 
means of aminopeptidase enzymes. 
 
Figure 1.8:- Schematic diagram of MHC class I antigen processing (Taken from 
www.innovitaresearch.org) 
 
MHC class I heavy chains, after being synthesized in the ER, bind to a protein called Calnexin. 
On binding of the heavy chain to the β2 microglobulin chain (β2m), calnexin is exchanged for a 
similar protein called calreticulin. β2 microglobulin is an obligate subunit of the MHC class I 
complex as its absence causes misfolding of the MHC class I molecule and its degradation. This 
complex of MHC class I heavy chain, β2 microglobulin and calreticulin associates with TAP 
molecules through another transmembrane protein called Tapasin. Tapasin is thought be 
responsible for coordinating peptide translocation and protection of class I- β2 m dimers from 
degradation. Finally the peptides translocated by TAP form a complex with class I- β2m dimers 
leading to dissociation of the complex from calreticulin and tapasin. This complex is then 
transported from the ER through the Golgi apparatus to the plasma membrane. 
Studies have shown that on average, 1.8x106 substrates undergo degradation per minute in a cell 
and a single MHC-peptide complex generation requires about 450-3000 substrates to be 
degraded (Rajagopal et al., 2004). 
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MHC class II antigen processing and Presentation 
Peptides presented by MHC class II molecules are generated in the endocytic vacuoles rather 
than by the proteasomes (Fig 1.9). Extracellular pathogens are internalised by antigen presenting 
cells through endocytosis or phagocytosis and become enclosed into endosomes. These 
endosomes become more acidic as they progress to the interior of the cell and fuse with 
lysosomes. The proteins produced by these pathogens are eventually degraded in this acidic 
environment by certain acid proteases such as cathepsins B, D, S and L (Janeway, 2001).  
Similar to MHC class I molecules, MHC class II molecules are generated in the ER but are 
prevented from binding to the pool of peptides due to the association with a protein known as the 
MHC class II associated invariant chain (Ii). The invariant chain forms a trimer with the MHC 
clas II α:β dimers. Moreover this chain might also be responsible for targeting class II molecules 
to the low pH endosomal compartment, where the MHC class II molecules are retained for 2-4 
hours (Janeway et al., 2001). During this time the invariant chain is cleaved in several steps. 
Initial cleavage generates a truncated form of the invariant chain, which still remains bound to 
the MHC class II molecule.  Subsequent cleavage releases it from the membrane bound form of 
Ii and leaves a smaller fragment called CLIP to the peptide binding groove of the MHC class II 
molecule. Late in the endosomal pathway, these MHC class II:CLIP complexes enter into a 
specialised MHC class II compartment, where it is believed that the actual loading of the MHC 
class II molecule takes place after the dissociation of CLIP. The loading of peptide and release of 
CLIP from MHC class II molecule is facilitated by an MHC like molecule known as HLA-DM. 
HLA-DM also catalyses the release of unstably bound peptides to MHC class II molecules and in 
the process ensures that the MHC class II:peptide complexes delivered on the cell surface are 
stable and can survive on the surface for a few days. 
 
Recently, a TAP and proteasome dependent antigen processing pathway was shown to exist for 
MHC class II peptides, however this pathway was only demonstrated in dendritic cells having a 
permeable endosome (Tewari et al., 2005). Moreover, endogenous antigens can also enter the 
MHC class II pathway and generate T-helper responses (Bogen et al., 1990). Cells produce 
excess of MHC class I and II molecules so that when the cell is infected by the pathogen, the 
peptides generated from the foreign antigens have sufficient empty MHC molecules to bind to. 
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Figure 1.9:- Schematic diagram of MHC class II antigen processing (Taken from 
www.innovitaresearch.org) 
 
(c) CD4+ T cells – Helpers and Co-ordinaters of the immune response 
On reaching the lymph nodes, mature DC present processed antigens to CD4+ T cells through 
MHC class II molecules. Recognition of an epitope on the DC surface by the T cells leads to a 
formation of an immunological synapse and cross-talk between the CD4+ T cells and the DC. 
This cross-talk is essentially through the CD40-CD40L interaction, which licenses DC to 
optimally activate antigen specific CD8+ T cells and on the other hand activates the CD4+ T 
cells and polarises them towards either Th1 or Th2 cells. T helper 1 cells provide cytokines 
which support for the development and maintenance of the CTLs from CD8+ T cells. On the 
contrary, Th2 cells secrete cytokines such as IL-4 and IL-5 and lead to development of an 
antibody response towards the antigen. Recently, Xiang et al (2005) have demonstrated the 
ability of the CD4+ T cells to acquire MHC class I peptide complexes from DC on initial 
encounter. These CD4+ T cells can then act as APC themselves in activating CD8+ T cells 
leading to anti-tumour immune response.  
 
Apart from this direct help in CTL generation, CD4+ T cells have been shown to possess 
multiple functions. CD4+ T cells can also recruit other immune cells such as macrophages and 
eosinophils to the tumour site (Wang, 2001). In several animal models, CD4+ T cells have been 
shown to mediate tumour rejection on their own (Daniel et al., 2005; Dudley et al., 2001; Lundin 
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et al., 2004). Indirect anti-tumour effects of the CD4+ T cells are mostly mediated by the 
secretion of IFN-γ, which has a pro-apoptotic and anti-proliferative effect on them; it also 
inhibits angiogenesis and by inducing upregulation of MHC class I molecules, makes tumour 
cells more susceptible to CTL mediated killing (Ikeda et al., 2002)). Several studies have also 
demonstrated the ability of CD4+ T cells to mediate tumour cell killing directly (MHC restricted) 
through Fas-FasL, granzyme-perforin and TRAIL pathways, generally employed by CTLs 
(Schattner et al., 1996; Thomas & Hersey, 1998a; Thomas & Hersey, 1998b). However, this is 
unlikely to be their main role as most of the tumours are MHC class II negative. 
 
Adoptive transfer clinical trials have reinforced the role of CD4+ T cell in the generation and 
maintenance of the CTL response. Dudley and Rosenberg have recently showed that adoptive 
transfer of CD8+ T cells alone provided little clinical benefit to the patients. However, when 
CD4+ T cells were included in the adoptive transfer, this led to objective clinical regression in 
more than 50% of the patients (Rosenberg & Dudley, 2004)). One of the most intriguing 
questions for immunologists has been the nature and mechanism of help provided by the CD4+ T 
cells to CTLs. Several studies have argued that T cell help is only required during the priming 
phase of the CTL response whereas other models have showed their requirement for the 
maintenance of the memory cells (Bevan, 2004; Buller et al., 1987; Cassell & Forman, 1988; 
Shedlock & Shen, 2003; Sun & Bevan, 2003). These discrepancies might be explained by the 
different models used in these studies and the nature of the antigen. Perhaps, pathogenic 
infections provide stronger danger signals to the DC, bypassing the need of CD40L provided by 
the CD4+ T cells, whereas cancer being a chronic disease would require this CD4+ T cell 
mediated help. Moreover, CD4+ T cells can provide help for DC and CTL induction in a CD40 
independent manner as well. This could occur either by cytokine release or by a contact 
dependant mechanism (Bachmann et al., 1999; Lu et al., 2000). 
Thus, CD4+ T cells control multiple arms of the immune response against cancer; including 
providing help in CTL induction and maintenance, recruiting other immune cells, mediating 
direct and indirect tumour cell killing. 
 
(d) CD8+ T cells - The Effector cells 
CD8+ T cells are considered as the main effector cells in defence against virally infected cells 
and tumour cells. After being licensed by the CD4+ T cells, DC are optimised to present antigen 
to CD8+ T cells in an MHC class I restricted manner. Several studies have argued that for 
optimal CTL activation, both CD8+ and CD4+ T cells have to recognise antigen on the same 
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APC (Ridge et al., 1998; Smith et al., 2004). Moreover, there is also evidence to suggest that 
CD4+ and CD8+ T cells need to be in contact with the APC at the same time. However, antigen 
carrying APC coming in contact with rare antigen specific CD4+ and CD8+ T cells at the same 
time seems unlikely. Recently, Castellino et al have provided support to this argument by 
showing that interaction of naïve CD4+ T cells with DC in the lymph nodes leads to chemokine 
secretion by CD4+  T cells (CCL3 and CCL4) and this chemokine gradient permits active 
recruitment of the naïve CD8+ T cells through the CCR5 chemokine receptor (Castellino et al., 
2006). Therefore, a two stage model, where APC activates CD4+ T cell first and then rendezvous 
with the antigen specific CD8+ T cell, seems more realistic (Ridge et al., 1998).  
 
Following activation, CD8+ T cells differentiate into specialised killer cells (CTLs) and migrate 
to the area of infected cells or to the tumour site. On recognising the same antigen on the surface 
of the cells, CTLs seem to form a stable synapse with the target cells and mediate their apoptosis 
by multiple mechanisms. The most common and important pathway employed by the CTL is the 
perforin-granzyme pathway. After 24-48 hours of T cell activation, granules of proteins are 
synthesised in the CTL and on junction formation with the target cells these granules are 
orientated towards the contact site (Yannelli et al., 1986). Initially the granules release perforin, a 
molecule found exclusively in the cytotoxic lymphocytes (CTL and NK cells). In the presence of 
calcium, perforin polymerises in the cell membrane of the target cells creating conduits for the 
clear passage of other CTL granular proteins (Stinchcombe et al., 2001). This is followed by 
release of other cytotoxic granules such as the granzymes by the CTLs. Granzymes are a family 
of serine proteases, of which about 11 types have been identified in humans and mice. Of these 
granzyme A, B, H and K are ubiquitously found in CTLs and only granzyme A and B are 
considered to play a major role in mediating cell death (Barry & Bleackley, 2002). It was earlier 
considered that perforin only performs the role of creating an entry for other granules. However, 
it has now been shown that in the absence of the perforin, granzymes remain trapped inside the 
vesicles of the target cells after entering them and perforin addition helps in the release (Pinkoski 
et al., 1998). Granzyme B on being released acts on the downstream pro-apoptotic molecules of 
the target cells such as caspase 8 and caspase 3, and ultimately leads to the apoptosis of the target 
cell (Darmon et al., 1995). Granzyme B is also capable of mediated caspase independent 
mitochondrial collapse of the target cells with release of cytochrome C, leading to cell death 
(Heibein et al., 1999). Up to 90% of the CTL mediated cytotoxicity is mediated by perforin-
granzyme pathway (Graubert & Ley, 1996). 
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Another important death mechanism is mediated through the Fas-FasL pathway. FasL is 
expressed on the T cells a few hours after activation (Shresta et al., 1998). This FasL acts as a 
ligand for the Fas receptors, a member of the tumour necrosis factor family of death receptors on 
the surface of the target cells. Engagement of the Fas receptors leads to aggregation of the 
intracellular death domains and ultimately formation of a death inducing signalling complex 
(Shresta et al., 1998). Further downstream substrates of this pathway causes activation of the 
caspases and instructs cells to commit suicide. Another contact dependant, although less 
important, killing by CTL is by TRAIL (TNF related apoptosis inducing ligand). TRAIL is 
expressed by various immune cells of the body including CTL and binds to its receptor on the 
target cells mediating their apoptosis similar to FasL (Hersey & Zhang, 2001). 
 
1.3 T cell Development and Tolerance – Relevance to Cancer 
 
Cells destined to become T cells differentiate from the pluripotent stem cells and leave bone 
marrow to travel to the thymus where further development and selection of T cells occurs. T cell 
receptor is formed by combination of α and β chains or γ and δ chains, which is similar to 
combination of light and heavy chains of immunoglobulin molecules. Both chains consist of a 
variable region (V) and a constant region (C). The genes encoding the variable regions consist of 
V and J segments for α chain and V, D and J regions for β chain. Each of the individual segments 
is encoded by multiple genes and recombination of these different gene segments results in the 
extraordinary diversity of the TCR. Recombination of the non-contiguous segments encoding the 
variable region of the T cell receptor, imprecise joining of “nicked” segments, addition of non-
germline nucleotides by DNA repair machinery and different pairing of the TCR α and β chains 
results in generation of more than 1 x 1015 αβ TCRs (Zuniga-Pflucker, 2004). However, this 
repertoire undergoes selection process in the thymus which reduces the diversity of the TCRs by 
3 to 100 fold (Zuniga-Pflucker, 2004). Lymphoid progenitors entering the thymus are double 
negative (DN) (CD4-CD8-) and following various stages of development, selection and lineage 
commitment, become single positive (SP, CD4+ or CD8+) and enter the medulla where they 
undergo central tolerance mechanisms before exiting to form the peripheral T cell repertoire (Fig 
1.10). 
Some of the TCRs on these thymocytes never bind to any MHC-peptide complex and are 
deprived of the survival signal provided by this interaction and thus undergo death by neglect. 
Thymocytes expressing TCR having very high affinity for any of the peptide-MHC complex are 
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eliminated by negative selection as these could lead to auto-immune reaction. However, the 
negative selection of T cells is not perfect and sometimes potentially auto-reactive T cells are 
released into the periphery (Anderton & Wraith, 2002). Lastly, the cells bearing TCR which 
binds to MHC-peptide complex with medium affinity receive a survival signal and these are 
positively selected. This T cell selection and the following lineage commitment occur in the 
thymic cortical region. Following lineage commitment, CD4+ and CD8+ T cells venture into the 
medulla where the stringent central tolerance mechanisms ensures that most of the tissue self-
antigen reacting T cells are deleted. Previously it was assumed that thymic cortical epithelial cell 
(TECs) do not express tissue specific antigens (TSA) and T cells reactive against them are dealt 
by other mechanisms i.e. regulatory T cells in the periphery. However, it has now been shown 
that the TECs, mainly medullary TEC (mTEC), normally express various TSA, a phenomenon 
termed as ‘promiscuous gene expression’ (Kyewski et al., 2002). By virtue of promiscuous gene 
expression, mTEC are perhaps the most important cells involved in the central tolerance, as they 
not only select the T cell repertoire against various self-antigens generally expressed in all cells 
but also eliminate T cells against numerous tissue specific antigens. Finally, after stringent 
quality control mechanism these CD4+ and CD8+ T cells migrate to the periphery and constantly 
analyse the peptides presented by the antigen presenting cells as well as other cells to identify 
any pathogenic invasion. 
 
Thus during the development of T cells, various mechanisms ensure to eliminate or anergise T 
cell clones with a potential to react against self antigens. And since most commonly shared 
tumour antigens are ‘over-expressed’ self antigens, to overcome tolerance and generate an 
immune response to these, remains a formidable challenge. 
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Figure 1.10:- Development of the lymphoid progenitor cell into SP T cells in the thymus  
(Taken from Zuniga-Pflucker, 2004) 
 
1.4 Cancer Vaccines 
 
Prevention of infectious diseases through vaccination has been immensely successful for 
diseases such as small pox, polio, tuberculosis, mumps etc. Traditionally vaccination is 
considered as a prophylactic therapy, where vaccination generates a memory response and 
prevents future infections by the infectious organisms. However, cancer vaccination can be 
subdivided into prophylactic and therapeutic vaccines.  
Data from numerous animal studies have shown the ability of different vaccines to generate 
antigen specific immune response and preventing the growth of tumour (expressing the particular 
antigen) in animals challenged. Prophylactic vaccines, although successful are not applicable in 
most cases of cancer, as it is difficult to predict cancer occurrence in humans. In cancers of 
known viral etiology, immunisation is able to prevent viral infection and consequent cancer 
development as observed in remarkable success of prophylactic human pappilloma virus 
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vaccines against cervical cancer (Harper et al, 2006; Koutsky et al, 2002). Similar vaccines may 
also be applicable for other virus induced cancers, such as hepatic cancer (hepatitis B/C virus). 
However, most human cancers are caused by mutations in normal cellular genes and predicting 
these mutations is complex. It may be possible in the future to base on the epidemiological data 
and genetic analysis, predicting a person’s susceptibility to particular types of cancer would be 
accurate enough to justify their prophylactic immunisation targeting common oncogenes. 
However, immunisation against known ‘self-antigens’ can induce auto-immune response and 
risk-benefit ratio will have to be properly evaluated in such cases. 
Thus far, most of the cancer vaccination studies have targeted their use for therapeutic 
application in humans. Unless stated otherwise, the term cancer vaccines will mean therapeutic 
vaccines.  
 
(i) Whole Cell Vaccines:- Whole cell vaccines consist of irradiated autologous or allogeneic 
tumour cells, with or without any in vitro modifications and many clinical trials have explored 
this method of cancer vaccination. Earlier clinical trials using autologous or allogeneic tumour 
cells, without any modification met with limited success. Subsequently, various approaches have 
been used, where the tumour cells have been modified in vivo to express either co-stimulatory 
molecules or secrete cytokines to enhance their immunogenicity (Ali et al., 2000; Palmer et al., 
1999). In a phase I clinical trial of prostate cancer patients vaccinated with irradiated autologous 
prostate tumour cells engineered to secrete GM-CSF, most patients generated prostate antigen 
specific T and B cell response (Simons et al., 1999). In metastatic melanoma patients immunised 
with autologous melanoma cells modified to secrete IL-12 cytokine, thus favouring the 
generation of a Th1 response and activation of the innate and adaptive immune system (Sun et 
al., 1998; Trinchieri, 2003), two of the seven patients developed DTH reaction to the autologous 
tumour cells, whereas one patient had a minor clinical response and generated tumour specific 
CD4+ and CD8+ T cell infiltrates into the metastases (Sun et al., 1998). This approach is 
restricted by the inability to generate large number of autologous tumour cells and is clinically 
impractical for larger clinical trials. 
 
Most of the recent clinical trials have been conducted using modified allogeneic tumour cell lines 
as they can be genetically modified and cultured to large numbers prior to injection.  Moreover 
cross presentation of antigen to T cells by the APCs does not require the tumour cells to be MHC 
matched with the recipient. One concern regarding the long term cultured cell lines relates to 
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changes of their antigenic profile, immunogenicity and gene expression; thus quality control and 
consistency of the vaccine is a central issue. 
 
(ii) Heat Shock Protein Vaccines:- Heat shock proteins are a large family of ubiquitously and 
inducible proteins involved in transport of intracellular peptides and assist in the folding and 
unfolding of proteins along with a host of other functions (Srivastava & Amato, 2001). Rejection 
of autologous tumours by animals immunised by HSP derived from the tumours, led to the 
identification of their role as a promising approach to cancer immunotherapy. The ability of 
tumour derived HSP to generate anti-tumour responses has been demonstrated for hsp gp96, 
hsp70, hsp90, hsp110, grp170 and calreticulin (Binder et al., 2004). Because HSP are involved in 
peptide transport to the endoplasmic reticulum, immunisation with purified HSP would 
potentially generate an immune response against all the peptides in the cell, bypassing the need 
for individual epitope determination as well as MHC restriction. HSPs seem to have an intrinsic 
adjuvant property and binding to specific receptors on APC results in their maturation and 
internalisation of the HSP-peptide complex followed by internal processing and presentation of 
HSP-associated peptides on MHC class I and II molecules (Singh-Jasuja et al., 2000). This 
property of HSPs could be extremely important as not only are they the first and only “natural” 
adjuvants of mammalian origin but they also fail to elicit an immune response to themselves and 
can generate a response to very low levels of bound peptide compared to conventional peptide 
immunisation (Nieland et al., 1996). HSP have been referred to as the ‘swiss army knives’ of the 
immune system due to their multiple roles in CTL and antibody generation as well as activation 
of DC and NK cells (Schild & Rammensee, 2000; Tamura et al., 1997). It has also been 
suggested that HSPs might be able to overcome tolerance to tumour cells by virtue of their 
ability to activate APC, and generating co-stimulatory signals (Li et al., 2002). In most of the 
HSP clinical trials vaccination was performed, following surgical excision of the primary 
tumour, HSP-peptide complexes were purified from the tumour and the autologous complexes 
were injected back into the patient. In one such trial, out of sixteen renal cell carcinoma patients 
immunised with 25μg of autologous tumour derived hsp gp96, three patients demonstrated 
complete tumour regression, three had partial responses and three showed prolonged stabilization 
of the disease (Amata et al, 1999, Srivastava, 2005). 
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Table1. 4 Examples of different Types of Cancer Vaccines used in clinical trials 
 
 
Vaccine Type 
 
Trial Details Results Reference 
Whole Cell Vaccines Prostate cancer patients  
immunised with irradiated  
autologous cells secreting  
GM-CSF 
 
 
Melanoma patients, autologous  
cells secreting IL-12 
 
Prostate cancer patients injected 
with 3 ID doses of allogeneic 
prostate cancer cells with BCG 
adjuvant 
 
Phase I clinical trial of 8 patient 
7/8 DTH responses, antibodies 
detected in 3/8 patients. No 
significant clinical response 
 
 
2/7 DTH responses, 1 minor  
clinical response 
 
PSA levels decreased in 11 of 
26 patients. Increased median 
time for disease progression of 
58 weeks vs 28 weeks for 
controls 
Simons et al, 1999. 
 
 
 
 
 
Sun et al, 1998. 
 
 
Michael et al, 2005. 
Heat Shock Proteins 300 Stage IV melanoma patients 
 
 
HSP (gp96) vaccine prepared for 
17/20 non hodgkins lymphoma 
patients enrolled in phase II 
clinical trial 
 
16 renal cell cancer patients 
injected with 25μg of Autologous 
HSP vaccine 
Increased survival observed in 
 vaccinated patients 
 
Stable disease in 8 patients 
from 6 to 19.8 months. 
1 patient had partial response. 
 
 
3 complete tumour regression, 
3 partial responses and 3 
disease stabilisation 
Srivastva PK, 2006. 
 
 
Oki et al, 2007. 
 
 
 
 
Amata et al, 1999. 
Peptide Vaccines 23 melanoma patients immunised 
with either gp100 peptide alone or 
with IL-2 
 
 
 
13 advanced melanoma patients 
 immunised with modified  
peptide plus IL-12 
 
Stage IV melanoma patients 
 immunised with peptides from  
melanoma antigens 
Post vaccination peptide 
specific T cell frequency 
increased in most pateitns but 
no tumour regression was 
observed 
 
Clinical regression of  
metastases observed in 13 out 
 of 31 patients 
 
No objective clinical response  
although few disease 
stabilisations 
Lee et al., 1999. 
 
 
 
 
 
Rosenberg et al, 1998.
 
 
 
Hersey et al, 2005. 
DNA vaccines Stage IV melanoma patients 
injected intranodally with  
plasmid vaccine 
 
22 metastatic melanoma patients 
were administered gp100 plasmid 
vaccine either ID or IM 
 
 
Phase I study of MART-1 
plasmid vaccine in patients with 
resected melanoma 
11 out of 26 immunological 
 responses with longer survival 
in 50% patients 
 
1 partial response, rest all had 
progressive disease. No patient 
showed T cell responses against 
gp100. 
 
No immunological or clinical 
responses observed 
Tagawa et al, 2003. 
 
 
 
Rosenberg et al., 2003.
 
 
 
 
Triozzi et al, 2005 
Dendritic cell  
vaccines 
16 melanoma patients immunised
with DC pulsed with cell lysates 
 or cocktail of peptides 
 
5 objective clinical responses  
(2 complete and 3 partial) 
 
 
Nestle et al, 1998. 
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17 metastatic renal cell carcinoma 
immunised with autologous tumou
to DC 
 
Phase I trial of 13 metastatic 
prostate cancer patients, DC 
transfected with autologous 
tumour derived mRNA were 
injected 
Objective clinical response in  
7 out of 17 patients (41%) 
 
 
In 6 patients, transient 
decrease of serum PSA was 
observed, although no long 
term clinical benefits 
Kugler et al, 2000 
 
 
 
Heiser et al., 2000. 
Recombiant viral  
vaccines 
Melanoma patients immunised  
with canary pox virus encoding  
gp100 
 
 
 
16 melanoma patients immunised
 with recombinant adenovirus 
expressing MART-1 
 
30 metastatic melanoma patients 
were injected with ALVAC virus 
encoding MAGE peptides 
44% patients generated antigen 
 specific response on virus 
vaccination but not peptide 
vaccine. No objective clinical 
response 
 
One complete response. Other 
patients had non-specific 
clinical responses due to IL-2  
 
1partial response and 2 
patients had disease 
stabilization. Evidence of CTL 
induction observed and 
correlated with clinical 
response 
Spaner et al, 2006. 
 
 
 
 
 
Rosenberg et al, 1998.
 
 
 
Van Baren et al, 
2005. 
Cellular Adaptive  
T cell Therapy 
Myeloablative chemotherapy  
followed by autologous TIL  
transfer 
 
Melan-A specific T cell clones 
injected in 10 metastatic 
melanoma patients with IL-2 and 
IFN-α 
Regression of metastases  
observed in 18 out of 35 
 patients (>50%) 
 
1 complete response and 6 
partial regression of metastasis 
or disease stabilisation. 
‘Epitope spreading’ observed 
Dudley ME et al, 2005.
 
 
 
Vignard et al, 2005. 
 
 
(iii) Peptide Vaccines:- Any peptide presented by the MHC molecule on the surface of tumour 
cells is a potential target for cancer immunotherapy. In 1992, the first study to identify a nonamer 
peptide recognized by cytotoxic T lymphocytes in cancer patient was published (Traversari et 
al., 1992). Since then, several studies have identified immunogenic peptides presented by the 
tumour cells in vivo and recognized by the cytotoxic T lymphocytes in cancer patients (Romero 
et al., 2004). Peptide vaccines can be easily produced under GMP conditions, are relatively 
cheap and seldom responsible for serious side effects. These properties have made peptide 
vaccines the most attractive candidate for cancer immunotherapy in the past decade. A number 
of clinical trials have been conducted using peptide vaccines, where initial trials involved 
immunising patients with MHC class I restricted peptides alone; in some instances peptide 
specific CTLs were generated but this immunological response delivered little clinical responses 
if any (Boon et al., 2006; Lee et al., 1999). However, most of the other clinical trials have not 
generated encouraging results. In two recent independent clinical trials of stage IV melanoma 
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and CML patients, immunising with peptide vaccines containing epitopes from melanoma 
antigens (gp100, MART-1, tyrosinase and MAGE-3) and bcr-abl protein respectively, no 
objective clinical response in terms of tumour regression or remission induction was observed 
(Cathcart et al., 2004; Hersey et al., 2005). Experience from animal models showed that for an 
effective and lasting response leading to tumour regression, it was essential to activate CD4+ T 
helper cells. This has led to intensification in the efforts to identify MHC class II restricted 
peptides (Rojas et al., 2005; Zarour et al., 2000). Recent trials have used a combination of MHC 
class I and II peptides, but available evidence is limited and further investigation is required.  
 
Limited clinical efficacy of the peptide vaccines can be attributed to a number of reasons 
including not being potent enough to break tolerance, immune escape, source of the MHC class 
II peptides (expressed by tumour cells) as well as the adjuvant and dose/schedule used for 
immunisation. Several approaches are currently been investigated to improve the potency of 
peptide vaccines. Modification of the anchor amino acids of the peptide can increase its binding 
affinity to MHC and TCR, inducing stronger immune response against tumour cells expressing 
native peptides. This approach has proved clinically beneficial in a significant clinical trial 
(Rosenberg et al., 1998). Peptide vaccines delivered through liposomes, nanobeads or in 
combination with CpG oligonucleotides have all shown an improved ability to generate high 
avidity CTLs; these approaches aim to deliver the peptide vaccines efficiently to the APC 
(Engler et al., 2004; Fifis et al., 2004). 
 
(iv) Dendritic Cell Vaccines:- DC being the most important antigen presenting cells, have been 
extensively used in immunotherapeutic approaches where antigen has been directed to them or 
where DC themselves have been modified and injected back into the same patient. Although in 
most mouse models DC have been derived from the bone marrow, in human clinical trials, DC 
have mostly been generated from the CD34+ monocyte precursors from blood by culturing them 
in vitro in the presence of GM-CSF and IL-4 (Caux et al., 1996).  
Over the years, researchers have devised various methods of manipulating DC for 
immunotherapeutic approaches (Banchereau & Palucka, 2005; Gilboa et al., 1998). Initial work 
involved pulsing DC with synthetic peptides from known antigens such as MART-1, tyrosinase 
or gp100 (Fong et al., 2001; Yu et al., 2001). However, the limitation of this strategy to specific 
MHC haplotypes led to either pulsing DC with antigens/tumour cell lysates or genetically 
engineering DC to express specific tumour antigens (Hsu et al., 1996; Lambert et al., 2001). 
These strategies preclude any knowledge of patient MHC type and are broadly applicable. 
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Another novel strategy has been to create hybrids of DC and tumour cells as these combine the 
whole antigen repertoire with the antigen stimulating capabilities of the DC (Rosenblatt et al., 
2005). “Feeding” DC with tumour cell lysates or eluted peptides requires access to a relatively 
large quantity of the patient tumour, which is not always feasible. Hence, more recent work has 
focussed on transfecting DC with messenger RNA derived from the tumour cells (Heiser et al., 
2000). Obtaining tumour tissues for nucleic acid isolation requires much less tissue along with 
advantage of being able to be combined with laser capture micro-dissection to specifically isolate 
tumour cells without surrounding normal  cells. Modifying DC to secrete immuno-stimulatory 
cytokines such as IL-2, IL-12 or IFN-α along with the expression of tumour antigens can 
enhance the magnitude of the CTL responses in murine models (Huttner et al., 2005; Kuwashima 
et al., 2005). Several clinical trials have reported encouraging results by using allogeneic or 
autologous DC (Dallal & Lotze, 2000; Murphy et al., 1996). 
 
Before DC based vaccination can be widely applicable in humans, several key points need to be 
addressed. DC consists of several different subsets and some of these can actually suppress the 
immune response instead of augmenting it. One study reported DC generated using IL-15 to be 
more potent stimulators of CTL response than IL-4 cultured DC (Mohamadzadeh et al., 2001). 
Hence, vaccination with the optimum DC subset in generating CTL responses will be crucial. 
Another recent study reported the presence of a novel interferon secreting killer DC (IKDC) 
subset in mice, which are capable of killing tumour cells as well as acting to present antigen; 
which property was predominantly dependent on activating factors (Chan et al., 2006). The 
existence of such a subset of DC in humans and whether they can be harnessed for 
immunotherapy remains to be proven.  The maturation status of the cells and method of 
maturation is another important consideration (Dhodapkar et al., 2001). Most groups use a 
cocktail of pro-inflammatory cytokines IL-1β, TNF, IL-6 and Prostaglandin E2 for DC 
maturation. However, another group reported a combination of IL-1β and TNF with type I and II 
interferons to yield more potent DC for the induction of CTLs (Banchereau & Palucka, 2005). 
Among other considerations the major ones are the site of vaccination, dose, schedule and the 
pre-conditioning of the DC and injection site. A recent study generated engineered DC with drug 
inducible CD40 molecule, which is a potent means of promoting CTL generation and clearing 
established tumours in murine model (Hanks et al., 2005). To overcome the possible limitation 
of generating larger number of DC from patients, several groups are enduring to develop 
artificial APC (Kim et al., 2004). 
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(v) DNA Vaccines:- DNA vaccines consist of an antigen encoding gene on a bacterial plasmid 
backbone.  Compared to peptide vaccines, which would be restricted to specific MHC 
haplotypes, DNA vaccines are unrestricted and can generate CTLs against multiple epitopes, 
being able to generate B cell as well as T cell immune responses (Pavlenko et al., 2004). Unlike 
viral vaccines, DNA vaccines are not influenced by the neutralizing antibodies against the viral 
vector. DNA vaccines can be administered in a number of ways such as intramuscular, 
intranasal, intramucosal or could be administered into the dermis by coating them onto gold 
particles and administered using a gene gun (Babiuk et al., 2003). Injected DNA can either be 
taken up by the somatic cells or the residing antigen presenting cells, depending on the site of 
immunisations. In the case of DNA transfecting somatic cells, APC pick up antigen by cross-
priming and their role is vital in initiating the immune response. The route of immunisation with 
DNA vaccines seems to be important as several studies in animal models have showed that 
intramuscular immunisation preferentially generates a Th1 response, whereas immunising with 
the gene gun generates a Th2 response, although this method requires 100 times less antigen 
(Weiss et al., 2002).  
 
DNA vaccination can be used in conjunction with other vaccination methods i.e. transfection of 
dendritic cells with plasmids encoding for tumour antigen or co-stimulatory/cytokine genes prior 
to injecting them. DNA vaccines, by virtue of intrinsic CpG motifs, provide the necessary danger 
signals leading to optimum activation of the APC. Recently, it has been shown that along with 
tumour antigen encoding plasmids, co-administration of plasmids encoding for dendritic cell 
chemotactic and growth factors enhances the antigen specific response in mouse models (Kim et 
al., 2000).  DNA vaccines encoding multiple class I and II peptide epitopes have also been 
designed for HIV and malaria targeting either the MHC class I or II processing pathway by 
addition of specific signalling sequences (Velders et al., 2001). DNA vaccines by themselves are 
considered weakly antigenic; however when used in combination with viral vectors in a ‘prime-
boost’ strategy they appear to be highly effective in generating antigen specific responses. 
Priming with plasmid vaccine followed by boosting with recombinant virus was shown to be 
highly effective compared to either of them alone (Amara et al., 2001). 
 
(vi) Recombinant Viral and Bacterial Vaccines:- Viral and bacterial vectors are considered as 
the most promising approaches to stimulate potent immune response, especially to ‘self antigens’ 
by activating the APC due to their intrinsic high immunogenicity and the immune system’s 
capacity to react to them.  Retrovirus, poxvirus, alphavirus, adenovirus and herpes simplex 
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viruses have been investigated in several animal models and shown to be effective in promoting 
anti-tumour immunity (Bonnet et al, 2000). Viral vectors can be injected systemically or intra 
tumourally and used to modify tumour cells ex vivo prior to injection (Ali et al, 2002).  Many 
viral vectors are disabled and safe to administer and ideally should infect dividing and non-
dividing cells and have the capacity to accept large inserts of genetic information. Adenovirus 
has also been shown to be extremely potent in the generation of immune response in animals, 
however their efficacy in humans could be limited as about 85% of the population has antibodies 
against common serotypes. Recombinant alphaviruses are potentially very safe vectors that could 
be used as they need to be co-transfected with a helper plasmid for the generation of infective 
viral particles. Moreover they induce apoptosis upon infection which would facilitate cross-
priming of the antigens. The immunotherapeutic potential of Disabled Infectious Single Cycle-
Herpes simplex virus (DISC-HSV) in a murine tumour model has been extensively investigated 
(Ahmad et al., 2005). It was shown that injecting DISC/GM-CSF virus intratumorally, led to 
tumour rejection in up to 70% of the mice and combining this with other modalities increased its 
therapeutic benefit (Ali et al, 2002; Ali et al, 2004).  
 
Recombinant bacterial vaccines from strains such as salmonella, BCG and Listeria 
monocytogenes are promising novel vectors for cancer immunotherapy since they can potentially 
be administered orally and are capable of infecting APCs directly. The dual phagolysosomal and 
cytoplasmic life cycle of listeria monocytogenes allows efficient processing of both MHC class 
II and class I antigens respectively (Gentschev et al., 2005; Weiskirch et al., 2001). 
 
(vii) Novel vaccine delivery systems:- Limited clinical responses by most clinical trials till date 
have compelled researchers to look for novel delivery vehicles and strategies to enhance the 
delivery of vaccines in order to generate more potent immune responses. Liposomes have the 
ability to deliver “drugs” directly to the cytosol of the cells by fusion with the cell membrane and 
releasing the drug internally. This property has been exploited to deliver antigens to APC and 
liposomes containing tumour antigens have also been shown to generate antigen specific 
responses (Mandal & Lee, 2002). Liposomal vaccination has been shown to be clinically safe 
and effective in generating long lasting CD4+ and CD8+ T cell responses in animal models and 
in patients with advanced stage follicular lymphoma. Antigens, either coupled to beads made of 
iron, silica or latex, or trapped in poly-lactide-co-glycolide (PLG) microspheres, have been 
shown to generate CTLs and in some cases are able to provide tumour protection in animal 
models (Tartour et al., 2000).  Exosomes have recently emerged as an alternative novel method 
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of immunisation. Exosomes are small membrane vesicles which are released from various cell 
types during fusion of multivesicular bodies with the plasma membrane (Cho et al., 2005), and 
carry both MHC class I and II antigens along with co-stimulatory molecules. These exosomes 
can be purified from various tumour cells and loaded with peptide ex vivo before injecting them 
into the patients. To overcome the reluctance of using viral vectors especially in 
immunocompromised cancer patients, virus like particles (VLP) have been designed, which 
consist of self-assembled proteins, derived from the viruses. These VLP are believed to be safer 
than conventional viruses and have similar potency. However, further research will be required 
to prove the clinical efficacy of these novel delivery vehicles. 
 
(viii) Cellular Adoptive T cell Transfer:- One of the major limitations for cancer immunotherapy 
has been their inability to generate sufficient numbers of activated CTL. To overcome this, 
Rosenberg et al have pioneered cellular adoptive therapy, where tumour infiltrating lymphocytes 
(TIL) are isolated from autologous tumours, expanded and activated in vitro before being 
injected back into the patients. His group has recently shown that patients receiving 
myeloablative chemotherapy in the form of cyclophosphamide and fludarabine, followed by 
adoptive T cell transfer of autologous TIL, generated objective clinical response (>50% tumour 
reduction) in 18 out of 35 treated patients (Dudley et al., 2005; Rosenberg & Dudley, 2004). 
Regression of metastasis in these patients was observed in sites such as lung, brain, liver, lymph 
nodes and subcutaneous tissues (Dudley et al., 2005). Alternative novel strategy has been to 
clone tumour antigen specific T cell receptor into autologous T cells prior to injecting these 
engineered T cells back into patients. Local IL-2 support is essential for the activated T cells in 
vivo, however exogenous IL-2 administration to patients can have serious side affects. Hence, 
TILs engineered to contain the IL-2 gene are being developed, the local secretion of which 
would promote their own growth (Rosenberg & Dudley, 2004). In a recent clinical trial, adoptive 
transfer of Melan-A specific T cells in melanoma patients, not only provided clinical regression 
in some patients but it also led to expansion of T cells of higher avidity for other Melan-A 
epitopes, suggesting that some of the remarkable success of adoptive transfer can be attributed to 
the ‘epitope spreading’ phenomenon (Vignard et al, 2005). 
 
1.5 Tumour Immune Escape 
 
Despite the extraordinary success of several vaccination approaches in animal models, their 
application in humans have had limited clinical benefit. Current research is serving to unravel the 
complexities of the immune system and cancer, which is leading to discovery of novel 
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vaccination strategies to overcome the immune escape and tolerance mechanisms. One of the 
major reasons for this is that cancers in humans unlike animal models evolve over many years 
and undergo selection process to generate cells which are not only less immunogenic but are in 
fact immunosuppressive. Tumours can develop multiple escape mechanisms, even in the same 
individual. These mechanisms can be broadly classified as escape from detection, lack of 
susceptibility to killing and tumour induced immuno-suppression (Malmberg & Ljunggren, 
2006; Muller et al., 2002). 
 
(i) Escape from Immune Recognition Detection: - Immunosurveillance mechanisms detect any 
developing tumour and eliminate them via adaptive and innate immune cells. However, tumours 
develop mechanisms to evade these cells by various mechanisms such as loss of antigen, defects 
in the antigen processing, loss of presenting MHC molecules as well as up regulation of 
inhibitory receptors. Targeting a single antigen can lead to loss or down regulation of that 
antigen. Adoptive transfer of T cells specific for Mart-1 antigen led to selective down regulation 
of Mart-1 in the recurrent metastases while retaining the expression of other melanoma antigens 
gp100 and tyrosinase (Yee et al., 2002). Another important mechanism might be a mutation in 
the antigen which would affect the processing and presentation of the targeted epitope 
(Hoffmann et al., 2000). Similar cases have been documented with other forms of vaccination; 
hence it is crucial to target antigens which provide a growth advantage to the cancer cells making 
their loss difficult. However, this might be insufficient as antigen processing and presentation 
defects can occur independent of antigen loss. Various defects such as total loss of MHC class I,  
specific loss of HLA-haplotype locus, allele loss or mutations in proteins involved in antigen 
processing and transport (TAP) have been reported in a number of human tumours. HLA class I 
down regulation has been observed in about 16-50% of solid tumours including cancers of 
breast, lung, colon, cervix, prostate and melanoma (Chang et al., 2004; Rees et al., 1988). 
Mutations or defects in the production of β2 microglobulin chain results in total HLA loss as the 
class I chains are not assembled in the ER (Rosenberg et al., 2003). In the extensively 
investigated DISC-GMCSF/CT-26 tumour model, escape mechanisms were investigated in 
responder and non-responder mice on application of viral therapy following tumour inoculation. 
In this model, approximately 60% of mice with progressive tumour growth displayed MHC class 
I down-regulation (which was reversible on in vitro culture), whereas no change was observed in 
animals with regressive lesions. These experiments clearly demonstrate the importance of this 
mechanism in generating escape variants and tumour progression (Ahmad et al., 2004; Ali et al., 
2002). However, total loss of HLA molecules would make these cells susceptible to NK cell 
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mediated killing in accordance with the ‘missing self’ hypothesis. To counteract this, cancer cells 
can selectively lose particular alleles which are targeted by immune cells and/or express minor 
HLA antigens which would inhibit the NK cells.  
 
A numbers of human tumours are known to express stress related molecules like MICA and 
MICB which can be recognised by the NKG2D receptors on NK cells leading to their activation 
and tumour cell lysis. To avoid this NK mediated killing, tumour cells can shed MIC molecules, 
which not only avoids their recognition but also leads to deactivation of the NK cells. Soluble 
MIC molecules have been detected in the serum of cancer patients and their binding to NKG2D 
receptors causes their endocytosis and degradation, thus contributing to inefficient NK cell 
mediated immunosurveillance (Holdenrieder et al., 2006).  
 
(ii) Lack of Susceptibility to Immune killing:- Another important mechanism of escape is 
decreased susceptibility to killing by the T and NK cells. T cells mediate tumour lysis mainly by 
granzyme/perforin pathway or death receptors Fas and TRAIL.  
 
Granzyme B can be inhibited by serine protease inhibitor (PI-9) and is generally produced by 
activated T cells. In physiological conditions its role might be to prevent degranulation and 
destruction of dendritic cells by activated T cells. However, several human tumours also over 
express PI-9 rendering them resistance to granzyme B mediated cytotoxicity (Malmberg & 
Ljunggren, 2006). Cathepsin B is another such enzyme, which can inactivate perforin and is 
expressed by human tumours. Receptor mediated apoptosis can be overcome by tumour cells 
through expression of decoy receptors, soluble FasL or down regulation of death receptors. 
Death receptors Fas and TRAIL consist of cytoplasmic ‘death domains’, which are activated on 
binding of ligands triggering the downstream caspases and ultimately leading to apoptosis of 
tumour cells. Certain tumours can express decoy receptors (TRAIL-R3 and TRAIL-R4) which 
lack these death domains making them resistant to apoptosis on ligand binding. Another 
important molecule expressed in certain cases is the flice inhibitory protein (c-FLIP), which 
inhibits caspase 8 activation and apoptosis mediated by death receptors such as Fas and DR5 
(Longley et al., 2006). Inhibiting the expression of c-FLIP was sufficient to sensitise human 
renal cell carcinoma cells in vitro (Brooks and Sayers, 2005). Over expression of other anti-
apoptotic molecules such as survivin and bcl-2 has also been reported in certain cancer patients. 
However, tumour cells are also known to express FasL, which could bind to Fas molecules on 
the T cell surface leading to their apoptosis. 
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(iii) Tumour Mediated Immunosuppression:- Tumour cells can directly inhibit the immune 
response via secretion of immunosuppressive cytokines such as TGF-β and IL-10 and high levels 
of these cytokines have frequently been reported in cancer patients. Vascular endothelial growth 
factor (VEGF) secreted by many tumours not only helps in tumour neo-vascularisation but is 
also known to suppress transcription of NF-κB, thereby preventing DC maturation and activation 
(Oyama et al., 1998). Recently, in a very elegant model of sporadic immunogenic tumour model, 
Willimsky and Blankenstein showed that tumours do not escape immune detection by losing 
their intrinsic immunogenicity but they induce tolerance and expansion of non functional T cells 
(Willimsky & Blankenstein, 2005). In this model, immunised mice remained tumour free 
throughout life whereas all non-immunised mice developed progressive tumours, thereby 
suggesting that existing T cells in non immunised mice to be tolerant and unable to mediate 
tumour rejection. This suppression could be a result of tumour antigen presentation to the T cells 
without any co-stimulatory molecules, making them anergic (Abken et al., 2002). Another 
frequently employed mechanism by the tumour cells is the production of enzyme Indoleamine 
2,3-di-oxygenase (Muller et al., 2005). IDO is ubiquitously expressed by normal tissues and 
catalyzes the rate limiting step in degradation of tryptophan. Over-expression of IDO at tumour 
sites depletes the essential amino acid tryptophan in the vicinity leading to growth arrest of T 
cells. Another possibility is that certain regulatory subsets of dendritic cells are also induced to 
produce this enzyme providing additional protection to the tumour cells (Munn et al., 2004). 
 
One of the most important immunosuppressive mechanisms is thought to be the induction of 
TReg cells. TRegs account for 2-5% of the total CD4+ T cell population in humans. 
Conventional TRreg are identified by CD4+CD25+Foxp3+ phenotype although other variants 
are also known. Regulatory T cells consist of mainly two subtypes, natural and induced. 
Naturally occurring TReg cells are likely to be selected in the developing thymus and maintain 
peripheral tolerance to self-antigens. Organ specific antigens expressed ectopically in the thymus 
could lead to the generation of these suppressor cells (von Boehmer, 2005). These TRegs can 
protect tumour cells since most of the tumour antigens are in fact ‘self-antigens’. Moreover, 
tumour cells can also induce TReg development for their survival. Initially, it was suggested that 
TReg act in an antigen independent manner, however, recent studies have identified antigen 
specific TRegs (Wang et al., 2004). One possibility is that tumour cells induce the development 
of these CD4+CD25+ cells from the CD4+ population of cells via immunosuppressive cytokines. 
Also, sub-immunogenic conditions during antigen presentation can lead to the generation of 
TReg (von Boehmer, 2005). The importance of this subset of T cells is underlined by the fact 
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that their deletion in combination with antigen specific immunotherapy has resulted in tumour 
regression of well-established poorly immunogenic tumours (Sutmuller et al, 2001). TReg cells 
have been shown to inhibit the proliferation of antigen specific CD4+ and CD8+ T cells in an IL-
10 and TGF-β dependant manner (von Boehmer, 2005). TGF-β has been suggested to be 
involved in certain cases but most studies suggest this suppression to be cell contact dependant 
(von Boehmer, 2005). The precise mechanism of TReg mediated suppression still remains 
controversial especially in vivo. Other well documented suppressor cells are the NKT cells and 
the immature myeloid cells. It has been suggested that the NKT cells produce IL-13, which 
activates the immature myeloid cells to produce TGF-β (Terabe et al., 2003; Terabe et al., 2004). 
Fortunately, this suppression is reversible and these tolerant T cells can be rescued by culturing 
them in cytokines such as IL-15 (Teague et al., 2006). 
 
Certain groups have also demonstrated shedding of minor HLA antigen HLA-G by tumour cells 
which induce apoptosis in antigen specific CD8+ T cells and NK cell inhibition (Chang et al., 
2004). 
 
1.6 MTA1 as a target for immunotherapy of cancer 
 
In spite of the remarkable progress in medical diagnostics over the past few years, many cancer 
patients are still diagnosed in the terminal stages of the disease, at which point the conventional 
modalities of treatment are mainly palliative. Over the last 25 years, incidence of cancer has 
increased by 24% in the UK. This has fuelled an interest in the identification of antigens 
involved in the metastatic progression of the cancer and their potential application for therapy. 
Some of the genes associated with metastases are the WNT5A, WNT11, HMG-1(Y), MMP-2, 
MAP kinase phosphatase-1, WDNM1 (extracellular proteinase inhibitor), Trop 2 (tumor-
associated calcium signal transducer-2), procollagen type IV alpha, secretory leukoprotease 
inhibitor, prenylated snare protein Ykt6, ceruloplasmin and chaperonin 10 (Kluger et al, 2004; 
Xie et al, 2004; Ebralidze et al., 1989; Dear et al, 1989; Basset et al, 1990). However, most of 
the antigens identified may not be applicable for therapy or indeed immunogenic. Hence, it 
would be very valuable to identify a metastasis associated gene which is immunogenic and could 
potentially be targeted by immunotherapy for late stage diseases or in a combination therapy at 
early stages to prevent metastatic occurrence. Metastasis Associated Tumour antigen 1 (MTA1) 
is such an antigen and was recently identified in our laboratory by applying SEREX technology 
and screening of prostate cancer cDNA libraries with autologous serum (Li G et al, 
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Unpublished), suggesting MTA1 to be immunogenic, at least for generation of CD4+ T cells as 
antibody production requires help from differentiated Th2 cells from CD4+ T cells. 
 
MTA1 was originally identified using a differential cDNA library screening using rat mammary 
adenocarcinoma cells (Pencil et al, 1993; Toh et al, 1994). MTA1 gene encodes an 82 kDa 
protein. Analysis of the gene sequence of MTA1 revealed that it has a proline rich region (SH3 
binding motif), putative zinc finger DNA binding motif and a leucine zipper motif. Moreover, 
the human MTA1 protein is also rich in SPXX motifs, which are usually expressed in gene 
regulatory and DNA binding proteins. Also, it contains three nuclear localization signals 
(Nicolson et al, 2003; Nawa et al, 2000). This evidence suggests that MTA1 might be localized 
in the nucleus and act to repress transcription. Indeed, through indirect immunofluorescence it 
was found that MTA1 was mainly localized in the nucleus (Nawa et al, 2000).  
 
Histone proteins help in the organization of the DNA into nucleosomes, which are regular 
repeating structures in the chromatin and the acetylation status of the histone proteins effects 
gene expression by altering the transcription of the genes (Marks et al, 2001). Recently, it was 
shown that MTA1 might be a part of the nucleosome remodeling (NuRD) and histone 
deacetylase complex (HDAC) (Toh et al, 2000). Moreover, expression level of MTA1 correlated 
inversely with the acetylation status of histone H4 in invasive oesophageal carcinomas, which 
correlated positively with the prognosis of the patients. Hence, it has been suggested that 
strategies inhibiting MTA1 function could prove to be a novel approach to treat certain cancers 
(Toh et al, 2004). 
 
Screening of various tumours and cell lines such as breast, esophageal, colorectal, gastric and 
pancreatic cancer, has shown MTA1 to be over expressed in metastatic cells as compared to the 
primary tumour (Tang et al, 2003; Sasaki et al, 2002; Toh et al, 1999; Nicolson et al, 2003). It 
has also been shown that expression of MTA1 enhances the cellular motility and invasive 
potential of the cancer cells (Hofer et al, 2004; Mahoney et al, 2002). MTA1 expression is also 
detectable in various normal cells, although at very low levels as compared to cancer cells. 
Moreover, cells expressing higher levels of MTA1 have a faster growth rate suggesting that it 
might be involved in cellular proliferation (Nicolson et al, 2003). Furthermore, experimental 
inhibition of MTA1 protein expression using antisense phosphorothioate oligonucleotides 
resulted in growth inhibition of human breast cancer cells (Nawa et al, 2000). Thus, MTA1 
might be essential for the growth and/or invasive potential of cancer cells and hence targeting 
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MTA1 might not allow cancer cells to generate antigen loss variants. Considering the expression 
pattern and the diversity of MTA1 expression in different tumours, MTA1 might potentially be 
an ideal target for immunotherapy. However, it is also expressed in normal tissues at lower levels 
and it might be considerably difficult to generate an immune response against and that too at the 
risk of auto-immunity. But, it has been shown in the past that immune response can be generated 
against self antigens like p53 and survivin without severe adverse effects (Murakami et al, 2004; 
Reker et al, 2004; Vierboom et al, 1997). However, till date, none of the published studies have 
investigated the immunotherapeutic potential of MTA1. 
 
Human MTA1 is 85% and 96% similar to murine MTA1 at the genetic and amino acid level 
respectively (Nawa et al, 2000). Moreover, its function and distribution have also been shown to 
be quite similar, which could allow development of murine model to explore immunotherapeutic 
potential of MTA1.  
 
1.7 Aims and Objectives of the study 
This study proposes to investigate the immunotherapeutic potential of MTA1 in a murine model 
as a pre-requisite for using human MTA1 as a target for immunotherapy in patients. Firstly, 
MTA1 will be validated as a target for therapy by confirming its over expression in various 
human cancers, compared to its expression in murine tissues and cell lines. Subsequent to its 
validation, this study will attempt to generate immune response against MTA1 in murine model 
and identify peptides epitopes for immunotherapy and immune-monitoring. Considering the 
‘self-antigen’ status of MTA1, potent vaccination strategies such as DNA and viral vaccines 
(syngeneic and xenogeneic) along with depletion of Tregs might be required and will also be 
evaluated. 
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2.1 Materials 
2.1.1 Reagents 
Culture Media Company 
DMEM Bio Whittaker, Europe 
1640 RPMI Bio Whittaker, Europe 
 
Supplements added to Culture Media Company 
Foetal Calf Serum (FCS) Bio Whittaker, Europe 
2-mercaptoethanol Bio Whittaker, Europe 
Penicillin/Streptomycin Bio Whittaker, Europe 
HEPES buffer Bio Whittaker, Europe 
Fungizone Bio Whittaker, Europe 
Geniticin (G418) Bio Whittaker, Europe 
 
Other Reagents  Company 
Trypsin Gibco, UK 
Versene Gibco, UK 
Heparin Sigma, UK 
DNAase Sigma, UK 
Collagenase Calbiochem, UK 
Trypan Blue Sigma, UK 
Lipopolysaccharide Sigma, UK 
 
Molecular Grade Chemicals Company 
Molecular Grade Water  Sigma, UK 
Absolut Ethanol BDH, UK 
Isopropanol Sigma, UK 
RNA Stat 60 AMS Biotechnology, UK 
Chloroform Sigma Aldrich 
Agarose Bioline 
Tryptone Oxoid 
Yeast Oxoid 
Bacteriological Agar Oxoid 
Sodium Chloride Sigma 
Kanamycin Sigma 
Tetracyclin Sigma 
Ampicillin Sigma 
Phenol-Chloroform IsoAmyl Alcohol Sigma 
Absolute Ethanol BDH 
α-Chymotrypsin Sigma Aldrich 
Aprotinin Sigma Aldrich 
BSA Sigma 
Sucrose BDH Lab Supplies 
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PBS tablets pH 7.2-7.4 OXOID 
Acetic Acid Fisher Scientific Ltd 
Tween 20 Promega 
Sodium azide Sigma 
Trypan Blue Sigma 
Ethidium Bromide Sigma 
Sodium Chloride Fisher Scientific Ltd 
Sodium Hydroxide Fisher Scientific Ltd 
Tris Fisher Scientific Ltd 
 
Other Reagents Company 
EMLA Anaesthetic Cream Astra Zeneca, UK 
Micro Scint 0 Packard 
Tritiated Thymidine Amersham 
Chromium 51 Amersham 
Incomplete Freunds adjuvant (IFA) Gibco 
 
2.1.2 Media, Buffers and Solutions 
 
Prepared as indicated 
 
T cell Media 
Ingredients Quantity 
Complete RPMI 500 ml 
10% FCS (by volume) 50 ml 
Glutamine 5 ml 
20 mM HEPES 10 ml 
50 μM 2 Mercaptoethanol 500 μl 
50U/ml Penicillin/Streptomycin 5 ml 
0.25 μg/ml Fungizone 500 μl 
 
 
BM-DC media  
Ingredients Quantity 
Complete RPMI 500 ml 
10% FCS (by volume) 25 ml 
Glutamine 5 ml 
20 mM HEPES 10 ml 
50 μM 2 Mercaptoethanol 500 μl 
50U/ml Penicillin/Streptomycin 5 ml 
0.25 μg/ml Fungizone 500 μl 
 
 PBS-BSA wash for FACS 
 
Ingredients Quantity 
PBS tablets 10/litre 
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BSA 0.1% (1g/litre) 
Sodium Azide 0.02% (0.2 g/litre) 
 
RIP Buffer 
 
Reagent gm/500 ml mM 
Sodium Chloride 4.38 150 
Tris 3.027 50 
EDTA, anhydrous 0.931 5 
 
 
Western Blot Lysis Buffer 
 
Ingredients Quantity 
RIP Buffer 5 ml 
Igepal 50 μl 
Deoxycholate acid 25 mg 
10% SDS 50 μl 
500 mM Benzamidine 10 μl 
100 mM PMSF 5 μl 
200 mM Sodium Valrpoate 25 μl 
1 M Sodium Fluoride 5 μl 
 
Other Buffers 
Buffer Composition 
PBS 1 tablet dissolved in 100 ml distilled 
water 
 
PBA PBS 
0.1% (w/v) BSA  
0.02% (w/v) Sodium Azide  
 
TBS 10mM Tris 
150nM NaCl 
pH 7.4 
 
1 x TAE 
Freshly prepared from 10x TAE 
40 mM Tris Acetate 
1 mM EDTA 
 
Glutaraldehyde Solution 0.1 M Sodium phosphate, pH 7.0 
1mM MgCl2 
0.25% Glutaraldehyde 
 
X-Gal Solution 0.2% X-Gal 
1mM MgCl2 
150mM NaCl 
3.3mM K4Fe(CN)6 
3.3mM K3Fe(CN)6 
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60mM Na2HPO4 
40mM NaH2PO4 
 
 
2.1.3 RT-PCR Enzymes, Restriction Enzymes and Reagents 
 
Reagent Company 
M-MLV-RT Promega 
Oligo dT Primers Promega 
RNasin Inhibitor Promega 
Taq Polymerase Bioline 
T4 Ligase Enzyme Promega 
EcoRI Restriciton Enzyme Promega 
BamHI Restriciton Enzyme Promega 
XbaI Restriciton Enzyme Promega 
AgeI Restriciton Enzyme Promega 
SpeI Restriciton Enzyme Promega 
ApaI Restriciton Enzyme Promega 
Pfu Polymerase Promega 
Phusion Taq polymerase Finnzyme 
TOPO-TA vector Invitrogen 
TOPO-Blunt Vector Invitrogen 
pcDNA3 plasmid Invitrogen 
SYBR Green Master Mix Biorad 
dNTPs Bioline 
DNA ladder (1Kb plus) Invitrogen 
10X Reaction Buffer Promega 
Magnesium Chloride Promega 
 
 
2.1.4 AntiBodies and Kits 
 
Cell line/Antibody Source/Manufacturer 
Goat anti-mouse FITC Sigma 
HB54 (HLA-A2.1) Hybridoma 
Anti-MTA1 antibody Santa Cruz 
Biotechnology,USA 
Rabbit Anti Goat-HRP antibody DAKO 
CD80 Cambridge Biosciences 
CD40 Hybridoma FGK-45 
CD25-FITC Serotec 
CD11c Hybridoma 
MHC II IA/IE BD Pharmingen 
Goat Anti-Mouse MTA1 Santa Cruz Biotech 
Mouse Anti-FLAG SIGMA 
Mouse Anti-FLAG FITC SIGMA 
Rabbit anti-goat IgG – HRP DAKO 
 60
Chapter 2  Material and Methods 
 
Streptavidin – HRP Zymed, USA 
Goat Anti-Mouse – HRP DAKO 
Anti-Rat FITC Serotec 
Anti-hamster FITC Serotec 
Anti-Goat FITC Sigma 
Mouse CD4: Dynabeads Mouse CD4 Dynal, Europe 
Mouse CD8: Dynabeads Mouse CD8 Dynal, Europe 
Mouse CD4: Detach A beads CD4 Dynal, Europe 
Mouse IFN-γ ELISA kit R&D Systems, UK 
Mouse IL-4 ELISA kit R&D Systems, UK 
Anti-Human HLA-DR (L243) BD Pharmingen 
 
 2.1.5 Laboratory Plastic ware, glass ware and sharps 
 
Item Company 
T25 and T75 tissue culture flasks Sarstedt, UK 
50 ml screw top tubes Sarstedt, UK 
10 ml and 5 ml pipettes Sarstedt, UK 
20 ml Universal tubes Sterilin UK 
Centrifuge Tubes (15ml) Sarstedt, UK 
Bijou tubes (7 ml) Sterlin, SLS, UK 
FACS tubes Elkay, UK 
10 ml syringes Becton Dickenson 
BD Microlance 3 needles Becton Dickenson 
24 well and 6 well flat bottom culture dishes Sarstedt, UK 
96 well round bottom plates Sarstedt, UK 
Pasteur pipettes Sarstedt, UK 
1.5 ml eppendorf tubes Sarstedt, UK 
0.5 ml eppendorf tubes Sarstedt, UK 
1.2 ml Cryovials TPP, UK 
Pipette tips < 1ml Sarstedt, UK 
96 well ELISA plates Costar, UK 
Petri dishes Sterilin UK 
25 ml Pipettes Sarstedt, UK 
10 ml Pipettes Sarstedt, UK 
5 ml Pipettes Sarstedt, UK 
Haemocytometer Weber 
96 well plate harvester filters Perkin Elmer 
Scalpels Swann Morton Ltd. 
PCR Tubes Micronic Systems 
0.2μm Filters Sartorius, UK 
Realtime PCR tubes Strategene, Germany 
0.5 – 10μl tips Sarstedt, UK 
20 – 200μl tips Sarstedt, UK 
200 – 1000μl tips Sarstedt, UK 
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2.1.6 Electrical Equipment 
 
Equipment Manufacturer 
Refrigerated centrifuge Mistral 1000, MSE 
Flow Cytometer Beckman Coulter 
Clenz Beckman Coulter 
Isoton Beckman Coulter 
Liquid Nitrogen Freezer Forma Scientific 
-80°C Freezer Ultima II, Revco 
Class II safety cabinets Walker 
37°C incubator Forma Scientific 
96 well plate harvester Packard 
Light microscope Olympus 
96 well plate reader Tecan 
Top count scintillation counter Packard 
Drying Cabinet Scientific Laboratory Supplies 
Ltd 
PCR Thermal Cycler Hybaid, Germany 
Water Baths Grant Instruments 
Real Time PCR Thermal Cycler Bio-rad 
Microscope Nikon 
Power Packs Bio-rad 
Electrophoresis gel tanks Bio-rad 
Microwave Matsui 
UV Spectrophotometer Sanyo 
Transilluminator Ultra Violet Products 
Whirlimixer Scientific Industries 
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2. 2Methods 
 
2.2.1 Determination of MTA1 Expression by Conventional RT-PCR 
 
2.2.1.1 Cell Lines and Tissues 
Various cell lines used in this study are described below in table 2. 
 
Table2.1:- Cell Lines and their descriptions 
Name Description Media Source 
CT-26 Murine colon carcinoma DMEM+10% FCS Prof Ian Hart (St Thomas Hospital) 
CL-25 Murine colon carcinoma expressing β-galactosidase 
DMEM+10% 
FCS+G418 
Prof Ian Hart (St 
Thomas Hospital) 
B16 Murine melanoma RPMI 1640+2 mM L-glutamine 
Richard Vile 
(Hammersmith 
Hospital) 
A20 Murine B cell lymphoma RPMI 1640+2 mM L-glutamine ATCC 
RENCA Murine Renal cell carcinoma RPMI 1640+2 mM L-glutamine 
Dr. Robert Wiltrout 
(National Cancer 
Institute, Bethesda, 
MD) 
EL4 Lymphoid cells RPMI 1640+2 mM L-glutamine 
Prof Ian Hart (St 
Thomas Hospital) 
CMT 93 Murine rectal carcinoma RPMI 1640+2 mM L-glutamine 
Richard Vile 
(Hammersmith 
Hospital) 
RMA/S Lymphoblastoid 
RPMI 1640+2 mM 
L-glutamine+10% 
FCS 
Dr. Colin Brooks 
(University of 
Newcastle) 
RMA/S-
A2 Transgenic lymphoblastoid 
RPMI 1640+2 mM 
L-glutamine+10% 
FCS+G418 
Dr. F Lemonnier 
(Institut Pasteur, 
Paris) 
EL4-
HHDII 
Transgenic Lymphoid cells 
expressing HHDII molecule 
RPMI 1640+2 mM 
L-glutamine+10% 
FCS 
Dr. F Lemonnier 
(Institut Pasteur, 
Paris) 
T2 Human Lymphoblastoid 
RPMI 1640+2 mM 
L-glutamine 
+G41810% FCS 
Dr. F Lemonnier 
(Institut Pasteur, 
Paris) 
BHK-21 Syrian hamster kidney DMEM+10% FCS ATCC 
293 Human Embryo Kidney DMEM+10% FCS ICRF 
K562 Chronic Myeloid Leukaemia  
RPMI 1640+2 mM 
L-glutamine+10% 
FCS 
ATCC 
 
Murine tissues were harvested from naïve Balb/c mice and immediately snap frozen in liquid 
nitrogen and stored at -80˚ C until RNA was isolated from them. 
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2.2.1.2 RNA extraction and cDNA synthesis 
Total RNA was isolated from the cell lines and the tissues using RNA STAT-60 (AMS 
Biotechnology, UK) following manufacturer’s instructions. Briefly, the tissues were grounded to 
a powder in liquid nitrogen and 1 ml of RNA-STAT60 added to them and stored at room 
temperature for 5 minutes. 0.2ml of Chloroform was added and the homogenate shaken 
vigorously for 60 seconds and left at room temperature for 3 minutes. Samples were then 
centrifuged at 14,000 rpm for 10 minutes. The aqueous phase was transferred to a fresh 
eppendorf and 0.5 ml of isopropanol was added to them. Samples were incubated at room 
temperature for 8 minutes followed by centrifugation at 14,000 rpm for 15 minutes. Supernatant 
was discarded and the pellet washed with 75% ethanol. RNA pellet was then dried and 
resuspended in molecular grade water and the concentration and purity of the RNA was 
measured on UV spectrophotometer. 
RNA was then reverse transcribed into cDNA as follows. 2μg of RNA was taken in an eppendorf 
along with 0.5μg of oligo d(T15) primer. Tube was heated at 70˚C for 5 minutes and then placed 
on ice. Following mix was then added to the tube 
5 μl of 5x Reaction Buffer 
1 μl of dNTPs (12.5 mM) 
25 units rRNasin Ribonuclease Inhibitor 
200 units of M-MLV Reverse Transcriptase. 
Nuclease free water was then added to make the final volume to 25 μl. Contents of the tube were 
gently mixed and heated at 39.2˚C for 80 minutes followed by cooling on ice and heating at 95˚C 
for minutes and then storing them at -20˚C. 
 
2.2.1.3 PCR amplification 
 
PCR was performed on a DNA Thermal cycler (Thermo Hybaid, USA). Primers were supplied 
by Sigma Genosys (UK). All the tissues and cell line samples were pre-screened for house 
keeping gene mGAPDH, which yielded a 400 bp product. 
For mMTA1 screening, primers used were 5’-GCGAGAGCTGTTACACCACA and 3’- 
ACTGCTGAGCACACTGGATG, which yielded a 508 bp product. For amplification by PCR, 
1μl of cDNA was supplemented with 5 μl of 10x PCR buffer, 0.8 μl each of 10mM dNTP, 20 
pM each of primer solutions, 1.25 unit of thermostable Taq polymerase, 1.5 mM MgCl2 
(Bioline), and water to a final volume of 50 μl. 
PCR for MTA1 was initiated by a melting step at 95˚ C lasting for 5 minutes, followed by 34 
cycles of denaturation at 95˚ C for 1 min, annealing at 55˚ C for 1 minute and extension at 72˚ C 
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for 1 minute. It was followed by a final extension step at 72˚ C for 5 minutes. All the primers 
used for the study are listed below in table 5. 
 
Table 2.2:- Primers used for PCR, Cloning and sequencing of murine and human MTA1 
Conventional PCR Primers (5’ > 3’) 
mGAPDH Forward ACTCCACTCACGGCAAATTC 
mGAPDH Reverse CCTTCCACAATGCCAAAGTT 
mMTA1-F GCGAGAGCTGTTACACCACA 
mMTA1-R ACTGCTGAGCACACTGGATG 
hGAPDH-F ACCACCAACTGCTTAGCACC 
hGAPDH-R CCATCCACAGTCTTCTGGGT 
hMTA1-F CGCTCAAGTCCTACCTGGAG 
hMTA1-R TGGTACCGGTTTCCTACTCG 
Primers for Murine MTA1 cloning 
mMTA1-F ACCATGGCCGCCAACATGTACAGG 
mMTA1-R CGCCTAGTCCTCAATAACAATGGGCTC 
mMTA1 Seq -1 AAAACTGGAGACCAAGGTGTG 
mMTA1 Seq -2 GAGAGCTGTTACACCACACA 
Primers for Human MTA1 cloning 
HMTA1-F ACCATGGCCGCCAACATGTA 
HMTA1-R GGCCCCTAGTCCTCGATGACGATGGGCTCG 
 
PCR products were visualized using a 1.5% (wt/vol) agarose gel containing 1 μg/ml of ethidium 
bromide (BDH Laboratories, UK). 
 
2.2.2 Determination of Human and mouse MTA1 expression by Real-time RT-PCR 
 
2.2.2.1 Human Cancer and normal tissues 
Samples of Breast, Gastric and Colon carcinoma mRNA, along with patient matched normal 
tissue mRNA, were kindly provided by Dr. Aija Line (Latvia). Mouse cell lines and tissues are 
described above. 
 
2.2.2.2  cDNA Synthesis from mRNA 
Reverse Transcription of the mRNA was performed as described earlier with exception of using 
Random primers instead of Oligo dT. 
 
2.2.2.3 Real-Time Quantitative PCR 
For preparing the standard curve, total RNA from a normal testis sample (T7) was serially 
diluted. Primers for various genes (mMTA1, mGAPDH, m18S, hMTA1, hGAPDH and h18S) 
were designed with the assistance of the Primer Vs program accessible from the following 
website: 
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(http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi.) 
All primers were designed to generate PCR products of approximately 100 bp in size to optimize 
the RT-Q-PCR. 
Table 2.3 Forward and Reverse primer sequences of primers used for RT-Q-PCR 
Gene Primer Sequences (5’ >  3’) 
mGAPDH-F CCACCCAGAAGACTGTGGAT 
mGAPDH-R TTCAGCTCTGGGATGACCTT 
mMTA1-F CTCCTGCTCAATGGGAAGTC 
mMTA1-R CTTCGGTGGCCATGTAAAAT 
m18SR-F GTAACCCGTTGAACCCCATT 
m18SR-R CCATCCAATCGGTAGTAGCG 
MTA-1 TW F CGCTCAAGTCCTACCTGGAG 
MTA-1 TW R TGGTACCGGTTTCCTACTCG 
GAPDH TW F ACCACCAACTGCTTAGCACC 
GAPDH TW R CCATCCACAGTCTTCTGGGT 
H18S F CAACTTTCGATGGTAGTCG 
H18S R CCTTCCTTGGATGTGGTA 
 
RT-Q-PCR was performed using Biorad real time Thermocycler (Biorad) using SYBR green 
fluorescent dye. Thermocycling for each reaction was done in a final volume of 12.5 μl 
containing 0.5μl of template, 6.5 μl of SYBR green master mix (Invitrogen, UK) containing Hot 
Start Taq DNA polymerase, and pre-optimised amounts of gene-specific forward and reverse 
primers. This was then made up to 12.5 μl with double distilled water. In each experiment, at 
least 4 no template controls were included to rule out any contamination and also to indicate the 
degree of amplification due to primer dimers. The cycling conditions for each gene were;  
Human MTA1  Human 18S ribosomal RNA 
50 ºC for 2 mins 
95 ºC for 8:30 mins 
95 ºC for 30 secs 
58 ºC for 1 min 40 cycles 
72 ºC for 30 secs 
95 ºC for 1 min 
58 ºC -10 secs (70 cyc for dissociation  
curve) 
50 ºC for 2 mins 
95 ºC for 8:30 mins 
95 ºC for 30 secs 
54 ºC for 1 min 40 cycles 
72 ºC for 30 secs 
95 ºC for 1 min 
54 ºC -10 secs (85 cyc for dissociation  
curve) 
Human GAPDH Murine GAPDH 
50 ºC for 2 mins 
95 ºC for 8:30 mins 
95 ºC for 30 secs 
95 ºC for 3 mins 
58 ºC for 20 secs 
72 ºC for 30 secs         40 cycles 
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58 ºC for 30 min 45 cycles 
72 ºC for 30 secs 
95 ºC for 1 min 
58 ºC -10 secs (70 cyc for dissociation  
curve) 
95 ºC for 1 min 
58 ºC for 1 min 
Murine MTA1 Murine 18S ribosomal RNA 
95 ºC for 3 mins 
58 ºC for 20 secs 
72 ºC for 30 secs         40 cycles 
95 ºC for 1 min 
58 ºC for 1 min 
95 ºC for 3 mins 
58 ºC for 20 secs 
72 ºC for 30 secs         40 cycles 
95 ºC for 1 min 
58 ºC for 1 min 
 
2.2.3 Determination of MTA1 protein expression 
2.2.3.1 Cell Lines 
 
Murine cell lines have been described in section 2.1.1. HaCaT cell line was a generous gift from 
Dr Hong Wan (Cancer Research, UK), and was cultured in DMEM+10% FCS. K562 cells were 
obtained from EUCAPS and were grown in RPMI 1640 +10% FCS, whereas MDA-MD-435 
cells were obtained from Queens Medical Centre (Nottingham) and were cultured in 
DMEM+10% FCS. 
 
2.2.3.2 Cell Lysate Preparation 
 
Cells were harvested and washed twice in ice cold PBS at 400 rpm for 3 min at 4°C. Cell pellet 
was resuspended in 500μl of lysis buffer (150mM NaCl, 50mM  Tris-Base pH 8.0, 5mM EDTA, 
1% v/v IGEPAL CA-630, 0.5% w/v sodium deoxycholate, 0.1% w/v SDS, 1mM benzamidine, 
0.1mM PMSF, 1mM sodium ortho-vanadate, 1mM sodium azide) and the tubes were agitated for 
30 min at 4°C. The tubes were then allowed to stand on ice for one hour followed by 
centrifugation at 14000 rpm at 4°C for 30 mins and supernatant transferred to a fresh eppendorf. 
For proteins from tissues, various tissues were harvested from naïve balb/c mice and tissues were 
homogenized using a homogenizer in lysis buffer and the above process repeated. The samples 
were stored at –20°C until analysis by protein assay and SDS-PAGE. 
 
2.2.3.3 Protein assay  
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Protein concentration was determined in the lysate preparation by performing a protein assay as 
described by the manufacturer protocol (Biorad). The standard was made of BSA diluted in lysis 
buffer in serial dilutions. Briefly, to 5 μl of the samples and standards 25 μl of Reagent A was 
added. To each well, 200μl of reagent B was then added. Each sample was run in duplicate. The 
reaction was left to develop for 30 min and the plate was read at 750nm on a Spectrafluor 
(Tecan). 
2.2.3.4 SDS-PAGE and transfer 
 
1x reducing buffer was added to all the samples and boiled for 5 min at 95°C to denature 
proteins, before being loaded on the polyacrylamide gel. As a standard, BSA was run with the 
samples. The gel was run at 90V through the 4% stacking gel (15% (v/v) acrylamide /bis, 25% 
0.5M Tris HCL pH6.8, 60% dH20 plus 0.1% (v/v) TEMED and 1% (v/v) 10% ammonium 
persulfate) and 120V through the 10% resolving gel (33.3% (v/v) acrylamide/bis, 25% 1.5M Tris 
HCl pH 8.8, 41.7% dH20 plus 0.1% (v/v) 10% ammonium persulfate). Proteins were then 
transferred at 13V onto nitrocellulose membrane for 40 mins using a semi-dry transfer system 
(Biorad) according to manufacturer instructions. 
 
2.2.3.5 Western Blotting 
 
Membranes were stained with Ponceau S, and the standard lane was cut from the rest of the 
membrane. The membrane was blocked overnight in 5% milk-TBS-T at 4°C under constant 
agitation. The primary antibody (anti-human/mouse MTA1 antibody, Santacruz Biotechnology, 
USA) was then added at 1:1000 dilution in 5% milk-TBS-T and incubated for 2 hrs at room 
temperature. After washing the membrane 4 times for 15 mins in TBS-T at room temperature, 
the secondary antibody (HRP conjugated) was added to the membrane at a 1: 1000 dilution in 
5% milk-TBS-T and incubated for 2 hour at room temperature. Membrane was washed 4 times 
for 15 mins at room temperature in TBS-T, and revealed using ECL chemioluminescence kit 
(Amersham). Hyperfilm ECL (Amersham) films were used to detect the luminescence. 
 
2.2.4 Cloning of Mouse MTA1 and Human MTA1 
 
Briefly, full length mouse MTA1 (Pubmed accession no NM_054081) was amplified from naïve 
mouse testis, using forward primer 5’-ACCATGGCCGCCAACATGTACAGG-3’ (141-161 
bases) and reverse primer 5’-CGCCTAGTCCTCAATAACAATGGGCTC-3’ (2214-2240 
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bases). PCR was performed for 40 cycles and was initiated by a melting step at 95˚ C lasting for 
5 minutes, followed by 40 cycles of denaturation at 95˚ C for 1 min, annealing at 68˚ C for 1 min 
and extension at 72˚ C for 4 min. It was followed by a final extension step at 72˚ C for 5 mins. 
For amplification by PCR, 1μl of cDNA was supplemented with 5 μl of 10x PCR buffer, 0.8 μl 
each of 10mM dNTP, 20 pM each of primer solutions, 1 unit of  pfu polymerase (Promega) and 
water to a final volume of 50 μl. Full size MTA1 cDNA band of approximately 2.1 kb was 
visualized on 1% Agarose gel, band extracted and cloned into TOPO-Blunt vector following 
manufacturer’s instructions. Cloned plasmid was isolated from multiple colonies and sequenced 
to confirm that there were no mutations (MWG-Biotech). For directional cloning, mMTA1 was 
digested using HindIII and XbaI double digest from TOPO-Blunt and inserted into pcDNA3 
mammalian expression vector (Invitrogen). 
For human MTA1 cloning (Pubmed accession no NM_004689) (Forward bases 188-201 and 
Reverse bases 2312-2337), PCR reaction was set up with Phusion Taq Polymerase (Finnzyme) 
and using the primers described earlier. PCR conditions were as follows:- 98˚C for 2 minutes, 35 
cycles of 98˚C for 20 seconds and 72˚C for 90 seconds followed by final extension step of 72˚C 
for 5 minutes. PCR product was run on gel and was band extracted followed by cloning into the 
TOPO-Blunt vector (Invitrogen) as Phusion Taq polymerase generates blunt end products. 
Human MTA1 sequence was confirmed by sequencing and was subcloned into pcDNA3 using 
BamHI and XbaI enzyme sites.  
 
2.2.5 Determination of Immunogenicity of MTA1 peptides 
 
2.2.5.1 Animals  
 
Balb/c and C57bl/6J mice were either bred in house or purchased from Harlan (Oxon, U.K.) and 
HHD II mice were a generous gift from Dr. F Lemonnier (Institut Pasteur, Paris). All animals 
were maintained in accordance with the Home Office Codes of Practice for the housing and care 
of animals.  
 
2.2.5.2 Peptides 
 
Murine MTA1 protein sequence was screened, using a web based algorithm (SYFPEITHI), for 
peptides potentially binding to H-2Kd and H-Ld molecules (Balb/c) or H-2Db and H-Kb 
molecules (C57bl/6). Human MTA1 protein sequence was screened for peptides binding to 
HLA-A2.1 molecules (HHD II) mice. Various peptides (Table 2) were chosen based on their 
binding score and were synthesized (Alta Biosciences, Birmingham, UK). 
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Table 2.4:- Peptides selected using SYFPEITHI to test for cytotoxicity 
Mouse 
Strain 
Peptide No Sequence MHC Motif Binding 
Score 
MTA1 622 KSYPTKVRLI H2-Kd 27 
MTA1 168 RYQADITDL H2-Kd & H2-Ld 28 & 22 
MTA1 436 RPGPNRNNM H2-Ld 23 
MTA1 298 KYGKDFTDI H2-Kd 26 
MTA1 148 VYDPQQKTL H2-Kd 25 
MTA1 551 SSSSVLSSL H2-Kd & H2-Ld 20 & 20 
Balb/c 
MTA1 208 QFLVVARSV H2-Kd 24 
MTA1 699 PAPVNDEPI H2-Db 29 
MTA1 496 YMPINSAAI H2-Db 25 C57Bl/6 
  MTA1 12 NSSSNPYLI H2-Db 24 
MTA1 22 YLIRRIEEL HLA-A2.1 30 
MTA1 57 ALADKHATL HLA-A2.1 30 HHD II 
MTA1 109 FLSRQLESL HLA-A2.1 27 
 
 
 
2.2.5.3 T2 binding assay 
T2 cells were harvested, counted and re-suspended at 4 x 106 cells per ml and were plated at 1.6 
x 106 cells/well in 40 μl volume in a 96 well plate. Peptides were added to these cells at 
100μg/ml, 10μg/ml and 1μg/ml in a 10μl volume and incubated overnight at 37˚ C. Cell were 
harvested the next day and stained with primary antibody for HLA-A2 (HB54 hybridoma 
supernatant), washed and stained with goat anti-mouse secondary. Cells were then washed and 
analyzed using a Flow Cytometer for the mean fluorescence intensity. 
 
2.2.5.4 Coating of gold particles by DNA 
DNA was coated onto 1.0 Micron gold particles (Biorad, Hemel Hempstead, Hertfordshire, UK) 
using manufacturers’ instruction and administered by Helios Gene Gun (Biorad). Breifly, 200 µl 
of spermidine was added to 16.6 μg of gold followed by sonication. 200 µl of 1M calcium 
chloride was added to DNA-Spermidine solution followed by incubation at room temperature for 
10 minutes. Tubes were spun at 13,000 rpm for 1 min and gold particles re-suspended in dry 
ethanol. After repeating the above step 2 more times, particles were resuspended in 0025mg/ml 
of PVP in dry ethanol. During these steps, tubing was dried using nitrogen for 15-20 minutes 
using nitrogen gas. Re-suspended gold particles were loaded into the dry tubing using a syringe 
and the tube replaced on the roller/dryer (Biorad). Following incubation for 30 mins, ethanol was 
gently removed using the syringe and the tube was rotated on the roller along with nitrogen gas 
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being passed through it for 5 mins. Bullets were then cut using guillotine and stored at 4ºC until 
used for immunisation. 
2.2.5.5 Immunisations 
All mice were immunized with 100μg of the CTL peptide along with 140μg of the helper peptide 
in 1:1 dilution in Incomplete Freunds Adjuvant (IFA) in a total volume of 100μl. The injection 
was given at the base of the tail. Mice were boosted with the same dose after one week. Helper 
peptide for the Balb/c mice was ISQ derived from ovalbumin and Hep B helper peptide was used 
for C57Bl/6 and HHD mice.  
In certain experiments, mice were immunised with gold particles coated with human or mouse 
DNA, using gene gun (Biorad). Three rounds of immunisations were undertaken at one week’s 
interval. 
 
2.2.5.6 LPS Blasts 
Spleens were harvested from naïve mice and single cell suspensions prepared. LPS blasts were 
set up in a T75 flask by culturing 60 x 106 spleen cells, in the presence of 1mg LPS and 7μg/ml 
of Dextran Sulphate. After 48 hours, the cells from the LPS blast flask were harvested, washed, 
resuspended in 5 ml of T cell media and irradiated. These LPS blasts were washed again and 
pulsed with the peptide for 1 hour at 37˚ C. After washing these cells were used for in vitro re-
stimulation of the splenocytes harvested from immunized mice.  
 
2.2.5.7 Harvesting Splenocytes from immunised mice and in-vitro re-stimulation 
One week after boosting, spleens were harvested from the immunized mice and single cell 
suspensions were prepared in sterile conditions. Cells were counted, resuspended and plated in a 
24 well plate at 2.5 x 106 cells/500μl. 5 x 105 /500μl irradiated and peptide pulsed LPS blasts 
were added to the splenocytes to make a final volume of 1ml in each well of 24 well plate. 
Supernatants were collected usually on day 3 and 5 for cytokine testing. 
 
2.2.5.8 Cytotoxicity Assay 
 
On day 5 of in-vitro stimulation, splenocytes were harvested, washed twice in serum free media, 
resuspended in CTL media, counted and used as effector cells. Target cells were harvested by 
trypsination (only CT-26), washed and labeled with chromium-51. A standard 4 h Cr-release 
assay was performed and the percentage specific cytotoxicity was determined using the 
following equation: %specific cytotoxicity = (experimental release-spontaneous 
release)/(maximum release-spontaneous release) x 100. 
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2.2.6 Proliferation assays 
2.2.6.1 Mice, Peptides and Immunisations 
FVB/N-DR1 and C57BL/6-DR4 colonies were bred at The Nottingham Trent University animal 
house. FVB/N-DR1 animals were received from Dr. Altman and C57BL/6-DR4 mice were 
purchased from Taconic. FVB/N-DR1 F2 mating positive animals were maintained inbred by 
ensuring they have a common F0 ancestor. Animals had already been PCR genotyped to verify 
that they were HLA-DR1 and HLA-DR4 positive.  
Peptides were selected using web based algorithms SYFPEITHI and PAPROC. 
Two peptides, which were predicted to bind to HLA-DR1 and HLA-DR4 molecules with high 
affinity were chosen and purchased from Alta Biosciences. 
Table 2.5 HLA-DR1/DR4 restricted peptides derived from MTA1 used in proliferation assays 
Peptide 
Region 
Sequence 
HLA-
DR1*0101 
binding score 
HLA-
DR4*0401 
binding score 
MTA1 497 R N P Y L P I N S A A I K A E 30 28 
MTA1 550 P D P V K S V S S V L S S L T 29 26 
 
Each animal was immunised with 100µg of the peptide, diluted in PBS and emulsified in 1:1 
dilution with incomplete Freunds adjuvant (IFA) (Sigma). 100µl of this peptide emulsion was 
administered at the base of each animal’s tail. Two rounds of immunisation with the same 
peptide were undertaken at seven-day intervals. For investigating the natural processing of 
peptides, in certain experiments mice were immunised with gold particles coated with human or 
mouse DNA, using gene gun (Biorad). Three rounds of immunisations were undertaken at one 
week’s interval. 
 
2.2.6.2 BM-DC generation for proliferation assay 
BM-DC were generated as described by Inaba and coworkers with modifications (Inaba et al, 
1992). Briefly, hind limbs of naïve mice were harvested and all muscle was removed using 
scalpel and tweezers. After cutting the ends of the bone, bone-marrow was flushed and the cells 
collected, centrifuged, re-suspended in 1ml BM-DC media and plated at 1x 106 cells per well/ml 
with 100ng/ml of mGM-CSF (X63 supernatant). On day 2 and day 4, non-adherent cells were 
washed out by gently removing 700µl of media from each well, and 750µl of fresh media 
containing GM-CSF added in its place. On day 7, BM-DC were replated with the 10µg/ml 
peptide of interest or control peptide for 4-6 hours. LPS was then added at 1µg/ml to induce 
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complete maturation. The cells were then incubated overnight at 37○ C, 5% CO2. The following 
day, BM-DC were washed in T cell media, re-suspended in 1ml of T cell media and pulsed with 
10µg/ml of peptide for 4-6 hours at 37○ C, 5% CO2. These cells were plated at 5 x 103 per well in 
a round bottom 96 well plate. BM-DC were always used at a 1 DC to 10 splenocyte ratio in 
proliferation assay. 
 
2.2.6.3 Splenocyte preparation and re-stimulation with peptide in vitro. 
Spleens of immunised animals were harvested and the cells flushed out with T cell media. Cells 
were collected and placed on ice while the spleen was being digested. The remaining tissue 
(spleen) was digested using an enzyme cocktail (0.1U/ml DNAase (Sigma) + 1.6 mg/ml 
collagenase (Sigma)) for 1 hour at 37○ C. Single cell suspension was prepared, counted and cells 
were plated in 24 well plates at 2.5 x 106 and 3.5 x 106 cells per well in 1 ml of T cell media for 
HLA-DR1 and HLA-DR4 mice respectively. 10 µg/ml of the peptide was added to each well.  
On day 6, cells were used at 5 x 104 cells per well as responders for the proliferation assay. 
 
2.2.6.4 Murine CD8+ T cell depletion 
Depletions were done on day 6, using CD8 specific dynabeads (Dynabeads Mouse CD8, Dynal) 
and following the manufacturer instructions. CD8 cells attached to the beads were depleted using 
a magnet. The remaining cells were collected, washed once with T cell media and subsequently 
used for the proliferation assay or plated in a 48 well plate (Rojas et al., 2005). Protocol for 
CD8+ depletion has been optimised in our laboratory and the remaining cells were shown to 
consist negligible number of CD8+ T cells. 
 
2.2.6.5 Proliferation assay for murine CD4+ T-cells 
The cells collected after T cell depletion, were re-suspended in 4 ml of T cell media and counted. 
These cells were then plated in 96 well round bottom plate at cell density of 5 x 104 cells per 
well. Peptide pulsed syngeneic BM-DC were used as antigen presenting cells in all the 
experiments. Responder cells were co-cultured with BM-DC either pulsed with the relevant 
peptide, an irrelevant peptide or no peptide in some experiments. Pulsed BM-DC were added to 
the wells at a density of 5 x 103  cells per well. To ascertain the MHC restriction of the response, 
MHC blocking antibody (L243 anti-HLA-DR, see appendix) was added to the relevant wells. As 
control a matched isotype antibody was also used in these experiments. Each culture was 
performed in triplicates or quadruplicates for approximately 60 hours. Tritiated thymidine 
(Amersham) was added at a final concentration of 0.037MBq/ml 16 to 18 hours prior harvesting. 
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Cells were harvested using a 96-well harvester (Packard) onto a 96-well UniFilters GF/C plate 
(Packard) and the plate was left to dry for 1 hour in a drying cabinet. 40 µl of scintillation fluid 
(Microscint 0, Packard) was added to each of the filter wells. Filters were counted on a Top-
Count scintillation counter (Packard). 
 
2.2.6.6 Second week proliferation and cytokine assessment of murine T cells. 
For HLA-DR4 mice, day 6 CD8+ depleted splenocytes were also cultured at 0.5-1 x 106/well in 
48 well plate for a further 7 days and proliferation was repeated as described in 3.8. 4-6 x 105 
splenocytes were plated with 4-6 x 104 peptide pulsed BM-DC in 48 well plates for assessing 
cytokine production.  
 
2.2.6.7 CD25+ Depletion and DNA immunisations for in vivo experiments 
Plasmid DNA vaccination was performed using helium propelled gene gun (Biorad) with 1μm 
gold particles coated with pcDNA3-mMTA1/hMTA1. Three rounds of immunisations were 
undertaken at a week’s interval. Where indicated, mice were immunised with 100-150μg/kg of 
cyclophosphamide (CPM) four days before the vaccination. Confirmation of CD25+ depletion 
was done by positively selecting CD4+ T cells, using CD4+ T cell isolation kit (Miltenyi), and 
staining for CD25+ cells (Serotec). 
 
2.2.7 Generation and optimisation of Semliki Forest Virus (SFV) particles  
2.2.7.1 Sub-cloning of mMTA1 in pSMART2b vector 
 All plasmids for the Semliki Forest Virus generation were kindly provided by Dr. Rod Bremner 
(University of Toronto and Toronto Western Research Institute). Following the cloning of 
mMTA1 in TOPO-Blunt, to sub-clone it into pSMART2b vector, TOPO-Blunt /mMTA1 was 
double digested with BamHI and NsiI. The digested products were run on the gel and the band 
corresponding to mMTA1 (2.1Kb) was excised and the DNA extracted and ligated in 
pSMART2b vector after digesting the vector with the same enzymes. Insert was confirmed by 
sequencing as well as by transfecting RENCA cell line with pSMART2b/mMTA1 followed by 
RT-PCR. 
 
2.2.7.2 Generation of virus particles 
Generation of SFV virus particles was optimized for SFV-βgal. For production of infective viral 
particles, pSCAβ and pSCAhelper plasmids were co-transfected in 293 cells at different molar 
ratios. Different methods of transfection were investigated (Electroporation, Calcium phosphate 
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and Lipofectamine). Calcium phosphate transfection was observed to be the most efficient 
method of transfection and combined with 1:3 molar ratio of pSCAβ: pSCAhelper gave the 
highest titer of virus and this combination was used in most of the experiments. 
Calcium phosphate transfection was performed using the ProFection® Mammalian Transfection 
System—Calcium Phosphate (Promega) and following the manufacturer’s instructions. Briefly, 
293 cells were plated at 5-8x105 cells/well/3 ml of media in a 6 well plate, a day before 
transfection. On the day of transfection, cells were washed once and media was replaced 2-3 hrs 
before transfection. DNA and HBS solutions were prepared in two separate sterile 1.5 ml 
eppendorfs. In one tube, 5-12 μg of DNA was diluted in water and 37 μl of 2M CaCl2 to make 
the final volume of 300 μl. This DNA mixture was added to 2xHBS solution in another sterile 
tube with constant vortexing. The DNA-HBS-CaCl2 mix was incubated for 30 minutes and 
added to the cells drop wise. After incubating the plate for 16-18 hours at 37ºC and 5% CO2, 
media was removed from the transfected cells, cells washed once with PBS and fresh media 
added to the cells. After further 48 hour incubation, mediated containing the lysed cells and virus 
was harvested following a freeze thaw cycle, spun at 2000 rpm for 10 minutes at 4ºC. After 
centrifugation, the supernatant containing the virus was transferred into a fresh tube and stored at 
-20ºC until use. Viral particles generated in the way were inactive and prior to use, they were 
activated by adding 1/20th of total volume of 10mg/ml of α-chymotrypsin to cleave the p62 
glycoprotein into E2 and E3 proteins. After 45 minute incubation at room temperature, 10mg/ml 
solution of aprotinin was added to 1/15th of total volume to stop the protease activity. 
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Figure 2.1 Schematic Representation of SFV expression vector generation 
 
2.2.7.3 Titration of Virus: - To calculate the titer of the virus, BHK-21 cells were infected with 
different volumes of activated virus for 45 minutes at 37ºC. After incubation, cells were washed 
once with PBS and incubated for 18-24 hrs after addition of fresh media. To visualise the 
infected cells by SFV-βgal, X-gal assay was performed on them. Briefly, cells were washed 
twice with PBS and fixed with glutaraldehyde for 15 minutes at 37ºC. Cells were washed with 
PBS twice after fixing followed by addition of 1 ml of Xgal solution per well. Colour was 
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allowed to develop for 2-3 hours and blue cells counted. Titer of virus was calculated taking into 
consideration the number of infected and uninfected cells as well as the surface area of a well in 
6 well plates and finally adjusting for the virus dilution used for cell infection. 
For titration of SFV/mMTA1 virus, after infection of BHK-21 cells as above, infected cells were 
visualised by immunohistochemistry. 18-24 hours post-infection, cells were fixed with -20ºC 
methanol for 1 min followed by addition of mouse anti-FLAG primary antibody (Sigma, UK). 
Following incubation at room temperature for 1 hour, cells were washed twice and secondary 
antibody (Goat anti-mouse HRP, DAKO) was added. After further 30 minutes incubation at 
room temperature, cells were washed and stained with DAB solution (DAKO). Colour was 
allowed to develop and infected cells (dark brown stained) were counted to determine the titer. 
 
2.2.7.4 Direct Immuno-fluorescence assay 
24 hours prior to transfection, 1x105 BHK cells/well were plated in 8 chamber slides. Cells were 
transfected with pSMART2b-mMTA1 using Lipofectamine and media replaced after 6 hours. 
24-36 hour after transfection, media was removed and cells fixed with -20ºC methanol for 1 min 
at room temperature. Anti-FLAG-FITC antibody was added at 1:1000 dilution in PBS for 1 hour 
at room temp, followed by washing with PBS 3 times. Slide was dried at 37ºC and mounted with 
fluorescent mounting liquid and images were acquired using a confocal microscope (Leica). 
 
2.2.7.5 BM-DC infection with SFV-Bgal 
 
BM-DC were generated as discussed before. On day 7, DC were harvested and replated at 5x105 
cells/500μl/well in a 24 well plate. SFV-Bgal virus were activated and 1x105 viral particles were 
added per well.  After one hour, 500μl of BM-DC media was added and cells incubated for 18-24 
hours before harvesting them. Cells were cyto-spun onto a slide and stained using X-gal assay. 
 
2.2.7.6 FACS for BM-DC phenotype analysis  
DC were harvested for FACS analysis. 2-5 x 105 of cells were used per tube. Cells were washed 
twice in PBS+0.1% BSA+0.02% NaN3 and incubated on ice for 30 minutes with primary 
antibody. Rat anti-mouse CD80, Macrophage/Monocyte marker (F4/80), DEC205, I-A (murine 
class II) and CD40, mouse anti-human HLA-DR and hamster anti-mouse CD11c monoclonal 
antibodies were used in these experiments (see appendix for details). Appropriate isotype 
controls were used in each experiment. Following incubation with the primary antibody, cells 
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were washed twice in PBS BSA and incubated for 30 minutes on ice with FITC coupled goat 
anti-rat IgG, goat anti-mouse IgG or goat anti-hamster IgG as secondary antibodies as 
appropriate. Finally the cells were washed in PBS+0.1% BSA+0.02% and resuspended in 300µl 
of sheath fluid and FACS analysis was performed. 
 
2.2.7.7 Viral immunisation and in vivo challenge experiments 
Mice were immunised twice with 1x106 SFV virus particles at 7 day interval as previously 
described. After 1 week of last immunization, mice were challenged with 8x104 CT26 cells for 
Balb/c or 4x105 EL4-HHD cells (HHD II) mice. Animals were monitored twice a week for 
tumour development and size and were sacrificed when the tumour reached a size of 100mm2 
according to the Home Office guidelines. 
 
2.2.7.8 Statistical Analysis 
Data are expressed as mean +/-SD and represent one of at least 3 separate experiments, unless 
stated otherwise. For proliferation and cytotoxicity assays, statistical analysis was performed 
using Student’s T test (unpaired). For RT-Q-PCR and in vivo tumour progression assays, 
analysis was performed using Prism 3.03 software (*=p<0.05, **=p<0.01, ***=p<0.005). 
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Chapter 3:- VALIDATION OF MTA1 AS A POTENTIAL ANTIGEN FOR                         
I MMUNOTHERAPY IN A MURINE MODEL 
 
3.1 Introduction 
 
Vaccines have been used for several infectious diseases and are responsible for the eradication of 
small pox and decreasing the incidences of diseases such as polio, mumps and rubella. 
Traditional vaccines for infectious diseases consist of live attenuated pathogens, and due to their 
success early cancer vaccines used whole tumour cell vaccines, which in mouse tumour models 
proved to be effective in preventing tumour, however they were not potent enough for tumour 
therapy. Since the identification of the first human tumour antigen (MAGE1) in 1991, 
considerable efforts have been made to search for novel tumour antigens, leading to 
identification of hundreds of potential targets for therapy. Antigen specific vaccination targeting 
MAGE, tyrosinase, carcino-embryonic antigen (CEA) and NY-ESO, amongst others have 
proved very successful in prevention and therapy of cancers in animal models (Ye et al., 2004; 
Muders et al., 2003). However, significant therapeutic benefits have eluded immunologists in 
human clinical trials. One of the reasons for their failure may have been due to the choice of 
antigens targeted.  
 
Cancers with viral aetiology have been targeted with vaccines against known viral antigens and 
these are proving to be successful in clinical trials (Harper et al, 2006). Viral antigens are highly 
immunogenic and the immune system has no previous experience, thereby eliminating the 
problem of tolerance. Moreover, highly restricted expression of these antigens in virus infected, 
normal or cancer cells precludes autoimmunity. However, most human cancers are the result of 
environmental and genetic factors rather than viral. Although tumour specific unique non-viral 
antigens are widely considered as good targets, their identification in each individual patient can 
be time-consuming and expensive, thereby not feasible for wider application. Thus, shared 
tumour antigens seem to be the most practical therapeutic targets for cancer immunotherapy as 
they are widely expressed in a variety of tumours. Ideally tumour antigens should not be 
expressed in normal cells. However, cancer cells arise from their normal counterparts and 
therefore share similar antigens. Several studies have demonstrated that as long as tumour 
antigens are not highly expressed in normal tissues, cancer vaccines generated auto-immune 
response is negligible or highly restricted (Schreiber et al., 1999; Trefzer et al., 2000). Some of 
the commonly targeted ubiquitously expressed antigens are MUC-1, p53 and HER-2/neu. MUC-
1 has been shown to be over-expressed in breast and pancreatic cancers, in addition to epithelial 
 79
                                                                                                                                             Chapter 3 
cells, fibroblasts and B-cells. CTL recognising MUC-1 peptides have been generated and shown 
to specifically recognise breast cancer cells (Grosso et al, 2004).  Similarly several studies have 
demonstrated CTL mediated lysis of p53 over-expressing tumour cells but not cells expressing 
normal levels of p53 (Murakami et al, 2004). The Her-2/neu proto-oncogene encodes a tyrosine 
kinase, widely over-expressed in breast and ovarian cancers and recognised by the immune 
system. Several target peptides have been identified from Her-2/neu, but more importantly, one 
study showed a commonly shared epitope between breast, colon, lung and renal cancers 
(Scardino et al, 2001). This underlines the utility of targeting a shared antigen. Another 
important characteristic of tumour antigen has to be its role in oncogenic transformation of cells. 
Antigen specific targeting of non-essential tumour antigens would eventually lead to down-
regulation of such antigens allowing cancer cells to escape (Yee et al., 2002). Hence, a rational 
vaccine strategy should target antigens involved in the maintenance of the cancer phenotype and 
having a non-redundant role in oncogenesis.  
 
Although technical advances in surgery and medicine have enabled us to surgically remove most 
primary tumours and treat residual disease, mortality rates due to cancers remains largely 
unaffected due to inability to target metastatic cells. Immunotherapeutic intervention to target 
metastatic cells seems to be an appropriate strategy, especially in combination with other 
therapies. This has led to a surge in interest for identification of metastatic related genes in 
cancer cells. Metastasis is a complex series of events starting from detachment of neoplastic cells 
from primary tumour, invasion of surrounding tissues and penetration of blood and lymphatic 
vessels, adhesion to endothelial cells of distant organs, extravasation, colonisation and 
angiogenesis. During these events, tumours cells also have to evade the immune system. Several 
genes are involved in controlling these events and their identification can not only provide a clue 
to this complex process, but also provide targets for therapy. Search for these genes have led to 
identification of several potential candidates in breast cancer such as mts-1, nm23, WDNM-2 
and stromelysin-3; which are potentially involved in metastases of breast cancer (Ebralidze et al., 
1989; Steeg et al, 1998; Dear et al, 1989; Basset et al, 1990). 
 
Amongst several genes involved in metastasis, MTA1 was first identified by Toh et al (1994), 
using rat mammary adenocarcinoma metastatic system.  Using derivatives of a single 13762NF 
tumour cell line with different metastatic potential, differential hybridisation screening identified 
10 genes, one of which was MTA1 (Toh et al., 1994). They also identified the human and mouse 
homologues of rat MTA1 gene and demonstrated human MTA1 expression in several human 
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breast cancer cells. Furthermore, MTA1 expression correlated with the metastatic potential of the 
human breast cancer cell lines; ratio of MTA1 expression in non-metastatic to invasive to 
metastatic cell lines was 1:2:4 (Toh et al., 1995). Rat MTA1 gene expression was also observed 
in several normal rat organs, indicating its essential function in normal organs as well as cancer 
cells. Contrary to its low level expression in normal tissues, MTA1 is highly expressed in testis. 
Spermatogenesis is a highly complex yet controlled process of proliferation, mitosis, meiosis and 
differentiation, and is likely to be controlled by a number of genes. Furthermore, spermatozoa 
are highly motile, contain specific proteolytic enzymes and adhesion molecules; properties which 
are generally associated with metastatic cells (Alberts et al, 1989). Recent study showed a direct 
interaction of MTA1 and endophilin 3 in the cytoplasm by using a yeast two-hybrid system, 
suggesting that MTA1 might also be involved in the regulation of endocytosis mediated by 
endophilin 3 (Aramaki et al., 2005).  
 
In 1998, MTA1 was shown to be a part of the novel Nucleosome Remodelling and Histone 
Deacetylase complex (HDAC) (Xue et al, 1998). In eukaryotes, genes are packed in chromatin 
and nucleosomes are the repeating units of chromatin. Nucleosomes consist of 146 base pairs of 
DNA wrapped around the core histone octamer, which are highly conserved proteins throughout 
evolution. This formation of genes makes them inaccessible to transcription factors. Acetylation 
of histone changes its conformation and makes DNA more accessible for transcription. This 
process of histone acetylation and deacetylation is controlled by multi-subunit chromatin 
remodelling complexes, histone acetyltransferases (HAT) and histone deacetylases (HDAC) 
(Marks et al, 2001). HDAC are primarily involved in making chromatin compact by removal of 
charge-neutralising acetyl groups. Transcription repression has been associated with cellular 
transformation in a number of studies. It has been proposed that HDAC may repress transcription 
of number of genes involved in cell-cycle arrest, differentiation and apoptotic cell death (Marks 
et al., 2001). Indeed, a number of compounds with HDAC inhibitory activity have shown great 
promise in inhibition of tumour growth in vivo and in vitro (Marks PA et al, 2000). Several of 
these compounds are already in clinical trials, suggesting the importance of targeting these 
complexes. Moreover, HDAC are also known to interact with transcription factors. Being a sub-
unit of HDAC, suggested that MTA1 has a role in transcription repression and gene regulation, 
and seems to have an essential role in transformation. MTA1 contains zinc finger and leucine 
zipper domains, generally observed in transcription factors, indicating that it can also function as 
a transcription factor. Thus, MTA1 is likely to have an essential role in the transformation 
process and could prove a valuable asset to target metastatic cells. Other members of the MTA1 
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family have since been identified, three members (MTA1, MTA2, MTA3) and six isoforms 
(MTA1, MTA2, MTA3, MTA1s, MTA1-ZG29p, MTA3L). MTA2 and MTA3 are also sub-units 
of the NuRD complex, whereas MTA1s was shown to interact with oestrogen receptor α in the 
cytoplasm, sequestering it and making breast cancer cells unresponsive to hormone therapy 
(Kumar et al., 2002). 
 
Just being essential for transformation does not make MTA1 a target for immunotherapy and it 
needs to be carefully evaluated as a potential target.  Other key parameters to be examined 
regarding MTA1 are, its expression level in various cancers and at different stages of cancer, the 
effect of its inhibition and over-expression in cancer and normal cells, respectively, and its 
immunogenicity. The initial identification of MTA1 in breast cancer led researchers to suggest 
its role in breast cancer progression. Indeed, a recent study showed that transgenic mice with 
increased MTA1 levels had extensive branching of the mammary glands and increased 
proliferation of the ductal and alveolar epithelial cells (Bagheri-Yarmand et al., 2004). 
Interestingly, 30% of these mice developed focal hyperplastic nodules and approximately 7% 
exhibited mammary tumours in 18 months. Studies have also revealed MTA1 over-expression in 
a number of different cancers such as gastrointestinal, ovarian, oesophageal, prostate and lung 
(Tang et al, 2003; Sasaki et al, 2002; Toh et al, 1999; Nicolson et al, 2003). In most of these 
studies, MTA1 over-expression was correlated with tumour progression, invasion and metastasis.  
To validate MTA1 as a potential target for immunotherapy, this aspect of the study was designed 
to investigate its expression in various human tumours compared with patient matched normal 
tissues. MTA1 mRNA levels were determined in gastric, colon, breast and prostate cancers. 
Furthermore, being 94% identical at protein level to the mouse MTA1, we validated a mouse 
model for investigating human MTA1 as an immunotherapeutic target. Expression of MTA1 was 
therefore determined in various murine tumour cell lines and normal mouse tissues using 
conventional RT-PCR. These results were confirmed and expression levels quantified using real 
time PCR. Rarely, mRNA levels of a gene do not correlate with its protein level and hence we 
compared MTA1 protein expression in murine tumour cell lines and normal tissues by western 
blotting. A recent study suggested MTA1 to be predominantly localised to the nucleus along 
with low levels in cytoplasm, contradicting previously published studies where MTA1 was found 
to be only localised in the nucleus. This also led us to investigate murine MTA1 localisation in 
cancer cells.  
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3.2 Results 
 
3.2.1 Expression of human MTA1 in human tumour tissues by RT-Q-PCR 
 
Previously published studies have showed over-expression of MTA1 in human gastric, colon, 
breast and prostate cancers, amongst others. To confirm these studies and for validation of 
MTA1 as a target for immunotherapy, MTA1 expression was investigated in colon, breast, 
gastric and prostate cancer samples and patient-matched normal tissues, using Real time 
quantitative PCR (RT-Q-PCR). Briefly, 2μg of RNA was reverse transcribed to generate cDNA 
using random primers from the samples. A maximum quantity was used for samples with very 
low concentration of RNA. RT-Q-PCR was performed for 40-45 cycles and the relative quantity 
of MTA1 was estimated by dividing the starting quantity of MTA1 by that of house keeping 
genes. It is noteworthy that two different housekeeping genes were estimated, GAPDH and 
ribosomal 18SRNA as suggested by several previously published studies (Bustin, 2000). Wide 
variations were observed in GAPDH values whereas 18SRNA values were the most consistent 
and were therefore used for all future analyses. Indeed, it has been documented that GAPDH 
mRNA levels are not constant as previously believed and should not be used for normalising 
PCR data as it can be widely affected by factors such as hypoxia, oxidative stress, pregnancy, 
during cell cycle and might even be up-regulated in cancers (Bustin, 2000). However, GAPDH is 
still widely used as a housekeeping gene, especially for conventional PCR. 
 
As seen in figure 3.1A, the relative expression of MTA1 in colon carcinoma samples is higher 
than the normal tissues, although the difference does not reach statistical significance. This might 
be due to the low number of samples available (n=10) and the fact that some cancer samples did 
not show an increase in the MTA1 expression. Indeed, individual MTA1 expression levels in 
each samples showed a clear increase compared to the normal tissues, with 6 out of 9 samples 
having an increased MTA1 levels, out of which 2 (Co21 and Co22) show a dramatic increase 
(>10 times) (fig 3.1B). Interestingly, patient Co22 also had lymph node involvement and 
previous studies in different cancers have related MTA1 levels to lymph node involvement and 
metastasis. Moreover, all three patients with lymph node involvement showed higher MTA1 
levels in their primary tumours. It is noteworthy that none of the patients had distant metastases, 
which are likely to have the highest MTA1 expression. 
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Figure 3.1:- Expression of MTA1 in colon carcinoma and patient matched normal colon 
tissue (A)Graph analysing nine tumour and normal tissues from patients (B) Individual patient 
 variation of MTA1 expression 
A 
B 
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Table 3.1 Colon Carcinoma sample information and their relative MTA1 expression 
Sample Code TNM Stage Differentiation Localisation Relative MTA1 
Expression 
Co425T 1.0.0 Moderate Rectum/Sigmoid 0.19 
Co425N    0.00 
Co437T 3.1.0 Low Sigmoid 0.24 
Co437N    0.04 
Co102T 3.0.0 Moderate Rectum 0.22 
Co102N    0.06 
Co27T 4.0.0 Moderate Sigmoid 0.54 
Co27N    0.55 
Co21T 3.1.0 Moderate Ascendens 0.45 
Co21N    0.03 
Co103T 3.0.0 Moderate Rectum/Sigmoid 0.14 
Co103N    0.60 
Co30T 3.1.0 Moderate Caecum - 
Co30N    0.09 
C022T 3.0.0 Moderate Rectum 0.68 
Co22N    0.03 
Co100T 3.1.0 Moderate Rectum/Sigmoid 0.39 
Co100N    0.12 
Co33T 3.0.0 Well Sigmoid 0.57 
Co33N    0.69 
 
 
Similar to the results obtained with colon cancer samples, over-expression of MTA1 was also 
observed in gastric cancer samples. Relative expression of MTA1 in gastric cancer samples were 
significantly higher than the normal tissues (p=0.0074) (fig3.2A). Moreover, individual variation 
of MTA1 expression in cancer showed dramatic increase of MTA1 levels in sample Ga418 (>10 
times) (fig3.2B). Overall, a significant increase was observed in 5 out of 10 samples. However, 
MTA1 expression level could not be correlated with the lymph node involvement or tumour 
progression in this study.  
 
 
 
 
 
 
 
 
 
 
 85
                                                                                                                                             Chapter 3 
Gastric Cancer Normal Tissues
0.0
0.1
0.2
0.3
R
el
at
iv
e 
M
TA
1 
Ex
pr
es
si
on
 
0
0.02
0.04
0.06
0.08
0.1
0.12
0.14
0.16
0.18
Ga55 Ga411 Ga438 Ga418 Ga201 Ga434 Ga47 Ga440 Ga421 Ga436
R
el
at
iv
e 
M
TA
1 
Ex
pr
es
s
Cancer Normal
 
Figure 3.2:- Expression of MTA1 in gastric carcinoma and patient matched normal gastric 
tissue(A) Graph analysing nine tumour and normal tissues from patients (B) Individual patient 
variation of MTA1 expression 
A 
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Table 3.2 Gastric Carcinoma sample information and their relative MTA1 expression 
Sample Code TNM Stage Differentiation Lauren’s 
Classification 
Relative MTA1 
Expression 
Ga55T 4.1.0 GIII Diffuse 0.08 
Ga55N    0.06 
Ga411T 3.0.0 GIV Intestinal 0.26 
Ga411N    0.06 
Ga438T 2.0.0 GII Intestinal 0.09 
Ga438N    0.07 
Ga418T 3.0.0 GIII Diffuse 0.14 
Ga418N    0.01 
Ga201T NA Low NA 0.09 
Ga201N    0.04 
Ga434T 2.0.0 GII Intestinal 0.15 
Ga434N    0.15 
Ga47T NA GIII Intestinal 0.14 
Ga47N    0.05 
Ga440T 3.1.0 GIII Diffuse 0.16 
Ga440N    0.03 
Ga421T 3.0.0 GIII Diffuse 0.08 
Ga421N    0.06 
Ga436T 2.0.0 GI Intestinal 0.26 
Ga436N    0.06 
 
 
To verify previously published studies of MTA1 over-expression in breast cancer samples, 
MTA1 expression was compared in breast cancer as well as the normal breast tissues. As 
expected, MTA1 expression was increased in breast cancer samples as compared to normal 
breast tissues, however, this did not reach the level of statistical significance. One of the reasons 
for that might be that several normal tissue samples had very low and/or poor quality RNA and 
could not be amplified for either the house keeping gene or MTA1 and had to be excluded from 
final analyses. Moreover, increased numbers of samples might be required to conclusively 
suggest MTA1 over-expression in breast cancer tissues. Individual patient variation could only 
be compared in four samples where two of them had significant increase in MTA1 levels in 
cancer tissue compared to normal tissue. Patient Br12 had more than 10 times increase in MTA1 
levels and it correlated with her tumour size, although information regarding the node 
involvement or metastasis was not available for this patient. Amongst the samples investigated, 
patient Br11 had the highest degree of node involvement but this could not be correlated with 
MTA1 expression. 
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Figure 3.3:- Expression of MTA1 in breast carcinoma and patient matched normal breast 
tissue(A) Graph analysing nine tumour and normal tissues from patients (B) Individual patient 
variation of MTA1 expression 
 
B 
 
In order to validate a mouse model for MTA1 immunotherapy, we investigated the expression of 
mouse MTA1 in normal mouse tissues and tumour cell lines. Several normal tissues (brain, 
kidney, lung, heart, testis, liver, thymus and spleen) were obtained from naïve mouse and 
immediately snap frozen in liquid nitrogen. Frozen tissues were crushed using mortar and pestle 
and mRNA was isolated from them using RNA-STAT60 (AMS Biotechnology, UK) and reverse 
transcribed using random primers. Expression of MTA1 was initially determined using 
conventional RT-PCR. All the samples contained non-degraded RNA as shown by normal 
expression of the house keeping gene mGAPDH (fig3.4a). MTA1 was found to be over-
expressed in all the tumour cell lines compared to the normal tissues except testis (fig 3.5). 
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Table 3.3 Breast Carcinoma information and their relative MTA1 express 
Sample Code TNM Stage Differentiation Histology Relative MTA1 
Expression 
Br1T 1.0.0 Moderate Infiltrative - 
Br1N    - 
Br2T 3.1.0 Low Infiltrative signet r 0.17 
Br2N    0.04 
Br6T 2.1.0 Moderate Infiltrative 0.04 
Br6N    0.08 
Br7T 2.1.0 Moderate Infiltrative 0.13 
Br7N    - 
Br8T 3.1.0 Moderate Infiltrative, medul 0.16 
Br8N     
Br9T - Fibroma NA 0.03 
Br9N    - 
Br10T 1.0.0 Moderate Infiltrative 0.2 
Br10N    - 
Br11T 2.3.0 Moderate Infiltrative 0.31 
Br11N    0.22 
Br12T 4.-.- NA Infiltrative 0.16 
Br12N    0.00 
Br13T 1.0.0 Moderate Infiltrative - 
Br13N    0.14 
 
3.2.2 Expression of murine MTA1 in mouse cancer cell lines and normal tissues 
 
(a) 
 mGAPDH 
 
 
(b) 
mMTA1 
 
Figure 3.4 Agarose gel electrophoresis of mGAPDH and mMTA1 following RT- PCR Lanes:-1, CT26; 
2, A20; 3, RENCA; 4, CMT 93; 5, B16; 6, Brain; 7, Liver; 8, Lung; 9, Muscle; 10, Spleen; 11, Kidney 
Following completion of RT-PCR, 20 μl of the final products were run on the 1.5% agarose gel. (a) 
Primers for mGAPDH were designed to amplify a 300 bp product. Bands were seen at the expected size, 
confirming that the band is mGAPDH. GAPDH PCR was performed for 24 cycles. 
(b) Primers for mMTA1 were designed to amplify a 508 bp product, which is the size at which the bands 
were seen confirming the expression of mMTA1. mMTA1 PCR was performed for 30 cycles. It can be 
clearly seen that the mMTA1 is highly expressed in the tumour cell lines compared to normal tissues. 
 
Although genomic DNA contamination could not be ruled out in the samples, the primers used 
were located on different exons and hence MTA1 amplification from genomic DNA would have 
generated a much larger band size. The level of MTA1 expression in the testis was similar to the 
tumour tissues. In comparison, all the normal tissues expressed MTA1 at very low levels. It is 
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noteworthy, that mMTA1 transcripts were also detected in muscle tissues, which contradicts 
previously published results, where no MTA1 expression was detected (Simpson et al, 2001). 
However, in those experiments, MTA1 expression was determined by in-situ hybridization, 
which lacks the sensitivity of RT-PCR. 
Expression of MTA1 was not limited to a particular strain of mice as tumour cells of different 
backgrounds expressed high levels of MTA1. Higher Expression of MTA1 in tumour cells and 
testis (data not shown) suggests that it might be important for the proliferation of cells. 
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Figure 3.5:- Real time PCR analysis of mouse MTA1 in mouse tumour cell lines and normal 
tissues (n=3) 
 
To confirm the data obtained from conventional PCR, murine MTA1 expression was determined 
and compared in tumour cell lines and normal mouse tissues using quantitative real time PCR. 
As for the human tumour tissues, mMTA1 was amplified for 40-45 cycles and its relative 
expression was determined by dividing the standard quantity of mMTA1 by that of house 
keeping gene 18S ribosomal RNA. As seen from figure 3.5, RT-Q-PCR confirmed the 
conventional PCR results with high relative expression of MTA1 in all cell lines tested compared 
to all the normal tissues, except testis. Importantly, low levels of MTA1 could be detected in the 
thymus by RT-Q-PCR suggesting its potential expression in adult thymus, which could lead to 
central tolerance and deletion of MTA1 specific T cells. 
 
 
 90
                                                                                                                                             Chapter 3 
3.2.3 Expression of MTA1 protein in mouse cancer cell lines and normal tissues 
 
                  1          2           3           4          5           6        7          8 
A 
Mouse 
B 
Human 
Figure 3.6 Western Blot of murine tumour cell lines, normal tissues and human tumour cell lines. 
30μg of protein was loaded in each lane and western blot performed by probing with anti human MTA1 
antibody cross reactive with murine mta1. 
A:- from 1-8, CT26, A20, RENCA, EL4-HHD, Liver, Lung, Brain, Kidney 
B:- from 1-3, HaCaT, K562, MDA-MB-435. 
 
Although murine MTA1 transcripts were detected at high levels in all the cell lines tested, it can 
be argued that the level of actual protein might be affected by post translational modifications 
and that RNA levels do not necessarily reflect levels of protein in the cell (Gygi et al., 1999). 
Indeed, MTA1 contains several phosphorylation sites which could influence its protein 
expression and function (Toh et al., 1997). Hence, to confirm the protein expression of MTA1 in 
cell lines and tissues, protein lysates were prepared from various cell lines as well as tissues by 
homogenisation. Protein concentration was determined in all the samples and western blotting 
was performed with equal quantities of proteins (30μg) and blots probed with MTA1 antibody. 
As seen from figure 3.6, an approximately 80KDa size immunoreactive band corresponding to 
MTA1 was observed in most of the samples. High level of MTA1 protein expression was 
observed in CT26, A20 and EL4-HHD cell lines, whereas, RENCA cells expressed the lowest 
levels of MTA1 protein. Several groups have previously reported MTA1 expression at lower 
level in normal tissues (Nicolson et al, 2003, Simpson et al, 2001). Interestingly, although 
MTA1 expression was detected at lower levels in tissues by RT-PCR, western blot was unable to 
detect protein expression in normal tissue lysates. This might be due to protein expression in 
tissues being lower than the detection threshold of the technique rather than non expression of 
MTA1. Furthermore, variable expression of MTA1 was also observed in the human tumour cell 
lines tested, with HaCaT and MDA-MB-435 cells expressing it at lower levels, and higher levels 
being expressed in CML cell line K562. Interestingly, in the human cell lines, two distinct bands 
could be seen, which could either be other MTA family members or a splice variant of MTA1. 
However, this needs to be further investigated. 
 Thus, MTA1 protein is preferentially expressed at higher levels in tumour cells compared to 
normal tissues. This suggests that MTA1 could be exploited as a target for immunotherapy 
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where the immune response would be predominantly directed against tumour cells with less 
likelihood of serious autoimmune reactions. 
 
3.2.4 Localisation of mouse MTA1 
 
Most studies have suggested that MTA1 is localised in the nucleus. However, two recent studies 
have contradicted this and showed MTA1 to have some limited cytoplasmic localisation as well 
(Yaguchi et al., 2005; Aramaki et al., 2005). To investigate the localisation of MTA1, murine 
MTA1 was cloned into the pSMART2b vector (see chapter 4). BHK cells were transfected with 
pSMART2b/mMTA1 vector using Lipofectamine and MTA1 localisation observed by 
immunofluorescence after staining for the FLAG tag. Mouse MTA1 was observed to be localised 
completely in the nucleus as seen in figure 3.7. 
  
  
Figure 3.7 Immunofluorescence assay for localisation of MTA1 in BHK cells after 
transfection with pSMART2b/mMTA1 A- no antibody, B-Isotype control antibody, C-Non 
transfected BHK and FLAG antibody, D-Transfected and FLAG antibody 
B A 
C D 
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3.3 Discussion 
 
Metastasis involves a complex series of events which are controlled by multiple genes and some 
of these genes are likely to be good targets for therapy. In view of the overwhelming failure of 
chemotherapy and radiotherapy regimes to control late stage metastatic disease, it becomes all 
the more vital to devise strategies targeting metastatic cells. MTA1 is one of the several antigens 
proposed to play a role in metastatic process and is a likely candidate for immunotherapy. 
 
Studies in the past few years have showed MTA1 to be over-expressed in various human 
tumours such as pancreatic, prostate, lung, oesophageal, gastrointestinal and breast cancers 
(Hofer et al., 2004a; Hofer et al., 2004b; Sasaki et al, 2002; Toh et al, 1999; Toh et al., 1997; 
Toh et al., 1995). In order to validate MTA1 as a target for therapy we confirmed the expression 
analysis of MTA1 in various human cancer tissues obtained from patients and compared it to the 
normal tissues. MTA1 expression levels were normalised to two different house keeping genes 
(GAPDH and rRNA), but due to non-reliability of GAPDH levels only 18SRNA levels were 
taken into account for normalisation. It has been recently reported in the literature that GAPDH 
is an un-reliable house keeping gene for normalisation in RT-PCR due to its wide variability in 
response to different factors and should not be the gene of choice for this purpose (Bustin, 2002). 
MTA1 was found to be over-expressed in both gastric and colorectal carcinomas (tumour/normal 
ratio>2), in 6 out of 9 colorectal cancers and in 5 out of 10 gastric cancers. However, mean 
expression level analysis were only statistically significant for gastric cancer. In individual 
colorectal cancers, MTA1 expression was correlated with the tumour size and lymph node 
involvement. This is slightly higher than the previously published study, where approximately 
40% of colorectal and gastric cancers over-expressed MTA1 compared to the paired normal 
colon or gastric epithelium respectively; which might be due to different techniques used in both 
studies, as Toh et al used semi quantitative PCR (Toh et al., 1997). However, in their study, 
clinical-pathological correlation of colorectal cancer showed that MTA1 over expressing 
tumours exhibited significantly deeper wall invasion and a higher rate of metastasis to lymph 
nodes and were likely to be at a more advanced Duke’s stage. Although, our results suggest a 
correlation between MTA1 expression and lymph node involvement, analysis of a larger set of 
samples is required to allow statistical comparison. Previous study had also established a link 
between MTA1 expression and serosal invasion, metastasis and vascular involvement for gastric 
cancers (Toh et al., 1997). Unfortunately, no such correlation was observed for gastric cancers in 
the present study. One of the main reasons for this could be that the RNA samples used in this 
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study were derived from primary tumours of patients who were still in a relatively early stage of 
the disease. The highest level of MTA1 expression is likely to be present in the metastatic cells, 
which none of the patients had and hence no correlation could be established between MTA1 
level and metastases. A similar pattern was observed in breast cancer samples. However, several 
normal breast tissue samples had either low or poor quality RNA and could not be amplified. For 
the individual samples evaluated, MTA1 levels could not be correlated to tumour stage. 
Interestingly, in a recently published study of 263 breast cancer patients, MTA1 levels did not 
correlate with tumour grade but with the microvessel density of the tumours (Jang et al, 2006). 
This suggests that MTA1 might also be involved in tumour angiogenesis and is a potential target 
for anti-angiogenic therapy as well. 
 
It is noticeable that in most cases, an increase in MTA1 expression in tumour tissue is only 3-4 
fold compared to normal tissue. This is in agreement with other studies showing an increase of 
various metastasis related genes by 2-4 fold in human tumours (Dear et al., 1989). Another 
essential aspect to consider during analysis of tumour antigens is the source of RNA as well as 
the technique used for obtaining the tissue. All the tissues used in this study were obtained from 
radical surgery and this usually results in tissue consisting of different cell types. RNA obtained 
from such tissues can be diluted out as a result of the presence of heterogeneous cell populations. 
The recent emergence of laser capture micro-dissection (LCM) has provided a crucial 
breakthrough for specifically isolating foci of tumour cells from a heterogeneous tumour 
population. This is achieved by selecting individual areas or cells and directing a brief laser pulse 
at the area to isolate them (Bustin, 2002). Indeed, it was recently observed that when compared 
to benign prostate tissue, MTA1 levels were not significantly elevated in prostate cancer samples 
obtained by radical prostatectomy. However, when similar study was performed with prostate 
cancer samples isolated using LCM, a significant difference was observed in MTA1 expression 
(Walton T, unpublished). 
 
Analysis of the expression data of MTA1 revealed that MTA1 was over-expressed in most 
cancers of different histological types. However, the question still remains whether MTA1 
expression increases as a result of the metastatic process or plays an essential role in the process? 
Firstly, low level expression in most normal tissues and high levels in testis suggests that it does 
indeed have a role in proliferation and migration of cells. Several recent studies have provided 
evidence supporting this hypothesis. Nawa et al showed that treatment of a human breast 
adenocarcinoma cell line, over-expressing MTA1, with anti-sense phosphorothioate 
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oligonucleotides inhibited its cell growth to 22% of mock treated cells, whereas similar treatment 
of cells expressing MTA1 at normal levels did not have any effect on their growth (Nawa et al., 
2000). Complementing this study, Mahoney et al demonstrated multiple effects of MTA1 over-
expression in human immortalised keratinocytes (HaCaT cells) (Mahoney et al., 2002). Over 
expression of MTA1 in HaCaT cells led to increased migration and invasion of immortalised 
keratinocytes, allowing them to grow in an anchorage independent manner as well as contributed 
to their expression of anti-apoptotic Bcl-2 family member Bcl-xl. More importantly, this was 
also confirmed in an in vivo mouse model of MTA1 dysregulation leading to development of 
mammary tumours (Bagheri-Yarmand et al., 2004).  
 
MTA1 was recently cloned in our laboratory using SEREX suggesting its immunogenicity, at 
least for the CD4+ T cells. Human MTA1 is 94% identical to mouse MTA1 at protein level and 
this led us to investigate MTA1 as a target for immunotherapy in a murine model. Most of the 
studies to date have concentrated on MTA1 expression in human tumours and tissues.  It was 
necessary to determine the relative expression of mouse MTA1 in tumour cell lines and normal 
tissues to validate using MTA1 as a target in the mouse model. Hence, initially, the expression of 
mMTA1 was determined; using RT-PCR, in murine cancer cell lines of different background and 
expression compared with that in normal murine tissues. MTA1 was found to be highly over-
expressed in all the tumour cell lines tested, whereas the expression in normal tissues was quite 
low compared to them. This result is in agreement with previous studies performed in humans 
and rats, where MTA1 expression in tumours was nearly two to four times that of normal tissues 
(Nicolson et al, 2003). However, previous studies failed to demonstrate expression of MTA1 in 
muscle cells, but in this study MTA1 appears to be expressed in muscle cells although at much 
lower levels (Simpson et al, 2001). The reason for this discrepancy may be that Simpson et al 
(2001) used Northern blotting, which lacks the sensitivity of RT-PCR. Furthermore, for relative 
quantification of MTA1 in tumour cells and normal mouse tissues, RT-Q-PCR was performed, 
which not only confirmed the results of conventional PCR but also showed MTA1 levels to be 
several fold higher in tumour cell lines compared to normal mouse tissues. However, the mouse 
tumour cell lines used were mostly derived decades ago and might have undergone additional 
genotype and phenotype changes during in vitro cultures, which would explain differences 
observed in human vs. mouse tissues (4 fold vs.  10 fold increase). Furthermore, in vivo 
expression of MTA1 (or other tumour antigens) could also be affected by the immune system or 
other regulatory mechanisms. 
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Hence, any immune response against MTA1 could also potentially lead to an autoimmune 
destruction of the organs expressing MTA1, although high level of protein expression is 
generally required in cells, for peptide-MHC complexes to be expressed on the surface in 
sufficient quantities to be recognised by CTLs (Stevanovic and Schild, 1999). This could help 
the CTLs generated against MTA1 antigen to distinguish normal tissues from tumour cells and 
thereby causing minimal auto immune reaction, if any. 
Furthermore, western blotting was performed to confirm and compare the protein expression of 
MTA1 in murine tissues and tumour cell lines and also to eliminate any possibility of post-
translational modifications altering the MTA1 protein expression, which was observed in all the 
cell lines tested although RENCA seemed to express it the least amount of MTA1 compared to 
other cells. Moreover, no MTA1 protein expression was observed in normal tissues by western 
blotting, which is likely to be due to lower sensitivity of western blotting compared to RT-PCR. 
However, this again confirms that MTA1 is expressed at very low levels in normal tissues, which 
could limit the auto immune response.  
Lastly, localisation of MTA1 was investigated using immuno-fluorescence and as expected 
showed nuclear localisation of MTA1. Two recent studies have contradicted previously 
published results and suggested that MTA1 might have limited nuclear localisation. Yaguchi et 
al identified several splice variants of MTA1 in mice and showed differential localisation of 
these variants (Yaguchi et al., 2005). Using a yeast two-hybrid system Aramaki et al showed that 
mMTA1 interacts with endophilin 3 in the cytoplasm and suggested its possible involvement in 
endophilin 3 mediated endocytosis (Arakami et al., 2005). Thus the results here contradict these 
studies and are in agreement with most other studies proving nuclear localisation of MTA1. 
Nuclear localisation does not sequester antigens from the immune system as revealed by a 
number of auto-immune diseases where antibodies are generated to nuclear antigens (Nakken et 
al., 2003). However, CD4+ T cells reactive to nuclear antigens undergo rigorous tolerance or 
deletion mechanisms (Nakken et al., 2003). 
 
Thus, the present study confirms that MTA1 has most of the characteristics of an ideal tumour 
antigen such as low level expression in normal tissues, important role in oncogenic 
transformation of cells as well as being a late stage disease antigen. Moreover, high similarity in 
protein sequence and function between mouse and human MTA1 makes it a convenient antigen 
to investigate its immunogenic potential in murine model, with direct application for human 
disease. However, being a self-antigen, tolerance to MTA1 is likely to be a key factor in 
generating immune response with the added risk of stimulating an auto-immune reaction. 
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Chapter 4:- Construction of Plasmid and Viral Vectors encoding MTA1 
 
4.1 Introduction 
In the past few years, gene based immunisation strategies have evolved dramatically for 
infectious diseases and cancer. Contrary to peptide vaccination, ‘gene immunisation’ can be 
applied to the whole population, without the need for identifying naturally processed peptides for 
different MHC haplotypes. This makes it widely applicable to general population. Another 
advantage of this method is its ease of production to good manufacturing practice (GMP) 
standards and cost of production. Apart from these, they can be delivered by multiple routes, are 
naturally immunogenic and activate multiple arms of the immune system (Pavlenko et al., 2004). 
Gene-based strategies can mainly be divided into two, ‘naked’ plasmid based as well as 
viral/bacterial vector vaccination. Moreover, apart from their direct administration as a vaccine, 
they can also be used to modify tumour cells and APC in vitro before injecting them in order to 
make them more immunogenic or increasing their antigen presenting ability, respectively. 
Wolff and colleagues first noticed the in vivo protein expression on injection of plasmid 
encoding for the protein, paving the way for a revolution in vaccination strategies (Wolff et al, 
1990). They observed that in vivo injection of DNA or RNA expression vectors encoding genes 
can lead to long term detectable protein expression (up to 2 months) in the muscles injected. 
Plasmid vaccination consists of a bacteria derived plasmid backbone encoding the gene of 
interest. Three essential components of a plasmid vector are expression cassette consisting of a 
promoter and a polyadenylation signal, antigen encoding gene sequence as well as an origin of 
replication and selection marker for propagation of plasmid in bacteria. Recent completion of the 
human genome project has provided immunologists with sequence information of virtually all 
genes in the human body and utilising molecular biology tools, it is now possible to clone these 
genes into expression plasmids with relative ease. DNA vaccines can be delivered intra-
muscularly, through skin via gene gun, administered orally through mucosal route, intra-
peritoneal and intra-dermal injections.  
Different immunisation routes might have different immunological outcomes. The ability of 
‘naked’ DNA vaccines to generate and polarise the immune response can be due to several 
pathways. Firstly, resident APC in the muscle may take up the plasmid directly to produce the 
protein, process it and present it to generate the immune response. Secondly, muscle cells might 
uptake the DNA but are inefficient antigen presenters. Release of proteins from the transfected 
muscle cells undergoing apoptosis and their uptake by professional APC can also generate 
immune response, termed ‘cross-priming’. Lastly, skin resident APC (langerhans cells) can be 
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directly transfected on intradermally administered DNA via gene gun (Condon et al., 1996). 
Thus different pathways are likely to be involved in DNA based immunisation although the final 
response might be the result of a combination of above three mechanisms.  
Table 4.1:- Advantages and Disadvantages of DNA vaccines  
Advantages Disadvantages 
Cost-Effective 
Easily Manufactured to GMP standards 
Safe 
Easy to administer 
Several routes of vaccination 
Low doses required 
Primers multiple arms of immune response 
Antigens can be linked to several co-
stimulatory molecules or cytokines 
Innate adjuvant properties 
Prior knowledge of antigen sequence 
Might require additional adjuvants 
Codon optimisation might be necessary 
Different routes of vaccination might generate 
response 
 
Several studies have provided contradicting results regarding polarisation of the immune 
response by gene gun and intra-muscular immunisation. Bombardment of skin with DNA coated 
gold particles uses 100-1000 times less DNA than other routes of vaccination. Saline–DNA 
immunisation either intramuscularly or intradermally leads to the generation of Th1 response and 
production of IgG2a antibodies in mice, whereas gene gun immunisation has been reported to 
generate a Th2 response and IgG1 antibodies. This polarisation of the response is independent of 
the dose of DNA and is likely to be influenced by the different cell types transfected with the 
injected plasmids (Torres et al., 1997; Felquate et al., 1997). Contradicting these studies, gene 
gun mediated DNA immunisation has been shown to provide protective and therapeutic anti-
tumour immunity mediated by CTLs (Condon et al., 1996; Bowne et al., 1999; Gold et al., 
2003). In these studies, vaccinating mice with as little as 1 μg of DNA through gene gun was 
enough to generate anti-tumour immune response.  
 
Recent years have also witnessed an unprecedented interest in use of viral vectors as alternative 
and more potent vectors for immunotherapy. Immunising with viral vectors can mimic natural 
viral infection, thereby generating more potent immune response and efficiently penetrate most 
cell types, which makes them particularly useful for in vitro or in vivo application. However, 
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there is also a wide spread concern regarding viral vectors for immunotherapy as there is a 
possibility of progressive viral infection, especially in immuno-compromised patients. This is 
evident by a number of different viral vectors being developed with high bio-safety levels and 
negligible chances of in vivo generation of infectious recombinant virus. New generation viral 
vectors have genes, essential for replication, deleted by genetic manipulation to make them 
attenuated. Other viruses such as avipox virus derived vectors take advantage of natural host 
restriction as they are unable to multiply in human cells. Another important characteristic for a 
viral vector is their low intrinsic immunogenicity, since antibody response to viral proteins can 
limit their efficacy as a therapeutic agent. Viral vectors commonly used for therapy include the 
following:- 
 
Table 4.2 Characteristics of Different viral vectors (Adapted from Bonnet et al., 2000) 
Vector Biology Pre-existing  
immunity in  
human 
Duration of  
Gene  
Expression 
Safety 
Retroviruses Diploid RNA  
strand 
No Good Risk of insertional  
mutagenesis 
Vaccinia  
viruses 
Double stranded 
 DNA  
replicative 
Yes Transient Well documented  
       safety 
Avipox viruses Double-strand  
DNA non  
replicative in  
mammalian cells 
Yes Transient Very good 
Adenovirus Double- 
stranded DNA  
(linear) 
Yes (highly 
immunogenic) 
Transient Good 
Adeno- 
associated viral 
 vector 
Single-strand  
DNA 
Yes Transient Risk of insertional  
mutagenesis 
Herpes simplex 
 virus 
Double- 
stranded DNA  
(linear) 
Yes Transient Neurovirulence,  
 
Alphavirus  
(SFV, EEV) 
RNA viruses 
 with replicon 
No Good Safe in animals, not fully 
characterised in humans 
SFV=Semliki Forest Virus, EEV=Equine Encephalitis Virus 
 
 
 
Adenovirus 
Adenoviruses are medium sized non enveloped double-stranded DNA viruses. There are more 
than 50 serotypes of adenovirus known of which serotype 2 and 5 have mostly been used for 
 99
                                                                                                                                             Chapter 4 
vector development (Jooss & Chirmule., 2003). They infect the cells using a viral fibre knob to 
bind to coxsackievirus receptor (CAR) and other co-receptors. Adenovirus replicate inside the 
nucleus of infected cell without integrating into their genome. They are associated with a number 
of infections in humans such as upper respiratory tract infections, conjunctivitis and other 
infections in immuno-compromised hosts. Consequently, they are capable of infecting a wide 
range of cell types. Their main advantages are high level of protein expression and relative ease 
of high titre generation. They are capable of generating cell mediated and humoral immune 
response in immunised animals. First generation adenovirus derived vectors had deletion in 
genes necessary for replication, which were followed with second generation vectors having 
deletions in other genes responsible for blocking host immune response. However, more than 
85% of the population has neutralising antibodies to adenovirus, precluding their use for human 
in vivo immunotherapy (Bonnet et al., 2000). Although antibodies to adenovirus have made their 
use limited, novel recombinant vectors, high protein expression, ability to infect dividing and 
non-dividing cell and use of uncommon adenovirus serotypes might still make them useful for 
immunotherapy 
 
Adeno Associated virus (AAV) vectors 
AAV are single stranded DNA virus of parvovirinae family of 4.7 kb genome. Eight different 
serotypes of AAV have been identified and wild types AAV1-6 have not been associated with 
any known human disease. AAV-2 has been the most extensively studied serotype for 
immunotherapy. AAV vectors can stably integrate into the human genome on chromosome 19 
(Jooss & Chirmule., 2003). They can infect dividing and non-dividing cells and their greatest 
advantage is their long term gene expression compared to other vectors (Bonnet et al., 2000). 
Recombinant AAV vectors need helper virus to replicate and this can also limit their production 
at high titres without a stable helper cell line. Moreover, they have a limited insert capacity (4.5 
Kb) which might preclude their use in cancer vaccination, since vector coding for multiple genes 
(antigens along with co-stimulatory/cytokine genes) is likely to be more efficacious compared to 
one encoding only the antigen. 
 
Poxvirus Vectors 
Poxviruses are large, enveloped double stranded DNA virus and are the only virus with intra-
cytoplasmic replicating capability. They can be generated to high viral titres using primary 
chicken embryo fibroblasts and their major advantage is their ability to accept large inserts (up to 
30 Kb). This would allow simultaneous insertion of multiple genes and wider application. 
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Among several poxviruses investigated, modified vaccinia Ankara strain (MVA) has shown high 
bio-safety profile and is highly efficacious as demonstrated in the small pox eradication 
programme (Bonnet et al., 2000). NYVAC stain was derived from the original Copenhagen 
strain by deletion of 18 open reading frames. Other poxviruses such as canarypox and fowlpox 
virus are potentially safer due to their inability to multiply in human cells. Poxvirus vectors have 
proved their efficacy in immunotherapy of cancers in animal studies (Jourdier et al, 2003). 
 
Herpes Simplex Viral vectors 
HSV are large, enveloped, double stranded DNA containing virus with a 152 kb genome. HSV 
viral genome encodes for 73 distinct genes, of which 38 are believed to be redundant and can be 
replaced with foreign genes. They are able to infect most types of dividing cell and do not 
integrate into the host genome. Moreover, several variants of HSV have been constructed with 
modifications to ensure that replication competent virus is not generated in vivo. DISC-HSV was 
derived by deleting the essential glycoprotein (gH) gene from HSV virus allowing the replication 
competent viruses to be formed only in competent cell line having the gH gene (Rees et al., 
2002). This provides DISC-HSV with an added level of safety. HSV vectors have good safety 
profile and have proven highly efficacious in animal models, where injection of DISC-HSV/GM-
CSF intra-tumorally led to tumour regression in 60% of mice with well established tumours. 
Being cytolytic, they are also likely to induce cross-priming (Ali et al., 2002). Moreover, 
previous exposure to HSV and antibody presence to it, was unable to decrease therapeutic 
efficacy of DISC-HSV. 
 
Retroviruses 
Retroviruses are diploid positive-strand RNA viruses. They are likely to integrate into the 
genome of the cell and hence carry a chance of insertional mutagenesis. However, retroviruses 
only infect dividing cells and are inefficient at infecting APC, which could limit its use for 
human in vivo application. It is particularly useful for in vitro modification of tumour cells due to 
stable integration and long term protein expression (Hodge & Schlom, 1999). Lentiviral vectors 
derived from the HIV-1 have generated a lot of interest recently for clinical gene therapy, due to 
their capability of infecting non-dividing cells as well. Replication incompetent vectors have 
recently been designed which uses either helper genes or packaging cell lines for virus 
generation and are considered safer for human application (Buchschacher & Wong-Staal, 2000). 
However, HIV derived vector systems still cause serious concerns for human therapy due to a 
possibility of wild-type virus generation in vivo. 
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Alpha virus  
Commonly used alpha viruses are Sindbis virus, Semliki forest virus (SFV) and Venezuelan 
Equine Encephalitis virus and have proved very efficient gene delivery vehicles. Alphaviruses 
have a single stranded RNA genome of approximately 12 kb and surrounded by an icosahedral 
capsid protein shell. They have the ability to infect different cell types, generate high level of 
protein and are cytolytic in nature, leading to cell lysis 48-72 hour post-infection. 
 
Semliki Forest Virus as choice of vector for immunotherapy 
SFV is a 65-70 nm spherical virus with a single strand RNA. Viral genome is surrounded by a 
nucleocapsid, which is formed by 240 copies of the capsid protein arranged to form an 
icosahedral shell. Nucleocapsid is surrounded by a lipid bilayer derived from host cell membrane 
into which glycoprotein spikes formed by proteins E1, E2 and E3 are inserted. SFV mRNA 
consists of two open reading frames (ORF), the first of which codes for the four non structural 
proteins and the second ORF codes for capsid and envelope proteins. SFV infects cells via 
binding of its envelope protein to different cell surface receptors (figure 4.1). Upon SFV 
infection, host cell protein synthesis shuts down in favour of virus encoded protein production 
(Riezebos-Brilman et al., 2006). 
 
Low infection efficiency, limited host range, safety and complexity of the system are some of the 
hurdles in viral vector based gene therapy. Recombinant SFV vectors for immunotherapy have 
generated considerable interest due to their ability to overcome these challenges. Because of 
genetic manipulation, recombinant SFV are inactive and have to be activated with α-
chymotrypsin before use, which makes it particularly safe for handling (Berglund et al., 1993). 
Also, they are only capable of a single round of infection; high level protein expression followed 
by apoptosis facilitating cross-priming and priming adaptive and humoral immune system also 
make them a popular choice. Due to dsRNA intermediates generated upon infection, they are 
potent in activating dendritic cells through TLR3 (Riezebos-Brilman et al., 2006). Moreover, 
humans do not have any antibodies to SFV, which allows them to be administered without 
decrease in efficacy due to neutralising antibodies. 
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Figure 4.1:- SFV structure (a) Schematic structure of SFV (b) Cryo-Electronmicroscopy image 
reconstruction (c) Schematic structure of genome of SFV and its recombinant SFV vector (taken 
from Riezebos-Brilman et al., 2006). nsP= non-structural proteins 
(c) 
 
Original SFV expression vector system employed a plasmid with SP6 RNA polymerase 
promoter and the structural protein coding region replaced with gene of interest (Liljestrom & 
Garoff., 1991). This was complemented with a helper RNA encoding for the viral structural 
proteins. Thus, upon co-transfection of both helper and gene coding RNA, recombinant virus 
particles are generated. Moreover, mutation in the p62 protein gene generates viruses which are 
inactive and have to be proteolytically treated with α-chymotrypsin. These two safeguard 
mechanisms make it unlikely for replication competent virus would be generated upon 
transfection or in vivo application for therapy. However, RNA based SFV expression system still 
require the generation of capped RNA transcripts in vitro and specialised handling conditions. 
These obstacles were overcome by DiCiommo and Bremner, who constructed a DNA based 
expression system by replacing the SP6 promoter with RNA polymerase II dependent 
cytomegalovirus immediate early (CMV IE) enhancer/promoter to drive transcription in vivo 
(DiCiommo & Bremner, 1998). Both helper and replicon plasmids were designed and conditions 
were optimised for co-transfection to generate high levels of virus titre. Co-transfection of both 
plasmids into BHK cells generated upto 20-30 pg/cell of virus encoded foreign protein 
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(DiCiommo & Bremner., 1998). This improved SFV expression system was later enhanced 
further by expanding the multiple cloning site as well as addition of FLAG and HIS10 epitope 
and affinity tags (DiCiommo et al., 2004). 
 
The SFV vector system has been evaluated in several animal models for generation or preventive 
and therapeutic immune response to cancer (Daemen et al., 2000; Daemen et al., 2003; Daemen 
et al., 2004; Ni et al., 2004; Riezebos-Brilman et al., 2005). Moreover, a recent study also 
demonstrated the ability of SFV vector to generate an immune response in an immune-tolerant 
mouse model, demonstrating its usefulness in breaking tolerance (Riezebos-Brilman et al., 
2005). Thus, ease of manipulation, good efficacy for therapeutic purposes as well as ability to 
overcome tolerance led us to investigate SFV expression system as a means for breaking 
tolerance to MTA1. 
 
In order to investigate application of plasmid DNA vaccination for generating immune response 
to MTA1, this study describes the construction of a plasmid expression vector coding mMTA1. 
Also, human MTA1 was cloned into the expression vector for investigating xenogeneic 
immunisation. Furthermore, both mMTA1 and hMTA1 were cloned into SFV vectors and virus 
generation optimised. This was followed by confirmation of protein production by the various 
vectors generated. 
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4.2 Results 
4.2.1 Cloning of mouse and human MTA1 into mammalian expression vector pcDNA3 
   
Figure 4.2 Agarose gel electrophoresis of full length mMTA1 following RT- PCR from mouse 
 testis for 40 cycles 
3Kb 
2.1 Kb 2Kb 
1.6Kb 
1Kb 
 
In order to immunise mice with full length plasmid as well as viral vaccination, the full open 
reading sequence of MTA1 was cloned into pcDNA3. Full length mouse MTA1(mMTA1) was 
first amplified from mouse testis using RT-PCR for 40 cycles, using a high fidelity Taq 
polymerase (Phusion, Finnzymes, UK). It is noteworthy, that mouse testis was used for 
generating amplified MTA and not a tumour cell line which might have mutations in the MTA1 
gene, although no documented mutations have been reported in MTA1 till date. After running 
the amplified mMTA1 on an agarose gel, a band corresponding to 2.1Kb (mMTA1) was clearly 
visible and was extracted (Fig 4.2). Since Phusion Taq polymerase generates blunt ended 
products, full length mMTA1 cDNA was cloned into TOPO-Blunt vector (Invitrogen), using 
manufacturer’s instructions. 
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Figure 4.3 Agarose gel electrophoresis after double digestion of TOPO-Blunt clones with
insertion. 
 
Briefly, blunt ended mMTA1 was incubated with 1μl of TOPO-Blunt vector and 1μl of salt 
solution for 5 minutes. TOPO vectors take advantage of the enzyme DNA topoisomerase I, 
whose function is to nick and re-ligate DNA fragments. Five minute ligation was enough for 
insertion of MTA1, without a need for addition of DNA ligase enzyme. Following the ligation, 
XL1B bacteria were transformed with TOPO-Blunt/mMTA1 and plated on LB agar with 
kanamycin for selection of clones containing the plasmid. After overnight incubation at 37˚C, 10 
colonies were picked and grown in LB broth with 50μg/ml of kanamycin overnight. Plasmids 
were isolated from the selected clones. To confirm the presence of mMTA1 insert in TOPO-
Blunt, EcoRI restriction digest was performed on the plasmids, since TOPO-Blunt vectors have 
EcoRI restriction sites at both ends of the insert (see appendix). As seen in figure 4.3 band 
corresponding to 2.1kb could be detected in 9 out of 10 clones picked. 
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Figure 4.4 Agarose gel electrophoresis of TOPO-Blunt/mMTA1 clones after BamHI-AgeI double  
digest (lanes 1 & 6-1kb plus ladder, 2-5 &7-12 TOPO-Blunt/mMTA1 clones) 
1600bp 
500bp 
600bp 
800bp 
 
Furthermore, blunt ended mMTA1 could insert in either forward or reverse orientation into 
TOPO-Blunt vector. Clones with mMTA1 in correct orientation could be either identified by 
sequencing or restriction digestion of mMTA1 with one enzyme cutting inside mMTA1 and 
other on the vector to generate specific sized bands. Indeed, Age I restriction enzyme cuts 
mMTA1-TOPO construct approximately 500bp upstream of the start codon. Hence, if mMTA1 
was in the correct orientation then BamHI-AgeI double digestion would generate a band of 
approximately 500bp on agar gel electrophoresis, and a band of approximately 1500bp would 
indicate it in the reverse orientation. As seen in figure 4.4, 3 clones had mMTA1 in the correct 
orientation. One of them was sequenced to confirm that there were no mismatches.  
After three attempts, full length mMTA1 clone was obtained with 100% identical sequence to 
published mMTA1 sequence. Finally, to sub-clone mMTA1 into pcDNA3, both TOPO-
Blunt/mMTA1 (clone 5) and pcDNA3 were double digested with HindIII and XbaI restriction 
enzymes and run on Agarose gel (Figure 4.5). Digested corresponding bands of pcDNA3 and 
mMTA1 were gel extracted and ligated overnight at 4˚C with T4 DNA ligase enzyme, followed 
by plating on LB agar with ampicillin and selection of clones. Clones were confirmed to contain 
mMTA1 by restriction digestion (data not shown). 
Similarly, human MTA1 was cloned from human testis into pcDNA3 after confirming 100% 
sequence homology to the published sequence (data not shown).  
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Figure 4.5 HindIII-XbaI double digest of TOPO-Blunt/mMTA1 and pcDNA3 (from left to right  
lanes 1-ladder, 3- TOPO-Blunt/mMTA1, 5-pcDNA3, 7-ladder) 
mMTA1 
clone 
 
           α-Tubulin 
 1 2            3 
Figure 4.6 Western-blot of 293 cells48 hours after transfection with pcDNA3/mMTA1 or pcDNA
expression vectors  and α-tubulin western blot as a control (Lane 1-control, 2-mouse MTA1, 3-human M
MTA1 
 
To confirm mouse and human MTA1 protein expression by pcDNA3 vectors, human embryonic 
kidney (HEK 293) cells were transfected with pcDNA3 encoding for either mouse or human 
MTA1 using lipofectamine 2000 reagent and following manufacturer’s instructions (Invitrogen) 
(see methods). 24-48 hours after transfection, lysates were prepared from the transfected cells, 
protein assay was performed and 20μg of protein of transfected and non-transfected control 
samples were loaded on 10%SDS-PAGE gels. Western blot was performed by transferring the 
gel proteins onto a nitrocellulose membrane and probed with either MTA1 antibody or α-tubulin 
antibody as a control. High levels of MTA1 protein expression was detected in cells transfected 
with expression vectors encoding the human or mouse MTA1, compared to control cell lysates 
(Figure 4.6). It is noteworthy that the MTA1 signal was observed in control cells (no 
transfection), which is in agreement with our previous results showing variable MTA1 
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expression in most tumour cell lines. To confirm that the increased expression of MTA1 
observed in transfected cells was not due to overall increase in the total protein loaded (although 
equal amounts of protein were loaded), blots were also probed with α-tubulin antibody as a 
control protein. No significant changes in α-tubulin levels were observed. These results were also 
confirmed by RT-PCR (data not shown). 
 
4.2.2 Cloning of mouse MTA1 into pSMART2b vector for SFV vector generation 
 
Figure 4.7 Double digest of TOPO-Blunt/mMTA1 and pSMART2b vector with BamHI and NsiI  
(Lanes 1-ladder, 2&3-TOPO-Blunt/mMTA1, 4-pSMART2b) 
 
Plasmids for SFV vector generation were obtained from Dr. Rod Bremner (Canada). In order to 
generate SFV/MTA1 vectors, human and mouse MTA1 sequences had to be cloned into either 
pSMART2a or pSMART2b vectors. Both these vectors are essentially similar except that the 
gene of interest, when cloned into them, will be in different reading frames. It is essential for the 
gene of interest to be in correct reading frame with the upstream capsid-flag tag for the protein to 
be produced using these vectors. From the sequencing data of TOPO-Blunt/mMTA1 and TOPO-
Blunt/hMTA1, it was determined that open reading frame of MTA1, when sub-cloned, would be 
in frame in pSMART2b vector and not in pSMART2a. To sub-clone MTA1 sequence from 
TOPO-Blunt vectors, TOPO-Blunt/mMTA1 was double digested with BamHI and NsiI 
restriction enzymes, along with pSMART2b vector (Figure 4.7). Digested vector (pSMART2b) 
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and MTA1 band were extracted and ligated overnight as described before. Clones of vector from 
transformed E.Coli XL1B cells were isolated and checked for insertion of mMTA1 by repeating 
the BamHI-NsiI digestion (Figure 4.8). As seen below, 3 clones with mMTA1 insertions were 
identified and were further used for confirmation of protein production after transfection. Similar 
procedure was repeated for SFV/hMTA1 vector generation (data not shown). 
 
 
Figure 4.8 BamHI-NsiI double digest of pSMART2b/mMTA1 (lanes 1-ladder, 2-6 pSMART2b/ 
mMTA1 clones 
 
To confirm production of MTA1 protein by pSMART2b-mMTA1/hMTA1 vectors, BHK cells 
were transfected with the vectors using Lipofectamine and protein production was confirmed by 
western blotting 48 hours after transfection. α-tubulin protein expression levels were used as 
controls. As seen in figure 4.9, high levels of MTA1 expression was observed in cell lines 
transfected with pSMART2b-mMTA1/hMTA1 vectors, confirming the in frame insertion of 
MTA1 sequences in pSMART2b vector. To confirm that MTA1 protein could not be produced 
by pSMART2a vector, mMTA1 was sub-cloned into the pSMART2a vector and protein 
production investigated after transfection as above. No protein production could be detected in 
this case (data not shown). 
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Figure 4.9 Western-blot of BHK cells 48 after transfection with pSMART2b/mMTA1 or hMTA1 
 (lanes 1-pSMART2b/MMTA1, 2-pSMART2b/hMTA1, 3- Control non transfected) 
FLAG tagged MTA1 83 kDa 
 
Wild –type MTA1 80 kDa 
 
4.3 Optimisation of SFV/βgal generation 
 
Figure 4.10 Xgal assay BHK cells 24 hours after infection with SFV-βgal vector generated using original 
 protocol and modified protocol A=non infected cells, B=Cells infected with virus generated without freeze/ 
 thaw, C=virus generated after modified freeze thaw protocol 
B C A 
 
SFV vector generation requires co-transfection of the helper plasmid as well as the replicon 
plasmid (containing gene of interest). Factors, such as method of transfection and molar ratios of 
the two plasmids are known to affect the titre of virus generated. Lipofectamine and calcium 
phosphate (Promega, UK) mediated transfection methods were first investigated for virus 
production via transfection of HEK 293 cells and results confirmed that CaPO4 transfection 
method was better (data not shown). Previously, it had been suggested that 24-48 hour post-
transfection of 293 cells with both plasmids, virus can be harvested from the supernatants of the 
cells (DiCommio & Bremner, 1998). However, virus titre obtained through this method was very 
low. We hypothesised that most of the virus was still inside the cell and cell lysis by 
freeze/thawing might increase the titre of virus obtained. To test this, supernatants of the 
transfected cells were collected before and after freeze/thaw, and virus harvested from them. 
Following activation, equal quantities of supernatant was used to infect BHK cells and β-
galactosidase protein expression was determined by performing an X-gal assay. A significant 
increase in virus titre was observed from the supernatant of cells after the freeze thaw cycles 
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(1.34x105 pfu/ml vs 2x106 pfu/ml) (Figure 4.10). Hence, this modified protocol was then used 
for virus harvesting. Moreover, different molar ratios (1:1, 1:2, 1:3) of pSCaβ and helper 
plasmids were transfected using CaPO4 and its effect on virus titer examined. No significant 
difference was observed by using different molar ratios of the plasmids; however a molar ratio of 
1:3 generated slightly better titer and it was decided to use this ratio for all future experiments 
(data not shown). 
 
4.2.3 Dendritic cell infection by SFV/B-gal 
 
   
Figure 4.11 Xgal assay 24 hour post-infection of dendritic cells with SFV/β-gal. A-Control non  
infected DC, B-Infected DC, C-FACS analysis for selected dendritic cell markers 
 
 A B 
 
C 
CD40 CD11c MHC II 
 
Recent studies have suggested that SFV vectors are inefficient in infecting DC and most of the 
immunological response to SFV immunisation was due to cross-priming, where the infected cells 
undergo apoptosis and antigens released from them are engulfed by APCs, processed and 
presented (Huckriede et al., 2004). To confirm these findings, dendritic cells were generated 
from bone marrow of balb/c mice and infected with SFV-βgal for 1 hour at 37ºC. 24-48 hours 
post-infection, X-gal assay was performed on them to verify the expression of β-galactosidase 
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enzyme. As seen in figure 4.11, although SFV infected only about 15-20% of the DC, it was still 
approximately 100 times more than that observed by Huckriede et al (0.14%)-(Huckriede et al., 
2004). These results were confirmed in two independent experiments and were independent of 
strain of mice, since DC derived from C57BL/6 background mice showed similar susceptibility 
to infection (data not shown). Moreover, maturation status of DC had no significant affect on 
their ability to be infected (data not shown). 
 
4.2.4 Determination of MTA1 expression after infection of BHK cells with SFV-mMTA1 
Figure 4.12 Immunohistochemisty staining of BHK cells 48 hour post infection of 
 SFV/mMTA1 (A-Non infected cells, B-SFV/mMTA1 infection) 
A B 
 
Finally, to confirm MTA1 protein production in cells infected with SFV-MTA1 vectors, BHK 
cells were infected with 1x106 pfu/ml of the activated virus for 1 hour and generation of FLAG-
tagged MTA1 protein was visualised using immunohistochemistry. Infected BHK cells were 
stained with FLAG M2 (Sigma, UK) primary antibody followed by anti-mouse secondary 
antibody conjugated to HRP. DAB solution was added after washing three times to visualise 
brown staining of the infected cells. As seen in figure 4.12, negligible background staining was 
observed in control cells, whereas dark brown staining was observed in infected BHK cells 
indicating FLAG tagged MTA1 production. Moreover, immunohistochemistry revealed MTA1 
to be localised in the nucleus, which agrees with our immuno-fluorescence assay.  
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4.3 Discussion 
Nucleic acid vaccines can be delivered in a variety of forms such as plasmid DNA or RNA 
based, through modification of cells in vitro and viral/bacterial vectors. Choice of vector is 
dictated by its purpose and application. Nucleic acid vaccines offer the flexibility and specificity 
of generating potent immune response against multiple antigens and in certain cases are also able 
to polarise that response. Vaccination with whole protein antigens is expensive and time 
consuming to generate. Moreover, injected proteins are likely to be degraded within a few days, 
whereas nucleic acid vaccination can direct protein expression in vivo for few months or longer 
due to integration in the host genome.  
 
4.3.1 Generation of mammalian expression vector encoding MTA1 
Various vaccination methods have been shown to generate immune prevention and rejection 
responses, such as peptide, DNA, viral etc. Although reverse immunology approaches and 
transgenic mice application have made the identification of immunogenic and naturally 
processed peptides from tumour antigens relatively quick, it can still be very difficult, especially 
for self antigens. Most of T cells specific for high affinity epitopes from self-antigens are known 
to be either deleted or tolerised via central and peripheral tolerance mechanisms. Hence, 
identification of peptides from such antigens might require testing hundreds of peptides with 
medium binding affinity to particular MHC molecule, which is time consuming and expensive. 
Nucleic acid vaccination overcomes this limitation as it allows vaccination with whole gene or 
part of it and is applicable to the whole population. Various co-stimulatory molecule or cytokine 
genes can be included in these vaccines; moreover, antigens can be directed to specific antigen 
processing compartments by including signal sequences (Liu et al., 2004; Stevenson et al., 
2004). As an alternate strategy to generate immune response against MTA1 derived peptides, 
mouse MTA1 was cloned into a mammalian expression vector. Moreover, recent studies by 
Houghton et al, have proved xenogeneic immunisation to be an extremely useful tool in breaking 
tolerance to several self-antigens (Bowne et al., 1999; Gold et al., 2003; Naftzger et al., 1996). 
Hence, to investigate xenogeneic immunisation, the human MTA1 gene was also cloned in an 
expression vector. Having assembled and constructed the expression vector, it is essential to 
confirm that it performs as expected before moving into in vivo studies. This was confirmed by 
transfecting cells with these expression vectors and analysing the mRNA expression of MTA1 
by RT-PCR (data not shown). However, mRNA level of a gene does not always reflect its 
protein expression, which needs to be confirmed independently. Human embryonic kidney 293 
cells were transfected with pcDNA3-mMTA1/hMTA1 plasmids using lipofectamine reagent and 
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MTA1 protein expression was determined after 48 hours by western blotting. High levels of 
MTA1 expression was observed in transfected cells compared to control non-transfected cells, 
establishing the protein expression capability of the generated expression vectors.   
 
4.3.2 SFV vector generation and optimisation  
Numbers of viral and bacterial vectors have been used in recent years for modification of cells in 
vitro as well as for in vivo application in animals and humans. Viruses and bacteria are naturally 
immunogenic and efficient at infecting different cell types which make them potent weapons for 
immunotherapy. Adenovirus and pox virus vectors are the most widely used viruses to date but 
they have their limitations as well. One of the most important considerations in choosing a vector 
is the possibility of generating replication competent vectors in vivo, which could be potentially 
lethal in immuno-suppressed cancer patients. 
Alpha viruses (Semliki Forest Virus, Sindbis virus, Venezuelan Equine Encephalitis virus) are 
generating considerable interest for immunotherapy approaches. Necessity to simultaneously 
transfect with two different plasmids (helper and replicon) for virus production, limits the 
chances of generating replication competent virus in vivo. As an added bio-safety level, virus 
produced is inactive and need activation by cleavage of p62 protein. These mechanisms make 
SFV as a safe option for human immunotherapy. Original RNA based SFV vector system was 
modified and improved by DiCiommo and Bremner by constructing a DNA based system, which 
obviates the need for in vitro transcription and makes manipulation easier. However, DNA based 
expression system does have an adverse effect on the titre of virus generated. Co-transfection of 
DNA plasmids produced titres of approximately 1-2x106 pfu/ml, whereas by transfecting in vitro 
transcribed RNA generated 10-100 times higher titre (DiCommio & Bremner., 1998; Liljestrom 
& Garoff., 1991).  
Recombinant SFV (rSFV) particle generation was optimised for various parameters known to 
affect it. Co-transfecting β-gal reporter plasmid along with helper plasmid allowed easy 
optimisation of virus production and titre. Firstly, different methods of transfection were 
compared (Calcium phosphate, Lipofectamine, GeneJuice) and the calcium phosphate method 
was determined to be cheapest and most reliable method for HEK 293 cells, as previously 
suggested (Bremner et al., 1998). Thereafter, different molar ratios of helper to replicon plasmid 
were co-transfected in order to determine the best concentrations. Although different ratios did 
not have significant effect on virus titre production, molar ratio of 1:3 was slightly better and was 
used for virus generation. Higher concentrations of helper plasmid would mean that most of the 
cells transfected with replicon plasmid would also be transfected with helper plasmid. Lastly, 
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virus harvested from cell supernatant of co-transfected cells was of low titre and previous 
experience in our laboratory suggested that most of the virus was retained inside the cells and 
lysing them was likely to enhance the titre. SFV is a cytolytic virus and replicates inside the 
infected cell for 48-72 hours before causing cell apoptosis. Indeed, a single cycle of freeze-thaw 
significantly increased the titre of the virus. SFV virus was also found to be efficient at infecting 
different cell lines (human and mouse) (data not shown). Finally, to generate recombinant SFV 
(rSFV) particles encoding mMTA1 and hMTA1, these genes were first cloned into pSMART2b 
vector. Protein expression from these vectors was confirmed by transfecting cells followed by 
determination of MTA1 protein expression 48 hours later by western blotting. Moreover, rSFV-
MTA1 particles were generated and after activation they were used for infecting BHK cells in 
vitro, leading to high level of MTA1 production, thus confirming viral activity and efficacy. 
 
4.3.3 SFV vector can infect dendritic cells 
CD8+ T cell priming is an essential requirement in most cases for tumour rejection. This CTL 
generation is related to the ability of vectors to infect DC directly or indirectly. Rationale for 
vaccine design for cancer requires knowledge of antigen presentation following vaccination. 
Following SFV vaccination in vivo, there are two likely scenarios. DC can either become 
infected directly, producing virus encoded proteins, degrading them and presenting them on 
MHC class I molecules or they may uptake antigens indirectly after lysis of other infected cells 
and present them on MHC class I molecules through cross-priming. Several studies have 
produced contradictory results regarding DC infection by SFV. Immunisation with DC pulsed 
with SFV encoding tumour antigens or cytokines has shown to be efficient in generating CTLs 
and tumour protection/rejection, which suggests that SFV can efficiently infect DC (Yamanaka 
et al., 2003; Yamanaka et al., 2002). However, these findings have been contradicted by 
Huckriede et al (2004), who revealed inefficient infection of DC by SFV in vitro (0.14% DC 
infection at MOI of 1000). Furthermore, they hypothesised that CTL priming in vivo by SFV 
immunisation was due to cross-priming. In order to prove this, they generated SFV particles with 
different abilities to produce stable influenza nucleoprotein (NP) and suggested that rapid 
intracellular degradation of NP would not produce enough protein for cross priming, whereas 
stable high level expression of NP may improve cross-priming. Indeed, ubiquitin tagged NP 
(rapidly degradable form) produced by SFV was inefficient in generating CTLs, whilst SFV 
producing high levels of NP generated more potent immune response as measured by 
cytotoxicity assay and tetramer analysis (Huckriede et al., 2004). Interestingly, SFV producing 
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NP at normal levels also generated good CTL responses, suggesting that cross-priming might not 
be the only mechanism for CTL priming on SFV immunisation. 
To resolve this discrepancy, we investigated the in vitro efficiency of SFV to infect Balb/c mice 
bone marrow derived DC. Modified protocol of Inaba et al (1992) was used to generate BM-DC 
from mice hind limbs and more than 80% cells expressed DC markers (CD11c, MHC class II 
and CD40)(fig 4.11c). In our hands, up to 20% of DC were infected with SFV/B-gal as 
visualised with B-gal assay (MOI of 10), compared to maximum of 0.15% by Huckeriede et al 
(Huckriede et al., 2004). This difference cannot be attributed to titre of virus used for infection as 
even at MOI of 1000, no significant change in DC infection by SFV was observed by Huckriede. 
Moreover, infectivity was independent of DC maturation status as well as strain of mice (data not 
shown). Different capabilities of DC infection by SFV in these studies could be due to different 
methods of SFV production used (RNA based vs DNA based) or the method of DC generation in 
these studies. It is noteworthy, that our method of BM-DC generation is very similar to that 
described by Huckriede et al, and is unlikely to cause this incongruity. Most of the viral vectors 
used are efficient at DC infection and can also cause maturation of the DC. Although, SFV was 
reasonably efficient at infecting DC, it did not seem to affect their maturation (data not shown). 
 
In conclusion, expression vectors for human and mouse MTA1, as well as the SFV vector for 
both were constructed and investigated for their ability to produce protein in vitro following 
transfection. These vectors need further in vivo investigation for their ability to generate immune 
response and tumour prevention/rejection. 
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Chapter 5 Investigating potential immunogenic and naturally processed peptides from 
MTA1 
 
5.1 Introduction 
 
Tumour vaccination employs tumour antigens in order to generate an immune response for 
rejection of cancerous cells. In general, antigens shed by tumour cells are taken up by the APC, 
processed and are presented on their surface bound to MHC class I and class II antigens (fig 5.1). 
These MHC-peptide complexes are recognised by the CD8+ and CD4+ T cells and this 
interaction along with other co-stimulatory molecules trigger the immune system to react against 
cancer cells presenting the same peptides (at least in case of CD8+ T cells).  
 
Figure 5.1:- Schematic diagram of interaction of DC with CD4+ and CD8+ T cells to initiate an
immune response. 
 
Identification of MHC class I and class II epitopes that can be processed and presented in vivo to 
prime T cells holds tremendous promise for several reasons. Firstly, immunisation with a CTL 
epitope is able to mediate tumour regression in several animal models and generate peptide 
specific CTLs in human cancer patients. Wild type or modified peptides (to increase MHC 
binding and immunogenicity) can either be delivered on their own with an adjuvant or pulsed on 
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DC before administration. Also, peptide vaccination is generally considered better than whole 
protein administration as immune system is likely to be tolerised to dominant portions of the 
protein but not all the peptides (Disis et al., 1996). Being convenient chemical entities, they are 
cheap, safe and easy to synthesise, and their administration is unlikely to generate serious ethical 
considerations, unlike viral vectors. Another important application of peptide discovery is their 
use for making of MHC class I tetramers, which have started to revolutionised immune 
monitoring of cancer patients before and after vaccination. Lastly, peptide identification can lead 
to sequence information of TCR with the ability to bind to it. Autologous T cells transfected with 
TCR for known naturally processed epitopes before adoptive transfer can remarkably increase 
the persistence of T cells and clinical benefits gained from it (Morgan et al., 2006). Thus, 
identification of these peptide epitopes holds immense promise for the field of immunotherapy 
and has led to intense efforts in the last few years for their discovery. 
 
5.1.1 Approaches for epitope identification 
Since the identification of the first human tumour antigen and CTL epitope, MAGE-1, rapid 
strides have been made for development of novel techniques for CTL epitope identification. Two 
most commonly used approaches are “direct immunology” and “reverse immunology” (Figure 
5.2). Direct approaches begins with documented T cell reaction against tumour cells and refines 
to identify the peptide, whereas the reverse approach predicts T cell epitope and then investigates 
its immunogenicity. 
 
1. cDNA expression cloning :- Screening of the genomic DNA library derived from melanoma 
cells using the autologous melanoma reactive CD8+ T cells led to the identification of the first 
tumour antigen MAGE-1 by Boon and colleagues in 1991 (van der Bruggen et al., 1991).  In this 
approach, DNA or cDNA libraries isolated from tumour cells are transfected into cells 
expressing the relevant MHC molecule and the resulting cells are then screened for their ability 
to generate an immune response from the tumour infiltrating T cells by means of either target 
cell lysis and/or cytokine release. Further experiments using truncating regions of MAGE-1 
gene, resulted in the identification of a small region of DNA encoding the peptide recognised by 
the CTL, thus leading to the discovery of the first nine amino acid peptide target (Traversari et 
al., 1992). Substantial improvements have since been made to this approach by constructing 
better expression libraries (Smith et al., 2001). However, one of the major limitations of this 
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approach is the isolation and generation of CD8+ T cell clones from the tumour infiltrating 
lymphocytes, which can be immensely difficult. 
  
Figure 5.2 Direct and Reverse Immunology approaches for epitope identification (Adapted from 
Stevanovic, 2002) 
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2. Biochemical Approach:- Peptides presented by the MHC class I epitopes can be directly 
identified by elution of the MHC class I-peptide complex from the surface of the tumour cells 
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and then analysing them by mass-spectrometry. Storkus et al pioneered this approach when they 
first eluted an MHC class I bound peptide from influenza A infected cells, by treating them with 
citrate phosphate buffer at pH3.3. Treating cells with this buffer led to the elution of the cell 
surface MHC bound peptide, which were subsequently fractionated by reverse-phase high 
performance liquid chromatography (RP-HPLC) (Storkus et al., 1993). Although, this approach 
was applied to the identification of a viral peptide, several tumour associated peptides have since 
been discovered via this method (Cox et al., 1994; Clark et al., 2001; Bonner et al., 2002). The 
advantage of this technique is the fact that it can directly identify naturally processed peptides, 
which can serve as part of peptide vaccines. Moreover, this approach is able to identify post-
translationally modified peptides. However, it requires large number of tumour cells to be 
generated for elution. Although MHC class I peptide elution has been reliably demonstrated by 
mild acid elution, identification of MHC class II peptides by this method has proved elusive 
owing to the variability of the length of the MHC class II peptides (Halder et al., 1997). Also, 
MHC class II molecules are fairly stable at pH 3.3 and can only be eluted at much lower pH, 
which is generally toxic to the cells (Danielle Barry, personal communication). Major limiting 
factor for this characterization is the requirement for highly sensitive equipment to identify low 
number of tumour specific peptides from thousands of irrelevant normal peptides. Moreover, 
identification of peptides presented on the surface of tumour cells does not guarantee its 
immunogenicity and they still need to be assessed in vitro assays.  
 
3. Reverse Immunology: - Knowledge gained from previously identified peptides through other 
approaches is used to predict peptides which are most likely to bind to particular HLA alleles. 
Use of this technique for peptide identification is known as ‘reverse immunology’ method. 
Protein sequence of the antigen of interest can be screened for potential immunogenic peptides 
using a number of algorithms available on the World Wide Web. ‘SYFPEITHI’ and BIMAS are 
the most commonly used algorithms for this purpose. In these algorithms, peptides are given a 
score according to their binding prediction to the various HLA molecules. This prediction score 
is based on presence of specific amino acids at the anchor positions of the peptide. For example, 
for HLA-A201 molecule, positions 2 and 9 are the anchor residues and presence of certain 
residues (aliphatic amino acids leucine, isoleucine, valine or methionine) at these positions 
would enable this peptide to bind this particular HLA molecule with strong affinity. Following 
 121
                                                                                                                                             Chapter 5 
prediction, the peptides are synthesised and their immunogenicity tested, using either in vitro 
models with human PBMC or transgenic mouse models. T cells are generated from PBMC of 
cancer patients/normal healthy donors or from transgenic mice (carrying particular HLA allele) 
after immunisation with the peptides. The final step in the approach is the testing the recognition 
of human tumour cells (expressing the antigen) by T cells, raised against these peptides. The 
drawback of this method is that the protein sequence of the antigen has to be known and 
immunogenicity of the peptide does not guarantee its natural processing. However, 
improvements have been made to the earlier versions of the prediction algorithms to account for 
the natural processing of the peptide. Several peptides, for MHC class I and class II molecules 
have been identified using this approach till date (Rojas et al., 2005; Touloukian et al., 2000; 
Zarour et al., 2000). The advent of MHC-transgenic mouse models has boosted efforts in epitope 
identification through ‘reverse immunology’ as they can save a considerable amount of time and 
resources, and have several advantages over cell cultures. Apart from efficient exploration for 
immunogenic peptides, natural processing can also be easily looked at in these transgenic mice 
by allowing in vivo cells to process genes/proteins and present peptides. Interestingly, natural 
processing of the transgenic mouse models and humans have shown to be similar as several 
peptides identified using transgenic mice have shown to be naturally processed by the tumour 
cells in humans (Rojas et al., 2005; Theobald et al., 1995; Theobald et al., 1997). However, it is 
noteworthy that transgenic mice do not necessarily process antigens as humans (Street et al., 
2002). Also, transgenic mice are only available for the most common HLA alleles. Another 
variant of this approach is using the predicted peptide to calibrate a capillary-chromatography-
mass spectrometric system and by comparing these results with the ones obtained after acid-
elution, naturally processed peptides can be identified. This approach has been termed as 
‘predict, calibrate and detect’ method, although it does not provide information regarding the 
immunogenicity of the peptide (Pascolo et al., 2001).  
 
Apart from the anchor residues in the peptide sequence, other amino acids also have an important 
role in HLA binding (Udaka et al., 1995). To overcome these limitations, recently more powerful 
tools such as multilayered artificial neural networks (ANN) and HMM have been developed. 
These tools have been reported to be more accurate in their predictions (approximately 80% 
sensitivity and specificity) (Viatte et al., 2006). A recent study used ANN to predict peptides 
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from known tumour antigens and further investigated peptides, most of which would not be 
predicted by motif based algorithms. Of the 7 peptides predicted, 6 generated good CTL 
responses and T cells specific for 4 of these peptides could be detected in melanoma patients 
(Bredenbeck et al., 2005). Interestingly, most of these peptides were not good HLA ligands, 
suggesting that in relying on popular motif based algorithms several immunodominant peptides 
may be neglected. This study also underlines the importance of MHC-peptide complex affinity 
for TCR instead of simply reliant on HLA binding to peptide. A recent study highlighted the 
limitations of this approach by directly identifying a peptide produced from gp100 antigen by 
splicing of the protein; such peptides would never be predicted by any algorithms as having 
immunotherapeutic potential (Vigneron et al., 2004). 
 
In spite of the progress achieved in the field of ‘reverse immunology’ for the prediction of MHC 
class I peptides, its application for MHC class II peptides has lagged behind. Apart from the 
ignored role of CD4+ T cells in anti-tumour response, MHC class II structure related difficulties 
have also hindered progress in this area. MHC class II peptides can vary between 12-22 amino 
acids in length due to an open peptide binding groove, with most peptides being 13 to 16 amino 
acids long. These peptides have no definitive amino or carboxy terminal making it extremely 
difficult to predict high binding peptides with higher accuracy (Touloukian et al., 2000). 
Although, several algorithms do provide MHC class II predictions, their sensitivity and 
specificity is lower than that of class I epitopes. 
 
5.1.2 Aims of the Chapter 
This study aims to predict immunogenic peptides from MTA1 using web based algorithms and 
testing them using syngeneic and transgenic mouse models. HHD II (HLA-A0201) transgenic 
mice would be utilised for class I peptides identification. Although the main focus would be on 
generation of CTL responses, MHC class II peptides would also be investigated using HLA-
DR0101 and HLA-DR0401 transgenic mice would be used for MHC class II peptides. Following 
determination of immunogenicity, natural processing of the peptides will be further analysed. 
 
 
 
 
 
 123
                                                                                                                                             Chapter 5 
5.2 Results 
 
5.2.1 Identification of HLA-A0201 restricted peptides from MTA1 using HHD II transgenic 
mice  
 
5.2.1.1 T2 Binding assay  
Human MTA1 protein sequence was screened for potential binding peptides to HLA-A2 using 
web based algorithm ‘SYFPEITHI’. Three peptides with highest binding affinity were selected 
and synthesized. These were named MTA1 22, 57 and 109. However the prediction of the 
algorithm does not necessarily mean that the peptide is a good binder to the HLA-A2 molecule. 
Hence, before testing the immunogenicity of these peptides in transgenic mouse model, their 
HLA-A201 binding affinity was tested in a T2 binding assay. T2 cells are human lymphoblastoid 
cells and express HLA-A2 molecules. However, they are TAP deficient, which is essential in 
transporting the peptides to the ER where they will bind to HLA molecules, hence T2 cells 
express empty MHC molecules on their surface, which are rapidly internalized unless stabilised 
by externally added peptide. T2 cells were incubated with different concentrations of the peptide 
for 12 hours and the stability of the HLA-A201 molecule was determined using FACS, after 
washing off the excess peptide.  
 
Binding of the peptide to the empty HLA-A2 molecules on the surface of the T2 cells stabilises it 
or else the HLA-A2 molecules are regularly internalized and degraded in the cell before being 
replaced by other empty HLA molecules. Thus, increased mean fluorescence intensity in the 
FACS analysis provides an idea of the binding affinity of the peptide i.e. a higher binding 
peptide will have higher mean fluorescence intensity than a weak binder. From the mean 
fluorescence intensity, the fluorescence ratio (FR) was calculated as follows:- 
 
FR=     Mean channel fluorescence of test peptides 
Mean Channel fluorescence of DMSO 
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Figure 5.3: - FACS analysis of the T2 binding assay for human MTA1 peptides for HLA-A201 
molecules.T2 cells which are TAP deficient  and express empty HLA-A201 molecules, were incubated 
with different concentration of  peptides overnight. Excess peptide was washed off and the cells were 
stained for the HLA-A201 using primary antibody (HB54) and secondary antibody (goat-anti mouse 
FITC) to determine the stability of the HLA-A201 molecules on the surface of T2 cells. Results shown are 
for 100μg/ml concentration of peptide. 
 
The fluorescence intensity was compared with DMSO as all the peptides were suspended in 
DMSO. Any peptide with FR<1 was considered as a non binder, 1<FR<1.5 was considered as a 
weak binder and FR>1.5 was taken as an indicator of a strong binder. Even though, the 
predictive binding scores for both MTA1 22 and MTA1 57 were the same, on T2 binding assay 
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MTA1 22 was observed to bind to HLA-A2 more strongly and hence stabilized more HLA-A2 
molecules on T2 cells as suggested by the fluorescence ratio (figure 5.3). FR for MTA1 22 was 
3.5 when used at 100µg/ml and it seemed to be a very strong binder, whereas for MTA1 57 and 
MTA1 109 it was 1.67 and 2.2 respectively at the same concentrations (figure 5.4 & table 5.1). 
Interestingly, although the predictive binding score for MTA1 109 is lower than MTA1 57, its 
FR is higher, suggesting that predictive binding score might give an idea of good binders but 
they are not necessarily accurate. Moreover, better binder to HLA molecules, do not necessarily 
guarantee immunogenicity and these results would have to be correlated with generation of an 
immune response when injected in the HHD II mice, which are transgenic for HLA-A2 
molecules. 
0
0.5
1
1.5
2
2.5
3
3.5
4
MTA1 22 MTA1 57 MTA1 109
FL
uo
re
sc
en
ce
 R
at
io
1uM
10uM
100uM
 
Figure 5.4 Fluorescence Ratio (FR) of human MTA1 peptides at various concentrations in T2 binding 
assay. Experiment was repeated twice with similar results. 
 
 
Table 5.1:- Results of T2 binding assay of human MTA1 peptides 
                    Fluorescence Ratio Protein Peptide Region  Predicted  
     Score        1μM      10μM     100μM 
PAP      135-143         24           -          -         5.58 
hMTA1        22-31         30        1.06        1.3         3.5 
hMTA1        57-65         30        1.2        1.39         1.67 
hMTA1      109-117         27        1.08        1.23         2.2 
PAP:-Prostate Acid Phosphatase was used as a positive control 
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5.2.1.2 Investigating immunogenicity of peptides predicted from human MTA1 sequence for 
HLA-A0201 (MTA1 22, 57 and 109) 
 
HHD II transgenic mice were immunised once with 100μg of the MHC class I peptides in 1:1 
emulsion with IFA as described in methods section. Murine MHC class II peptide derived from 
hepatitis B was used as a helper peptide for each immunisation. Seven days after immunisation, 
splenocytes were harvested and re-stimulated in vitro with LPS blasts loaded with relevant 
peptide for 5 days. On day 6, the immunogenicity of the peptides was determined by evaluating 
the T cells generated against these peptides in a standard 4 hour chromium release assay. 
RMAS/A2 cells, relevant and irrelevant peptide pulsed were used as targets to determine the 
specificity of the response (Figure 5.5). Peptide specific killing of pulsed RMAS/A2 cells was 
detected for peptides MTA1 22 and MTA1 57. Minimal lysis of RMAS/A2 cells pulsed with 
irrelevant peptides was observed confirming the specificity of the immune response. Moreover, 
this lysis was completely blocked by HLA-A2 antibody, further consolidating the fact that T 
cells generated were capable of killing in an HLA-A2 restricted manner (data not shown). T cells 
could not be generated against MTA1 peptide 109 and hence was deemed non-immunogenic and 
no further experiments were carried out with this peptide (data not shown).  
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Figure 5.5 Cytotoxicity assay using T cells generated from HHD II mice immunised with hMTA1  
peptides 22(A)(n=4) and 57(B) (n=4) 
 
 
 
5.2.1.3 Determination of natural processing of immunogenic peptides 
 
In order to investigate the natural processing of MTA1 peptides, we decided to use the gene gun 
mediated full length MTA1 DNA vaccination followed by in vitro evaluation of splenocytes 
from the immunised mice for specific peptides. To validate this strategy, p53 cDNA was used as 
a positive control. Mice were immunized 3 times (7 days interval) with a p53 encoding plasmid 
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using a gene gun. A week after the last immunisation, splenocytes were harvested and re-
stimulated with a previously published naturally processed p53 149 peptide (Theobald et al., 
1995). Following five days of in vitro re-stimulation, T cells generated against this peptide were 
evaluated in a cytotoxicity assay against target cells pulsed with p53 149 peptide or an irrelevant 
peptide. As seen in figure 5.6, peptide specific killing was observed only for EL4-HHDII cells 
pulsed with the p53 149 peptide, whereas no killing of irrelevant targets was observed. As a 
control for this experiment, splenocytes harvested from naïve mouse were re-stimulated similarly 
and evaluated for killing. No peptide specific killing could be generated from naïve mice (data 
not shown). Thus, in vitro re-stimulation is not enough to generate peptide specific CTLs against 
p53 peptide 149. This suggests that in mice immunised with p53 cDNA, p53 protein was 
produced and processed, presenting p53 149 peptide in vivo to prime specific T cells against it, 
which were then expanded in vitro with the use of LPS blasts. 
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Figure 5.6:- Cytotoxicity assay using T cells generated from HHD II mice immunised with plasmid 
encoding p53 followed by a 5 day in vitro re-stimulation with p53 149 peptide. Result shown is a 
representative of 2 independent experiments (n=4)(***=p<0.0001) 
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Figure5.7:- Cytotoxicity assay against EL4/HHD II cells pulsed with MTA1 peptides after 3 
immunisations with MTA1 DNA and in vitro restimulation with MTA1 22(A) and 57(B) peptides. 
As a control EL4/HHDII cells pulsed with p53 149 peptide were used. Results shown are 
representative of two independent experiments (n=4). 
A 
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Natural processing of MTA1 peptides 22 and 57 was investigated after immunising with MTA1 
plasmid using gene gun. However, no peptide specific killing was observed in these experiments, 
suggesting that both immunogenic peptides identified for MTA1 were not naturally processed 
(Figure 5.7). Other strategies were also used to confirm this finding. T cells generated against 
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these peptides after peptide immunization (as before) were evaluated for the killing of human 
HLA-A2+/MTA1+ tumour cell line as well as for EL4/HHD cell line, transfected with human 
MTA1 (to increase the expression of MTA1) (data not shown). Later experiment, also confirmed 
that the non killing of EL4/HHD cells was not due to low surface expression of the processed 
peptide, which were below the activation threshold level for mediated CTL lysis. 
 
5.2.2 Identification of MHC class I peptides from murine MTA1 peptides in syngeneic 
Balb/c mice 
 
5.2.2.1 Optimisation of Immunisation protocol for balb/c mice 
 
Unlike for the HHD II mice, a single immunisation with peptide emulsified in IFA was not 
sufficient to generate peptide specific CTL. In order to optimise this method, the TPH peptide 
(derived from β-galactosidase) was used as a control. Various parameters were evaluated to 
determine the best protocol for optimisation and in vitro re-stimulation (Figure 5.7). Firstly, a 
single immunisation regime was compared to immunise and boost regime, followed by LPS blast 
mediated in vitro re-stimulation (fig 5.8 A & B). It was observed that boosting after seven days 
of immunisation was more potent in generating peptide specific CTLs as observed from the 
cytotoxicity assays. Potent in vitro re-stimulation may cause antigen induced cell death of the 
peptide specific T cells. To investigate this possibility, two different in vitro re-stimulation 
methods were compared. LPS blast mediated re-stimulation generated a more potent peptide 
specific T cell response, as observed by higher killing in cytotoxicity assay (25% vs 5%), 
although specific killing was observed with both methods (fig 5.8 C & D). Adjuvants are also 
likely to affect the potency of the immune response generated. CpG as an immune modulator has 
been highly successful in a number of animal models and is also currently being used in human 
clinical trials. Hence, CpG as an adjuvant was compared to IFA (fig 5.8 E & F). In balb/c mice, 
immunising with peptide and CpG was unable to generate any significant CTL response. 
Whether this is related specifically to the strain of mice, is not known and needs further 
investigation, as CpG was found to be a very potent adjuvant in C57BL/6 mice (data not shown).  
Thus, for all future immunisations in balb/c mice, two rounds of immunisations seven days apart, 
followed by LPS blast mediated re-stimulation was considered the optimum protocol. 
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Figure 5.8:- Optimisation of immunisation protocol in Balb/c mice with TPH peptide. Cytotoxicity 
assay against A20 cells pulsed with TPH or non pulsed after immunisation I Balb/c mice with TPH Imm 
and boost (B) Immunised once (C) In vitro restimulation with blasts (D) restimulation with peptide (E) 
CpG as an adjuvant (F) IFA as adjuvant. Results shown are representative of two independent 
experiments. (n=6). 
 
 
 
 
 
 
 
E 
*** *** 
*** *** 
** 
* ** **  
F 
*** *** 
*** *** 
 132
                                                                                                                                             Chapter 5 
5.2.2.2 Identification of immunogenic peptides from MTA1 in syngeneic Balb/c mice 
 
Protein sequence of murine MTA1 antigen was screened for potentially immunogenic peptides 
using a web based algorithm “SYFPEITHI”. Seven peptides were selected based on their binding 
score to H2-Kd or H2-Ld MHC motifs for Balb/c mice. Three of the peptides were able to 
generate CTL (figure 5.9). Peptides which generated CTL response in more than 50% of mice 
tested and the specific killing was at least twice than the non-specific were considered as 
immunogenic. MTA1 622, 208 and 168 were immunogenic as they generated CTL which 
demonstrated moderate killing when used against A20 cell line pulsed with the relevant peptide. 
The killing was specific for the relevant peptides as no killing was observed against irrelevant 
peptide pulsed targets. The A20 cell line expresses high levels of murine MTA1 antigen but were 
not killed by the CTLs generated against either MTA1 622, 168 or 208, when unpulsed A20 cell 
line were presented as targets to them. These results suggest that none of the above immunogenic 
peptides were naturally processed. MTA1 peptide 298 generated a positive CTL response in only 
1 out of 3 mice and was considered as only weakly immunogenic (figure 5.10D). 
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Figure 5.9 Cytoxicity assays for MTA1 peptides 
mMTA1 622 (a) (n=5/10), 208(b)(n=2/4) and 168 
(c) (n=2/5) in syngeneic Balb/c mice. Results shown
are representative of three independent experiments.
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Figure 5.10 Cytotoxicity assays for murine MTA1 peptides 436 (A), 148 (B), 551 (C) and 298 (D) 
 Results shown are representative of three independent experiments (n=4). 
 
Other murine MTA1 peptides (436, 148 and 551) were also tested in cytoxicity assays but none 
of them were immunogenic (figure 5.10). The inability of the peptide specific CTLs to lyse A20 
cells (naturally over-expressing MTA1) was not cell line dependant as peptide specific CTLs 
were also found to be unable to lyse CT-26 and Renca cells (data not shown). To confirm these 
findings, immunogenic and non immunogenic peptides were all tested for their ability to 
generate peptide specific CTL after DNA immunisation of mice using gene gun as explained 
before. None of the peptides were able to generate CTLs (data not shown).  
 
This data confirms that most of the peptides evaluated were not immunogenic and the ones that 
were immunogenic were not naturally processed. It is widely established that tolerance 
mechanisms ensure the deletion or tolerisation of high affinity CTLs for ‘self antigens’. It is 
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noteworthy, that the peptides used in this study were chosen to represent both high and medium 
binding affinity epitopes. 
 
5.2.3 Identification of immunogenic HLA-DR restricted peptides using HLA-DR0101 and 
HLA-DR0401 transgenic mice 
 
MTA1 was recently identified in our lab as a SEREX antigen, which indicates that it is capable 
of generating an antibody response, which in turn is dependent on the CD4+ T helper cells (Li et 
al, 2004). Hence, we also investigated the immunogenicity and naturally processing of MHC 
class II peptides (specifically for HLA-DR4 and HLA-DR1) from MTA1 antigen. Two peptides, 
MTA1 497 and 550 were selected based on their predicted binding affinity to HLA-DR4 and 
HLA-DR1 molecules specifically. Mice were immunised twice with the peptides, following 
which splenocytes were harvested and re-stimulated for 6 days in vitro with the peptide. These 
cells were co-cultured with peptide pulsed syngeneic BM-DC in order to detect peptide specific 
proliferation.  As seen from figure 5.11, both peptides induced specific proliferation in HLA-
DR4 mice, where as no response was obtained in HLA-DR1 mice. However, MTA1 497 induced 
response in 1out of 3 mice (Figure 5.11D), whereas MTA1 550 proved to be highly 
immunogenic as it generated proliferation of CD4+ T cells in 3 out of 3 mice tested (Figure 
5.11C). For both these peptides specific proliferation could be blocked by HLA-DR antibody 
(L243) and not by control antibody, confirming HLA-DR restricted proliferation. These results 
were also confirmed by ELISA for secretion of IFN-γ and/or IL-5 in supernatants of splenocytes 
re-stimulated with peptides in vitro. 
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Figure 5.11:- Proliferation results of MTA1 497 (A) and 550 (B) peptides in HLA-DR1 (A and 
B) & HLA-DR4 (C and D) transgenic mice. Mice were immunized with 100μg of peptide in 1:1 
dilution with IFA and boosted one week later. Splenocytes were harvested a week later and restimulated 
in vitro with the peptide for 7 days and then tested for proliferation by incubating them with syngeneic 
BM-DC pulsed with peptide(n=4). 
 
 Next, the natural processing of MTA1 497 and 550 peptides in HLA-DR0401 peptides was 
investigated. To achieve this, HLA-DR4 transgenic mice were immunised 3 times with 
pcDNA3/hMTA1 using gene gun, followed by re-stimulation of splenocytes from these mice 
with peptides in vitro. After 5 days of re-stimulation, proliferation was performed using DC 
pulsed with relevant peptides or an irrelevant (Flu) peptide. It was expected that if any of the 
peptides were processed and presented in vivo during immunisations, DC would prime CD4+ T 
cells against them and a week of in vitro re-stimulation would expand them further, allowing 
their proliferation, when presented with the same peptide by DC. No peptide specific 
proliferation was observed for both these peptides, suggesting that none of them were naturally 
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processed (figure 5.12). To confirm these results, natural processing was also investigated using 
a recently described method (Rojas et al., 2005). Following two immunisations with peptides, 
splenocytes were harvested, re-stimulated with peptides and their proliferation investigated using 
DC as APC pulsed with lysate of cells demonstrating either high expression or very low 
expression of MTA1. As a control, splenocytes harvested from mice immunised with Flu peptide 
were used. Results obtained by this method confirmed previously obtained results suggesting 
that MTA1 497 and 550 were not naturally processed (data not shown). 
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Figure 5.12:- Proliferation assay to evaluate natural processing of MTA1 487 (A) and MTA1 550 (B) 
peptides. HLA-DR4 transgenic mice were immunised 3 times with pcDNA3/MTA1 using a gene gun. 
Splenocytes were harvested from these mice and after 5 days of in vitro re-stimulation with peptides, 
proliferation assay was performed using DC as APC to present relevant peptides of control (Flu) 
peptide. L243 and isotype control antibodies were used to confirm restriction of response. Result shown 
is representative of 2 independent experiments (n=6). 
 
 137
                                                                                                                                             Chapter 5 
Finally we sought to determine whether it is possible to generate an immune response to the full 
MTA1 sequence following DNA immunisation. Moreover, several studies indicate the tendency 
of immune response to be skewed towards Th2, hence we immunised HLA-DR4 transgenic mice 
with pcDNA3/hMTA1 intramuscularly and repeated the proliferation assay using DC transfected 
with hMTA1 or βgal as a control. No specific proliferation was observed in this case and 
immunogenicity of MTA1 could not be determined (Figure 5.13). Similar study was also 
performed for class I response in a cytotoxicity assay, where antigen (MTA1) specific killing 
was not observed.  
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Figure 5.13:- Proliferation (A) and cytotoxicity assay (B) after intramuscular immunisation of HLA-
DR4 and HLA-0201 transgenic mice with pcDNA3/hMTA1. DC transfected with MTA1 were used as 
APC in proliferation assay. In the cytotoxicity assay, EL4-HHD II cells pulsed with lysate of cells either 
over-expressing MTA1 (CL-1) or low MTA1 expressing MTA1 (Renca) were used as targets (n=4). 
 
Table 5.2 summarises the peptides investigated in this study for their immunogenicity. These 
results suggest that either MTA1 is not immunogenic owing to deletion of most antigen specific 
T cells or the immunisation protocols used in this study have been unable to break tolerance to 
MTA1 and more potent strategies need to be designed. 
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Table 5.2:-Summary of the peptides tested and their immunogenicity 
Mice Strain Peptides Immunogenicity No of 
Mice 
tested 
Cytokines
IFNγ/IL-
5 
MTA1 622 Yes 5/10 2 
MTA1 168 Yes 2/5 1 
MTA1 436 No 0/4 0 
MTA1 298 No 1/3 0 
MTA1 148 No 0/3 0 
MTA1 551 No 0/4 0 
Balb/c 
MTA1 208 Yes 2/4 0 
MTA1 699 Yes 4/4 2 
MTA1 496 Yes 4/4 2 C57BL/6 
MTA1 12 No 0/2 0 
MTA1 22 Yes 4/4 ND 
MTA1 57 Yes 4/4 2 HHD II 
MTA1 109 No 0/4 0 
MTA1 497 No 0/4 ND HLA-DR0101 MTA1 550 No 0/4 ND 
MTA1 497 Yes 3/4 ND HLA-DR0401 MTA1 550 Yes 2/4 ND 
ND=Not done 
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5.3 Discussion 
 
5.3.1 Human MTA1 derived class I peptides 
 
Several studies in animal models have shown the efficacy of peptide specific CD8+ T cells to 
provide protection against tumour challenge or completely eradicate established tumours. One of 
the most convenient methods of immunization has been the use of peptides with an adjuvant; this 
obviates the need to generate any vectors, are well tolerated and perhaps the safest mode of 
vaccination. Immunisation of Her/2-neu transgenic mice with a Her-2/neu CTL epitope was 
shown to be effective in protection as well as therapeutic experiments in these animals (Gritzapis 
et al., 2006). A major factor limiting the success of immunotherapy in vivo is the inadequate 
number of T cell generated. Recent clinical trials have shown incredible success in patients 
treated with adoptively transferred T cells. These T cells are generally isolated from the TIL and 
expanded in vitro; peptides presented by DC or artificial APC in vitro can be used efficiently for 
this purpose. Adoptive T cell therapy is also limited by the number of T cells generated for in 
vivo injections. In another recent trial, genetically modified T cells expressing a specific TCR 
were used to immunise metastatic melanoma patients. Two months post-infusion, more than 10% 
of peripheral circulating lymphocytes consisted of transferred T cells, leading to objective 
clinical regression in some patients (Morgan et al., 2006). This TCR cloning and patient 
monitoring is only possible if the identity of peptide targeted is known. Moreover, clinical trials 
conducted with dendritic cells pulsed with peptide have also shown promising results. In a 
recently conducted trial of 20 metastatic renal cell carcinoma patients, DC pulsed with MUC-1 
peptide induced objective clinical regression of metastasis in 3 patients and stabilised the cancer 
in 4 others (Wierecky et al., 2006). Thus peptide identification from known tumour antigens 
forms an essential component of immunotherapy for several cancers. 
 
Limited success in human clinical trials of the peptide vaccines has been ascribed to the limited 
range of epitopes used as well as targeting peptides expressed by most common alleles only. 
Effective peptide vaccine for cancer would have to target multiple epitopes from several antigens 
and presented by different MHC alleles, to minimise the chances of immune escape through 
antigen or MHC down regulation. Considering the benefits of peptide identification, we sought 
to identify CTL epitopes from MTA1 using the ‘reverse immunology’ approach in transgenic 
and syngeneic mouse models. MTA1 sequence was screened using computer-based algorithm 
 140
                                                                                                                                             Chapter 5 
‘SYFPEITHI’ to identify potentially immunogenic peptides. It was hypothesized that T cells 
repertoire to MTA1 would be limited in syngeneic balb/c mice, whereas HHD II transgenic mice 
are less likely to be tolerant to hMTA1. Minor differences in the protein sequence can have a 
major impact on immune response in case of ‘self antigens’. Hence, we decided to investigate 
immunogenic CTL peptides from mMTA1 in balb/c mice and hMTA1 in HHDII mice. Peptides 
were chosen for both syngeneic balb/c mice as well as transgenic HHD II mice. Of the 3 peptides 
selected for evaluation in HHD II mice, 2 were immunogenic as demonstrated by development 
of peptide specific CTL in cytotoxicity assay. However, CTL generated against these peptides 
were neither capable of killing murine EL4-HHD II cells (expressing MTA1) nor human tumour 
cells MCF-7 (HLA-A0201+, MTA1+). It is noteworthy, that CTL generated from transgenic 
HHD II mice have been shown to efficiently lyse human tumour cells in an MHC restricted 
manner (Gritzapis et al., 2004; Gritzapis et al., 2006). These results were confirmed by 
investigating in vivo presentation of these peptides following gene gun immunisation. Moreover, 
inability to generate immune response in HHD II mice was not dependant on method of 
immunisation as even intra-muscular immunisation produced the same results (data not shown). 
 
The Immunisation protocol had to be optimised when using balb/c mice as single immunisation, 
as in HHD II mice, this was not potent enough. This could be due to strain differences in the 
mice as HHD II mice have been generated from the C57 background. Also, binding affinity of 
peptide is also likely to play a major role in this. Following optimisation, seven MHC class I 
epitopes, including high and medium binding affinity peptides, were evaluated for 
immunogenicity. Three of these were immunogenic but not naturally processed, since CTL 
generated against them could only lyse peptide pulsed target cells but not unpulsed cells 
naturally over-expressing mMTA1. To confirm these results, peptides were also used to re-
stimulate splenocytes from pcDNA3/mMTA1 gene immunised mice and tested in a cytotoxicity 
assay (data not shown). This suggested that MTA1 immunisation was unable to prime CTLs to 
these peptides in vivo following gene immunisation. Of course, the possibility that the 
immunisation strategy was not potent enough, cannot be neglected. 
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5.3.2 Identification of MHC class II peptides and role of CD4+ T helper epitopes in 
immunotherapy 
Due to the overwhelming evidence of CD8+ T cells being directly responsible for killing of 
tumour cells in vitro and in vivo, CD4+ T cells had been neglected during the early years of 
cancer immunotherapy. The result of this was that the phenomenal success of peptide vaccines in 
animal models was not translated in human clinical trials (Chen et al., 2004; Lee et al., 1999). 
Different animal models have produced contradictory results regarding CD4+ T cell role in anti-
tumour immune response. It is hypothesised that pathogenic infections produce strong ‘danger 
signals’, leading to up-regulation of CD40 molecules on DC thereby bypassing CD4+ T cell 
help. This phenomenon has also been observed in non-pathogenic tumour models, which 
contradicts the above theory. CD4+ T cell help might be dependent on the MHC class I epitope 
affinity. Franco et al showed that peptides with high affinity for their MHC class I molecules do 
not require CD4+ T cell help [31]. Generation of CTL is influenced by the period of MHC 
restricted peptide display on APC, TCR-MHC binding affinity/duration and whether or not 
CD4+ T cell mediated help is necessary. Considering that most MHC class I epitopes for over-
expressed self antigens are likely to be of low-medium binding affinity, CD4+ T cell help would 
prove critical for their generation.  Gradually, CD4+ T cells have taken the centre stage due to 
their central role in orchestrating multiple arms of the immune system. Not only is T cell help 
required for optimal effector and memory CTL response (Ali SA, 2000), but in certain animal 
models CD4+ T cells have been shown to mediate tumour regression via an IFN-γ mediated 
mechanism (Egilmez et al., 2002). 
 
Although, most studies seem to suggest that CD4+ T cells do not need to recognise peptides on 
the surface of tumour cells in an MHC restricted manner for inducing cell lysis, several others 
have shown that it is likely in some cases. Independent studies have shown CD4+ T cells to 
directly mediate tumour cell lysis through TRAIL, FasL and granzyme-perforin dependent 
pathways, traditionally employed by CTL (Echchakir et al., 2000; Schattner et al., 1996; Thomas 
& Hersey., 1998a; Thomas & Hersey., 1998b).  Another debate has been the source of the CD4+ 
T cell epitope, where some researchers suggest to use an irrelevant (derived from foreign antigen 
i.e. tetanus toxoid and hepatitis B), whereas others have argued the importance of using helper 
epitope from the same antigen as CTL epitope in a peptide vaccine (Slingluff et al., 2001).  
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MTA1 was recently identified in our laboratory using SEREX technology, which relies on high 
titre IgG antibodies in cancer patient’s serum towards cancer antigens. This antibody production 
is supported by T helper 2 cells, implying the presence of CD4+ T cells against MTA1. In order 
to investigate this, we evaluated two peptides derived from human MTA1 in HLA-DR1 and 
HLA-DR4 transgenic mice. MTA1 497 and 550 peptides were shown to be immunogenic in 
HLA-DR4 but not in HLA-DR1 transgenic mice. However, both of the peptides were found not 
to be naturally processed as neither DNA immunisation primed CD4+ T cells in vivo nor the 
cells generated through peptide immunisation proliferated in response to DC presenting 
processed MTA1 gene or cell lysates containing high level of MTA1. Although, it is generally 
assumed that CD4+ T cells are less likely to be tolerised against ‘self-antigens’, recent studies 
have suggested that nuclearly localized antigens are not averse to mechanisms of central and 
peripheral tolerance (Nakken et al., 2003). Considering the overwhelming number of epitopes in 
the medium binding affinity group, it was deemed impractical and costly to screen large number 
of peptides to identify naturally processed peptides, although we believe that there is a likelihood 
of it existing. 
Prediction of naturally processed CD4+ T cell epitopes is much more difficult compared to CTL 
epitope due to larger peptide size and variability of amino acid number. Surface elution of MHC 
class II peptides, although possible, is technically more difficult (Peakman et al., 1999). Recent 
emergence of ANN and HMM based methods might make this prediction easier and more 
accurate. Another recently evolving strategy has been the use of overlapping peptides spanning 
the whole protein sequence of an antigen. PBMC from cancer patients can then be tested against 
these peptides for release of cytokines or killing, providing evidence of T cell existence against 
some peptides in vivo (Vittae et al., 2006). However, constructing an overlapping peptide library 
is still quite expensive and there might be other issues relating to the purity of individual peptide 
pools. 
 
5.3.3 Tolerance and its affect on T cell repertoire 
 
For years it has been believed that the T cell repertoire is purged of the self antigen reactive high 
affinity T cells in order to protect the host from auto-immune reactions. This theory has recently 
been questioned by several reports suggesting that in several cases high affinity self-reactive T 
cells can escape thymic deletion and escape into the periphery. This could either be due to non 
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expression of self antigen in the thymus, inefficient processing of antigen in thymus or due to 
insufficient density of peptide-MHC levels in thymus to reach the threshold for deletion of 
thymocytes (Houghton & Guevara-Patino, 2004). Also, cryptic epitopes, which are not processed 
efficiently by cells, are likely to escape from inducing deletion (Gross et al., 2004). Thus, high 
affinity T cells for self antigens can also be possibly found in the peripheral T cell pool. 
Moreover, TCR have a very high level of cross reactivity. Theoretical calculations estimate that a 
single TCR can potentially react to 1x106 different peptide antigens (Mason, 1998). These 
properties of T cells offer cancer immunologists a window of opportunity to reactivate these T 
cells for mounting an attack against cancers expressing self-antigens.  
 
Apart from central deletion mechanisms, T cells encountering self antigens in the periphery are 
anergised and require much higher levels of antigens or mutated antigens to be re-activated 
(Kawahata et al., 2002). MTA1, being expressed at low levels in the thymus and other normal 
tissues, is likely to be affected by both these mechanisms. Whether the thymus plays a role in 
deletion of T cells against MTA1 is still unknown and would be relying on presentation of 
MTA1 derived peptides in the thymus to developing thymocytes. However it is likely that 
peripheral tolerance mechanisms do have an affect on T cells reactive against MTA1. Clearly, 
more potent strategies are needed to overcome anergy and generate immune response to MTA1. 
Modification of wild type peptides in order to increase their binding affinity to MHC or TCR has 
been shown to be effective in several studies. In a transgenic mouse model expressing human 
TCR for gp100 peptide, Yu et al showed that inability of wild type peptide to generate immune 
response was due to fast dissociation rate of peptide and that modification of the peptide 
increased the stability of peptide-MHC molecules, leading to activation of transgenic T cells (Yu 
et al., 2004). Similarly, another study demonstrated modified p53 peptides to be more 
immunogenic, CTLs generated against it to be efficient in recognizing wild type peptide as well 
as being able to lyse tumour cells expressing p53 gene (Petersen et al, 2001). However, the 
challenge lies in being able to identify peptides likely to benefit from modification as medium to 
low binding group of peptides from a given tumour antigen can be extremely large. To overcome 
this limitation, Alan Houghton’s group has shown xenogeneic immunisation, which exploits 
natural variation in sequences of mouse and human homologue genes, to be highly effective in 
breaking tolerance against tumour associated self-antigens (Gold et al., 2003).  
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Cytokines such as IL-15 have also been shown to rescue tolerant CD8+ T cells in a transgenic 
mouse model. In another TCR transgenic model, T cells against self-antigen expressed in liver 
are tolerised but can be rescued to proliferate and react against antigen by IL-15 cytokine, and 
these T cells were able to protect mice against leukaemia. This study confirms that high affinity 
T cells are not necessarily deleted and given the right method, can be rescued for tumour 
immunotherapy (Teague et al, 2006). 
 
5.3.4 Strategies for enhancing the potency of peptide vaccines 
 
Major criticism against peptide vaccines has been their lack of immunogenicity or potency. 
Injected peptides in vivo can be degraded by proteases, leading to rapid clearance. These 
limitations can be overcome by using potent adjuvant and correct immunisation strategies. 
Combining peptides with oil based adjuvant would lead to depot formation of peptide with slow 
release, thereby avoiding rapid clearance through proteases. Also, GM-CSF as an adjuvant can 
be beneficial due to its ability to recruit professional APC to the site of injection. Other adjuvants 
used with peptide vaccines with high efficacy are IL-2, IL-12, CpG oligonucleotides and 
interferons (Buteau et al., 2002). Peptide based vaccination can also be benefited by targeting 
them to specific compartments of APC by injecting them in a DNA form with signalling 
sequences. Also, linking peptides to nanobeads, liposomes or linker sequences are more 
efficacious in targeted delivery of peptides (Engler et al., 2004; Fifis et al., 2004). 
 
In conclusion, reverse immunology approaches were unsuccessful in identification of naturally 
processed peptides from MTA1, for MHC class I and class II peptides. Inability to identify these 
peptides could either be due to non-existence of such peptide specific CTLs (due to deletion in 
thymus) or more likely due to inaccurate prediction and ineffective vaccination methods to 
overcome tolerance for re-activation of anergised T cells. Strategies such as xenogeneic DNA or 
viral vectors might be able to overcome this limitation and will be investigated in future studies 
for MTA1 immunotherapy. 
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Chapter 6:- Evaluation of MTA1 as an immunotherapeutic target in an in vivo model using 
DNA based vaccine 
 
6.1 Introduction 
 
DNA based vaccines have revolutionized the field of immunotherapy in several ways. In-spite of 
various advantages of peptide vaccines, lack of knowledge of immunogenic tumour specific 
peptide epitopes, which can be targeted by therapy, is likely to be a major limitation. Moreover, 
as seen in this study, identification of naturally processed peptides from tumour shared ‘self-
antigens’ (which form the bulk of tumour antigens), can be quite difficult. Deletion of high 
avidity T cells against self antigens ensures that only T cells with low to medium binding affinity 
are allowed to survive in the periphery and they too could be under the control of peripheral 
tolerance mechanisms. Prediction of peptides using web based algorithms predicts literally 
hundreds of peptides with medium to low binding affinity for a given antigen, and screening all 
of them is impractical and expensive, especially for individual HLA alleles. DNA based vaccine 
not only obviates this need for individual peptide identification, but can also generate antibody 
and CTL response simultaneously, which could mediate tumour protection or regression. 
 
DNA based vaccination methods have demonstrated good efficacy in mediating tumour rejection 
in animal models. Gene gun mediated immunisation of HLA-A0201 mice with plasmid DNA 
encoding for immuno-dominant epitopes from HPV16 and HPV17 were able to protect mice 
from a lethal challenge of tumour cells expressing these antigens. However, DNA immunisation 
was less effective at treating established tumours compared to viral vaccine in the same study 
(Eiben et al., 2002). Interestingly, antigens used in that study were highly immunogenic as they 
are derived from a virus (HPV). In another study, intramuscular immunisation of murine 
tyrosinase related protein -1 (mTrp-1), enabled mice to be protected from a lethal challenge of 
poorly immunogenic B16 melanoma cells (Bronte et al., 2000). In the same study, the 
vaccination of mice with a recombinant vaccinia virus encoding mTrp-1 led to tumour regression 
of well established B16 tumours. It is noteworthy, that mTrp-1 is a ‘self-antigen’ expressed in 
normal skin; although previous studies had revealed that regression of melanoma coincided with 
vitiligo, in this study no autoimmune reactions were observed. More importantly, DNA vaccines 
have shown to be safe in several human clinical trials, although lack of objective clinical 
response has also been their feature. 
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Several strategies have recently been devised to increase the immunogenicity and potency of 
‘naked’ DNA vaccines.  For instance, linking the DNA encoded protein to ubiquitin, targets it to 
MHC class I processing pathway and is found to be more effective in CTL generation (Velders et 
al., 2001). Similarly, gene can be targeted to the endosomal/lysosomal compartment by linking it 
to lysosome associated membrane protein (LAMP-1) for efficient processing and presentation to 
CD4+ T cells (Ji et al., 1999). Addition of co-stimulatory or cytokine genes in the plasmid 
enhances the potency and effectiveness of the vaccine. Although several cytokine genes have 
been combined with DNA vaccination, GM-CSF is one of the most commonly used cytokine as 
an adjuvant. Co-administration of plasmids encoding GM-CSF and gp100, generated potent 
immune response for mediating tumour protection and regression, and enabled to do so at very 
low levels of gp100 plasmid (Rakhmilevich et al., 2001). GM-CSF is a strong chemoattractant 
for the dendritic cells and this strategy essentially uses this property to target administered 
antigens to professional APCs. Tumour cells manage to anergise T cells by expressing the 
antigens without any co-stimulatory molecules on their surface. To overcome this limitation, 
DNA vaccines co-administered with co-stimulatory molecules has been attempted and are shown 
to be more effective in generating CTL response capable of mediating protection in mice (Corr et 
al., 1997). Other advances facilitating antigen delivery to APC such as in vivo electroporation, 
mucosal jet injection as well as encapsulation of DNA into microparticles/liposomes has further 
enhanced the efficacy of DNA vaccines (Liu et al., 2004). 
 
One of the criticisms of DNA cancer vaccines has been their lack of immunogenicity and 
inability to break tolerance against ‘self antigens’. In recent years, Houghton and colleagues have 
endeavoured to overcome this by pioneering the use of xenogeneic (vaccinating with a 
homologous gene from another species) immunisation (Bowne et al., 1999; Gold et al., 2003). 
Modification of amino acids in specific locations on a peptide can increase its binding to MHC 
or TCR, thereby overcoming tolerance to native peptide specific low avidity T cells. But this 
strategy still needs to identify these low immunogenic naturally processed peptides. Xenogeneic 
immunisation uses the same strategy but has additional advantages of DNA vaccine. Several 
tumour associated ‘self-antigens’ are highly conserved in humans and mice, probably owing to 
their essential role in cell survival. Minor differences in amino acid sequences of such conserved 
proteins can be used i.e. mouse genes to immunise humans or vice versa, for bypassing immune 
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tolerance to self antigens. This is achieved not only by the generation of modified peptides with 
increased affinity for MHC or TCR but may also be due to altered processing and presentation of 
cryptic epitopes. Immune response, leading to tumour protection and/or regression, against 
several self antigens such as gp75, trp-2 and gp100 has been generated using this approach 
(Weber et al., 1998; Gregor et al., 2004; Bowne et al., 1999). Interestingly, the immune response 
generated against self-antigens was shown to be mediated by different immune cells, depending 
on the antigen. When Trp-1 antigen was targeted, the immune response was mediated by NK 
cells and B cells, whereas CD4+ and CD8+ T cells were responsible for mediating tumour 
rejection in case of Trp-2 (Bowne et al., 1999). Furthermore, xenogeneic immunisation can be 
used in combination with other adjuvants such as anti-CTLA4 antibody to enhance their efficacy 
and overcome other peripheral tolerance mechanisms like regulatory T cells (Tregs) (Gregor et 
al., 2004).  
 
Apart from the recessive tolerance mechanisms, the immune response to tumour antigens is also 
controlled by dominant regulatory mechanisms, mainly suppressive T cells. Although several 
subpopulations of suppressive cells have been discovered (NKT cells, GR1+CD11c+ myeloid 
cells), perhaps the most important cells are the regulatory T cells (Tregs).  Recent years have 
seen remarkable interest in the role of these cells and the importance of Tregs in controlling the 
immune system is underlined by the fact that their depletion in animal models leads to severe 
auto-immune diseases; and their adoptive transfer causes their abrogation. Tregs have been 
divided into two subgroups, naturally occurring and induced. Tregs can be induced to develop 
from CD4+ T cells depending on the antigen stimulation conditions (Chakraborty et al., 1999) 
and have the phenotype CD4+CD25+; however in the recent years it has emerged that most T 
cells can express CD25 upon activation. FOXP3 (Foxp3 in mice), a member of the 
forkhead/winged helix member of transcription factors, is now regarded as the marker of choice 
for detecting these Tregs, which are defined by the phenotype CD4+CD25+Foxp3. Forced 
expression of Foxp3 can convert normal CD4+ T cells into having a suppressive phenotype and 
has been shown to be critical for their development. Apart from these, other surface molecules 
such as glucocorticoid induced tumour necrosis factor receptor (GITR) and CTLA-4 are 
frequently expressed by the Tregs (Sakaguchi, 2004).  
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Numerous studies have shown the immuno-suppressive effects of Tregs on CD4+ and CD8+ 
proliferation as well as the cytolytic capability of CTLs (Sakaguchi, 2004). Different models 
have demonstrated multiple mechanisms used by CD4+CD25+ Tregs for suppression of immune 
response. Cytokines like IL-10 and TGF-β may be responsible for Treg mediated suppression in 
some cases, whereas in others cell-cell contact was critical. Contact dependant inhibition of T 
cells may be mediated by CTLA-4 and/or GITR, however, their role is still being investigated 
(Read et al., 2006). Treg mediated modulation of the APC activity (down-regulation of co-
stimulatory molecules) has been deemed responsible for this. Interestingly, in vitro studies have 
revealed that antigen specific stimulation of Tregs was necessary for their suppressive action, 
although once activated, suppression was non-specific. However, if Tregs suppress other T cells 
in a non-specific manner then how does the adaptive immune system manage to respond to 
pathogens? One possibility is that potent stimulation of CD4+ and CD8+ T cells might be able to 
overcome Treg mediated immuno-suppression. Indeed, a recent study suggested that activated 
CD8+ T cell mediated release of IFN-γ was able to overcome Treg mediated immuno-
suppression and led to development of antigen specific CD4+ T cells instead (Nishikawa et al., 
2005). By establishing a clone of CD4+ TIL, a recent study managed to identify Tregs with 
specificity for the LAGE-1 antigen, re-enforcing the belief in existence of antigen specific Tregs 
in the periphery (Wang et al., 2004). 
It has become evident that the thymus produces Tregs as a separate subpopulation of T cells. 
High level of antigen expression in the thymus during development of thymocytes seems to be 
responsible for their development from antigen specific T cells (Sakaguchi, 2004). Several 
studies have also suggested that Tregs and CD4+ T cells, with identical antigen specificity, can 
co-exist in the periphery, and Tregs are approximately 10-100 times more sensitive to the antigen 
compared to effector CD4+ T cells. It has been hypothesized that Tregs exist in the periphery 
and are constantly stimulated by the APC presenting self-antigens in a non-inflammatory 
context, thereby controlling the actions of potential auto-reactive T cells.  
 
Frequency of Tregs is increased in peripheral blood, TIL and tumour draining lymph nodes of 
cancer patients. Moreover, in a recent study of ovarian cancer, Treg accumulation at tumour sites 
correlated with poor prognosis of patients (Curiel et al., 2004). In the same study, secretion of 
chemokine CCL22 by tumour cells and macrophages was shown to be responsible for Treg 
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accumulation in tumours, underlining their importance in immuno-evasion by cancer cells.  
Complementing the human studies, depletion of Tregs along with antigen specific vaccination 
has been shown to induce tumour regression in several animal models (Shimizu et al., 1999; 
Onizuka et al., 1999). Different groups have sought several strategies for Treg depletion.  
 
Several studies have used anti CD25 antibody for depletion of Tregs as CD25 is highly over-
expressed on them (Shimizu et al., 1999; Onizuka et al., 1999). Although useful in mouse 
models, it is unlikely to be used in humans as activated T cells also seem to express CD25 and 
this antibody is likely to deplete them as well. Glucocorticoid-induced tumour necrosis factor 
receptor family related protein (GITR) and CTLA4 are responsible for cell-cell contact 
dependant inhibition of effector T cells.  Hence, anti GITR and anti-CTLA4 antibodies have also 
been recently employed, as they block the inhibitory effects of GITR and CTLA4 molecules, 
making immunotherapy more efficacious (Yamaguchi & Sakaguchi., 2006).  Moreover, these 
antibodies can be used in combination for enhanced effect (Ko et al., 2005). Denileukin diftitox 
or Ontak (IL-2 diptheria toxin fusion protein) is currently being used in patients of non-
Hodgkin’s lymphoma and cutaneous T cell lymphoma (Baecher-Allan & Anderson., 2006). 
CD25 molecules form the α-chain of IL-2 receptor and Ontak might lead to depletion of Tregs, 
since they express highest levels of CD25. Ontak binding to cells introduces diphtheria toxin in 
CD25+ cells, causing their lysis. Pharmacological agents have also demonstrated some efficacy 
in Treg inhibition. Low dose cyclophosphamide selectively induces apoptosis in Tregs and has 
shown to enhance vaccination efficacy in mouse models (Ghiringhelli et al., 2004). Similarly, in 
patients receiving fludarabine based chemotherapy for chronic lymphocytic leukaemia, a 
decreased frequency of Tregs was observed. Confirming this study, Beyer et al, demonstrated 
enhanced sensitivity of CD4+CD25+ T cells to fludarabine then CD4+CD25- cells (Beyer et al., 
2005).  
 
Considering the inability to break tolerance and identify naturally processed peptides by simple 
peptide vaccines, it was decided to investigate other potent methods of vaccination such as DNA 
vaccination, xenogeneic vaccination, viral vaccines as well as combining them with Treg 
depletion.  
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6.2 Results 
6.2.1 Evaluation of syngeneic DNA immunisation for MTA1 
Full length murine MTA1 was amplified from mouse testis and cloned into TOPO-Blunt shuttle 
vector. Sequencing was performed to exclude possibility of any possible mismatches during 
amplification, following which mMTA1 was cloned into pcDNA3 mammalian expression vector 
(invitrogen) (see chapter 4). Mouse MTA1 protein expression from pcDNA3-mMTA1 was 
confirmed by transfecting a cell line followed by western blotting assay 24-48 hours later from 
cell lysate of transfected and non-transfected cell line. Gene gun immunisation has been used 
recently with good efficacy in several murine tumour models. Hence, we coated 1 micron gold 
particles (Biorad) with the MTA1 expressing construct pcDNA3-mMTA1 (preparation and 
characterisation of construct is described in chapter 4). These DNA coated gold particles were 
then administered intradermally three times at seven day interval to the shaved abdomen of 
balb/c mice using a helium gene gun (Biorad). A week after final immunisation, mice were 
challenged with 8x104 CT-26 cells subcutaneously and monitored twice a week until the tumour 
size reached 1mm2, when mice were euthanized as per the home office schedule. No significant 
difference in either tumour growth rate or survival benefit in immunised mice was observed 
compared to the control gene immunised or naïve mice (n=5) (fig 6.1). Although, a slight 
increase in survival was observed in 1 out of 5 mMTA1 immunised mice, the difference was not 
significant and was inconclusive. 
 
Considering the possible development of tolerance to MTA1 in syngeneic Balb/c mice, 
xenogeneic immunisation was evaluated as an option to overcome tolerance. After cloning 
hMTA1 into pcDNA3 and confirming protein expression in vitro using this vector (see chapter 
4), gold bullets coated with pcDNA3-hMTA1 were prepared as before and were used to 
immunise mice. As controls, mice immunised with pcDNA3-mMTA1, empty pcDNA3 and 
naïve mice were also challenged with CT-26 cells. Unfortunately, no significant survival benefit 
was observed in these experiments, suggesting that even xenogeneic immunisation was unable to 
generate immune response to MTA1 (fig 6.2). Similar experiments were also performed in HHD 
II transgenic mice and challenged with EL4-HHD II cells (which express MTA1 at high levels) 
with identical results. However, EL4 HHD II cells were inconsistent in tumour growth in HHD II 
mice and hence the results of in vivo experiments from them were not considered and all further 
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experiments were performed in balb/c mice. It has been observed in our laboratory that immune 
activation using gene gun vaccination in HHD II mice might be antigen dependent i.e. 
immunising with p53 gene was highly effective, whereas it was inefficient for another tumour 
antigen (HAGE) (McArdle et al, unpublished observations). 
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Figure 6.1:- Tumour Challenge experiment following gene gun immunisation in balb/c mice 
Balb/c mice. (A) Tumour growth rate (B) Survival Curve. Mice were immunised 3 times with 
gold particles coated with pcDNA3-mMTA1 at 7 day intervals, followed by challenge with CT-26 
cells. No significant survival benefit was observed in vaccinated mice compared to controls. 
Results shown are representative of two independent experiments with 5 mice per group. 
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Figure 6.2:- Tumour Challenge experiment following syngeneic and xenogeneic MTA1 gene 
gun immunisation in balb/c mice. (A) Tumour growth rate (B) Survival Curve. Mice were 
immunised 3 times with gold particles coated with pcDNA3-mMTA1 or pcDNA3-hMTA1 at 7 day 
intervals, followed by challenge with CT-26 cells. No significant survival benefit was observed in 
vaccinated mice compared to controls. Results shown are representative of two independent 
experiments with 5 mice per group. 
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Several studies have suggested that gene gun immunisation is more likely to polarise the immune 
response to Th2 type, and this response is not inefficacious in generating anti-tumour immunity 
due to lack of CTL generation. To exclude this possibility, we immunised balb/c mice IM twice 
at seven day interval with 100μg of pcDNA-mMTA1/hMTA1 genes or control genes along with 
100μg CpG as an adjuvant. Seven days after the final immunisation, mice were challenged with 
CT-26 cells as before. The results obtained were similar to those obtained using gene gun 
vaccination, where no significant suppression of tumour growth or survival advantage was 
observed in vaccinated mice compared to non-vaccinated mice (fig 6.3). Approximately 20 days 
after tumour challenge, all animals had to be sacrificed as their tumours reached 1cm2. It is 
noteworthy that even xenogeneic intramuscular immunisation was unable to generate any 
response at all.  
Thus, plasmid DNA immunisation on its own was unsuccessful in generating any immune 
response to MTA1 in this model.  
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Figure 6.3:- Intramuscular syngeneic and xenogeneic MTA1 immunisation followed by tumour  
challenge and monitoring for tumour growth (A) and percent survival (B). Result shown is a  
representative of two independent experiments. 
 
 
6.2.2 Combination of cyclophosphamide and gene gun immunisation  
 
Regulatory T cells (Tregs) have been shown to suppress immune response to self antigens and to 
tumours. It was hypothesized that peripheral regulatory T cells might be involved in suppressing 
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the immune response to MTA1. To test this possibility, it was decided to deplete the Tregs and 
combine it with MTA1 vaccination. Anti CD25 (PC-61) antibody binds to IL-2α receptor and 
inhibits their proliferation, and has been used in various studies for this purpose. However, 
although purification of antiCD25 antibody from the PC-61 hybridoma cell line was attempted, 
insufficient amounts of antibody were obtained. As an alternative, it was decided to use low dose 
cyclophosphamide for Treg depletion. Naïve balb/c mice were injected twice with either 
100µg/kg or 150µg/kg, followed by isolation of CD4+ T cells from the spleens four days later 
and stained for CD25+ cells. As shown in figure 6.4, compared to naïve mice, the number of 
CD4+CD25+ T cells had decreased by almost a third following cyclophosphamide 
administration (7% vs 2.1%). Noticeably, increasing the dose of cyclophosphamide from 
100µg/kg to 150µg/kg did not make a significant difference (2.1 vs 2.7%). Cyclophosphamide at 
higher doses can be immunosuppressive and might lead to depletion of CD4+CD25- T cells as 
well; hence 100mg/kg was used as the optimum dose of cyclophosphamide for Treg depletion. 
Moreover, our results were supported by other studies, showing 100mg/kg cyclophosphamide as 
being efficacious in Treg depletion (North et al., 1982; Ercolini et al., 2005). It is however 
important to remember that, Treg depletion is only temporary and these repopulate the periphery 
within 7-9 days. 
 
Figure 6.4:- FACS staining for CD25+ cells after isolation of CD4+ T cells from naïve and 
cyclophosphamide administered mice. CD4+ T cells were isolated from naïve (A) or mice injected with 
100mg/kg(B) or 150mg/kg(C) of cyclophosphamide twice at 5 day intervals and stained for CD25+ 
cells. 
 
To combine Treg depletion with MTA1 specific vaccination, we injected mice with 100µg/kg of 
cyclophosphamide and immunised four days later with pcDNA3-mMTA1/hMTA1 using a gene 
gun. Following three immunizations at three days interval, mice were challenged with CT-26 
7% 22.1% .1 2.7%  2.1% 
A B C 
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cells and monitored for tumour development and survival. Treg depletion using 
cyclophosphamide combined with MTA1 specific vaccination was not able to produce any 
significant survival benefit or delay in tumour growth in these mice compared to control animals 
(fig 6.5). However, the possibility of immunisation protocol (e.g. timing) not being optimum 
could not be ruled out. 
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Figure 6.5:- Combination of cyclophosphamide (CPM) and genegun immunisation. Balb/c 
mice were immunised thrice with CPM 4 days before gene gun immunisations of pcDNA3-
mMTA1/hMTA1, followed by CT-26 challenge 7 days after last vaccination and monitored for 
tumour growth rate (A) and survival (B). Result shown is a representative of 2 independent 
experiments with 5 mice per group. 
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6.2.3 SFV as a vector for immunotherapy using a ‘non-self’ antigen 
 
Following the failure of DNA vaccination to generate an immune response to MTA1, it was next 
decided to investigate viral vaccination. To demonstrate the ability of SFV vector to generate 
antigen specific immune response in vivo, naïve balb/c mice were immunised with SFV-βgal 
twice at 3 days interval (1x106 pfu). A week after the booster immunisation, splenocytes were 
isolated from the immunised mice and re-stimulated in vitro for 5 days with immunodominant 
TPH peptide from beta-galactosidase (bgal) followed by evaluating the specificity of CTLs 
generated in a cytotoxicity assay using either CT-26 or CL-25 tumour cells  which is a CT-26 
derived clone transfected with the bgal gene). TPH peptide specific cell lysis was observed with 
40% of CL-25 cells lysed by T cells generated from SFV-βgal immunised mice, whereas 
negligible lysis of CT-26 cells was observed, suggesting that immune response generated was b-
gal specific (fig 6.6). More importantly, negligible lysis of CL-25 cells was observed when TPH 
specific T cells were generated from naïve mice or control SFV immunised mice (data not 
shown). These results suggest that β-gal protein was efficiently produced in vivo upon SFV-βgal 
immunisation and TPH peptide was naturally processed and presented to prime naïve TPH 
specific CTLs. 
 
Next, SFV was compared with other viral vectors (Adenovirus-βgal and DISC-βgal) in terms of 
generating TPH specific CTLs. Following two immunisations of naïve balb/c mice with either of 
SFV-βgal, Adeno-βgal or DISC-βgal, splenocytes were stimulated with TPH peptide for 5 days 
in vitro as before evaluating them in a cytotoxicity assay. As seen in figure 6.7, TPH specific 
CTLs generated from all three groups of mice were able to specifically lyse CL-25 cells.  Non-
specific killing in terms of lysis of CT-26 cells was less than 5% (data not shown). Although, all 
three vectors were able to generate CTL responses against TPH, at 1x106 pfu, SFV-βgal proved 
to be most potent and generated approximately 60% lysis of CL-25 cells (fig 6.7). Surprisingly, 
Adenovirus was least effective in these experiments generating a maximum of 10% killing. 
Previously published experiments using SFV have demonstrated good efficacy when using 1x106 
pfu particles in generating antigen specific immune response (Ni et al., 2004). Moreover, 
attempts to further concentrate SFV virus by sucrose gradient method were unsuccessful. Thus it 
was decided to use this titre for immunisations in the following in vivo experiments. 
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Figure 6.6:- Cytotoxicity assay using CTLs generated from SFV-βgal immunised mice. Balb/c 
mice were immunised twice with 1x106 pfu SFV-βgal at 4 day interval. Splenocytes were 
harvested seven days after last immunisation, re-stimulated in vitro for 5 days with 
immunodominant TPH peptide (from beta galactosidase protein), followed by testing the CTLs 
generated in a standard 4 hour chromium release assay against CT-26 or CL-25 cells. 
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Figure 6.7:- Comparision of SFV-βgal with Adeno-βgal and DISC-βgal vectors at 1x106 pfu 
for their ability to generate Bgal specific CTLs. Balb/c mice were immunised with 1x106 pfu of 
either of the vectors twice, followed by in vitro restimulation of splenocytes from these mice 
with TPH peptide and were evaluated in cytotoxicity assay against CL-25 cells. 
(p<0.001)Statistical analysis done using student’s t test. 
 
Furthermore, to determine whether this in vitro cytotoxicity translated into anti-tumour immune 
response in vivo, balb/c mice were immunised twice with 1x106 pfu SFV-βgal particles and after 
seven days of last boost, mice were challenged with either CL-25 or CT-26 cells subcutaneously. 
These animals were then monitored for tumour development and survival. A significant delay in 
tumour progression was observed in all the mice immunised with SFV-βgal and challenged with 
CL-25 cells. More importantly, this translated into significantly improved survival of these mice 
(p=0.0007) and upto 50% of the animals were completely protected from tumour challenge (Fig 
6.8A). Control mice (PBS injected) developed rapidly progressing tumours and had to be killed. 
This study also assessed SFV-βgal in a therapeutic study. In this experiment, balb/c mice with 
well established palpable (2-3 mm2) tumours were immunised with 1x106 pfu SFV-βgal intra-
peritoneally and monitored for tumour growth rate. As seen in figure 6.8B, mice vaccinated with 
SFV-βgal displayed slow tumour progression and survived significantly longer, although all 
mice eventually succumbed to the tumours. In comparison, both control groups of mice (injected 
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with PBS or SFV-βgal immunisation in mice having CT-26 tumours) developed progressive 
tumours. Considering the fact that no effect of SFV-βgal immunisation was observed in mice 
harbouring CT-26 tumours, it was presumed that the immune response developed was antigen 
specific (βgal) and the delayed tumour growth was not a result of a non specific activation of 
immune system due to the virus administration. 
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Figure 6.8:- Tumour protection (A) and therapy (B) studies using SFV-βgal. (A) Balb/c mice were 
immunised twice with 1x106 pfu of SFV-βgal followed by CL-25 tumour challenge seven days later. 
Animals were monitored for tumour growth rate and survival benefit. (B) Ten days after injecting 8x104 
CL-25 cells, mice were immunised twice with 1x106 pfu of SFV-βgal and monitored for tumour growth. 
Results shown are a representative of two independent experiments with 5 mice per group. 
B A 
 
6.2.4 SFV vector for immunotherapy targeting MTA1 
 
Having established SFV as a reasonably efficient vector for anti-tumour immune response, it was 
next decided to investigate SFV vaccination for MTA1. Murine and human MTA1 were cloned 
into pSMART2b vectors as described previously (chapter 4). Co-transfection of pSMART2b-
mMTA1/hMTA1 along with a helper plasmid in 293 cells was used to generate SFV-mMTA1 
and SFV/hMTA1 particles. 1x106 pfu SFV-mMTA1/hMTA1 particles were used to immunise 
naïve balb/c mice twice, followed by challenge with CT-26 tumour cells seven days later. 
Delayed growth of CT-26 tumours was observed in mice immunised with either SFV-mMTA1 
or SFV-hMTA1. A statistically significant survival benefit was observed in SFV-hMTA1 
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immunised mice compared to control (p=0.022) (fig 6.9); although SFV-mMTA1 immunised 
animals also showed delayed tumour growth and survived longer, it was not statistically 
significant (p=0.055). Further experiments need to be carried out to improve on this result by 
using higher titre of the virus and/or combining it with other immuno-modulatory agents, but 
lack of time did not permit it. 
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Figure 6.9:- Delayed CL-25 tumour development following SFV-mMTA1/hMTA1 vaccination. 
Balb/c mice were immunised twice with 1x106 pfu of SFV-mMTA1/hMTA1 followed by CT-26 
tumour challenge seven days later. Animals were monitored for tumour growth rate (A) and 
survival benefit (B). Results shown are representative of two independent experiments with 5 mice 
per group. 
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6.3 Discussion 
 
Previous attempts to identify naturally processed epitopes from MTA1 antigen were 
unsuccessful and hence we decided to target the full length MTA1 gene for therapy. This would 
obviate the need to identify peptides for therapy, although without known epitopes, monitoring 
an immune response to MTA1 could be difficult.  
 
6.3.1 Syngeneic plasmid DNA vaccination 
In this study, firstly syngeneic balb/c mice were immunised with gold particle coated with 
pcDNA3-mMTA1, using a helium gene gun, followed by challenge of tumour cells over-
expressing MTA1. The inability to protect mice in this study was not surprising, considering that 
several groups have questioned the limited potency of DNA vaccines, especially when using 
gene gun. It was also difficult to generate anti-tumour response in mice whilst targeting beta-
galactosidase antigen using this method (data not shown). Although, gene gun immunisation has 
been successfully used for mediating anti-tumour immune response, most studies have targeted 
foreign antigens, which are highly immunogenic (Curcio et al., 2003). Whether this method is 
potent enough to break tolerance to self-antigens is not clear. Indeed, a similar study using gp75 
antigen demonstrated the inability of different strategies to overcome tolerance in a syngeneic 
model, whereas xenogeneic gp75 (insect or human) was potent enough to generate CTL response 
in mouse model (Naftzger et al., 1996). In that study, syngeneic gp75 vaccine as a cell based, 
purified protein, peptide and in combination with different cytokines was unable to generate any 
antibody or CTL response to mouse gp75.  Moreover, different routes of vaccination 
(intraperitoneal, sub-cutaneous and intradermal) were also unable to break tolerance to gp75, 
whereas gp75 produced in insect cells or human gp75 vaccination was able to generate auto-
antibodies capable of mediating tumour rejection. Interestingly, no CTL responses were detected 
in any of those experiments; leading the authors to hypothesise that gp75 might be processed 
exclusively through MHC class II pathway (Naftzger et al., 1996). Another interesting study 
clearly demonstrated the differences of gene gun mediated vaccination in non-tolerant and 
tolerant animal models. In wild-type balb/c mice, intra-dermal immunisation of rat-her2/neu 
plasmid using gene gun was able to provide complete protection in immunised mice and this 
immune response was dependent on CD4+ and CD8+ T cells, among other cells. However, the 
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same experimental therapy was unable to provide any protection in Her2 tolerant Balb-neuT 
mice (Curcio et al., 2003; Cavallo et al., 2006). 
 
6.3.2 Xenogeneic plasmid DNA vaccination 
 
Subsequently, this study assessed xenogeneic immunisation as a means to overcome tolerance as 
suggested by several recent studies. This strategy of vaccinating syngeneic balb/c mice with 
human MTA1 gene was also unsuccessful in mediating anti-tumour immune response as 
observed by no protection to tumour challenge in the mice immunised with hMTA1 gene. 
Furthermore, to exclude the possibility that the mode of vaccination may have been responsible 
for the inefficient priming in vivo, we repeated the same experiment but immunised the mice 
intramuscularly with 100μg of syngeneic and xenogeneic plasmids with CpG as adjuvant. 
Intramuscular immunisation did not enable vaccinated mice to reject CT-26 tumour cells over 
expressing MTA1 either. Xenogeneic immunisations have been successfully used by Alan 
Houghton’s group to overcome tolerance against several self-antigens and mediate tumour 
protection/rejection (Gregor et al, 2005). However, there are key differences in their studies and 
this study targeting MTA1. Antigens targeted by Houghton and colleagues have mainly been 
melanoma differentiation antigens (gp100, gp75, tyrosinase and trp-2), whereas MTA1 is a 
ubiquitously expressed self antigen, which may result in more profound tolerance to MTA1 than 
tissue antigens. Notably, realtime PCR results in this study suggested MTA1 mRNA to be also 
expressed in the thymus at low levels (fig 3.5). It would be interesting to determine whether the 
protein expression of MTA1 in the thymus could lead to central tolerance and deletion of MTA1 
specific T cells. Indeed, a similar strategy targeting prostate specific membrane antigen (PSMA) 
resulted in generation of auto-antibodies but no CTL response (Gregor et al., 2005). Thus, 
success of this strategy could be vitally dependent on the antigen targeted and its expression 
pattern. Also, antigen similarity between mouse and human homologues of these differentiation 
antigens is between 65-85% (gp100-77% identical, trp-2-83% identical), compared to 94% 
similarity between human and mouse MTA1 (Zhai et al., 1997; Bowne et al., 1999). It is 
possible that protein difference within a certain range might be crucial to be able to break 
tolerance i.e. difference of 23% between human and mouse gp100 could be one of the major 
factors enabling xenogeneic vaccination to break tolerance, whereas a 6% difference between 
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MTA1 sequences is not sufficient to modify the processing and binding of CTL epitopes from 
mMTA1. Other possibility for inefficiency of xenogeneic immunisation in this study could be 
attributed to the codon bias. Most amino acids can be coded by different genetic codes (for eg:- 
lysine can be coded by AAA or AAG) and different species tend to have a certain bias for these 
genetic codes, especially related to the GC content. This affects the stability of the mRNA and 
the translation efficiency through tRNA. It is known that codon bias exists in certain species 
affecting the translation efficiency of xenogeneic genes in them. Intramuscular plasmid DNA 
vaccination encoding an epitope from listeria monocytogenes was unable to generate any CTL 
response when the wild type sequence was used for vaccination, whereas when the codons were 
optimised for the mouse system, the translation efficiency of the epitope in vivo increased 
remarkably. Moreover, improved translation efficiency due to codon bias correction translated 
into epitope specific CTL generation and partial protection of mice from listeria infection 
(Uchijima et al., 1998).  
 
6.3.3 Combination of Cyclophosphamide (CPM) and plasmid vaccination 
 
Finally, to enhance DNA vaccine potency, either depletion of Tregs or inhibiting their 
suppressive action has been shown to enhance anti-tumour immune response against self 
antigens. CTLA-4 molecule expressed by Tregs binds to B71/B72 molecules on APC surface 
and inhibits their antigen presentation efficiency. CTLA-4 antibody can inhibit this interaction, 
thereby increasing vaccination efficiency. Anti CTLA-4 antibody in combination with 
xenogeneic DNA vaccination was able to generate CTL and anti-tumour response to self 
antigens (Gregor et al., 2004). Similarly, anti-GITR antibody in combination with xenogeneic 
DNA vaccine enhanced CTL response to self antigen (Cohen et al., 2006).  Other studies have 
shown that depletion of Tregs can be equally effective in generating anti-tumour immune 
response (Turk et al., 2004; Onizuka et al., 1999). Low dose cyclophosphamide has been shown 
to be toxic to Tregs by inducing apoptosis in them and this led us to investigate a combination of 
low dose CPM with DNA vaccine (Ghiringhelli et al., 2004). Four days after CPM 
administration Treg population decreased to approximately 2% from 7%, which is in agreement 
with previous studies.  In this study, balb/c mice were immunised with 100μg/kg of CPM 
followed four days later by DNA vaccine three times at seven days interval and challenged with 
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CT-26 cells. This strategy, depletion of Tregs along with DNA vaccination, was unable to 
provide significant protection in mice, which developed progressive tumours. Although, this 
study failed to generate MTA1 specific immune response, role of Tregs in suppression of MTA1 
specific CTLs is still inconclusive and further work needs to be done to optimise Treg depletion 
either with CPM or PC-61 (anti IL-2α) antibody. Also, other methods for suppression of Treg 
function (anti GITR and anti CTLA-4) alone or in combination with DNA or viral vectors for 
MTA1 might need to be investigated. 
 
The success of DNA vaccination is crucially reliant on the efficient translation of injected 
plasmid, duration of expression and the cells targeted by immunisation. In hindsight, inefficient 
translation of gene-gun and intramuscular DNA vaccinations cannot be ruled out as a cause for 
inefficient immune response in these studies. Several recent studies have endeavoured to 
increase DNA efficiency protocols by injection of plasmid intramuscularly followed a few 
seconds later with electric pulses, which remarkably enhanced vaccination efficacy in animal 
models. Vaccination by electroporation increases cell permeabilisation at injection site, thereby 
facilitating plasmid entry into cells. Also, infiltrating DC and other inflammatory cells due to the 
electric field, could further enhance the immunogenicity of plasmid coded antigen (Cavallo et 
al., 2006). Based on evidence from several studies described above, significant improvements 
can be undertaken to vaccination protocol used for MTA1 in this study, before MTA1 can be 
ruled out as an immunotherapeutic target. 
 
6.3.4 SFV vector as an immunotherapeutic agent 
Finally, it was hypothesised that delivering MTA1 in a highly immunogenic setting could trigger 
a potent immune reaction and would be able to overcome peripheral tolerance mechanisms, 
which might influence anti-MTA1 immune response. The SFV vector was chosen due to several 
reasons; relative ease of manipulation, safety profile, ability to prime cell-mediated and humoral 
immune responses, high level protein expression and negligible chance of integration in host cell 
genome (Daemen et al., 2000). In this part of the study, SFV potency to generate an immune 
response to foreign antigens was first evaluated. SFV-βgal particles were generated and tested 
for their capability to generate immune response to an immunodominant TPH peptide from β-
galactosidase antigen. CTLs generated in balb/c mice by SFV-βgal immunisation were capable 
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to specifically killing CL-25 cells, which have been stably transfected to express βgal antigen. At 
a similar dose, SFV was more potent than adenovirus and DISC-HSV in terms of generating 
higher cytotoxicity against relevant target cells. However, these experiments were only 
performed at one concentration (1x106 pfu), and higher dose of adenovirus and DISC-HSV 
might be equivalent or better than SFV. It is noteworthy, that several studies have used doses of 
up to 1x108 pfu for the above viral vectors for anti-tumour immune responses.  
 
SFV vectors have been evaluated in a number of animal models for their efficacy in generating 
CTL responses and anti-tumour immune response. Immunisation of naïve C57BL/6 mice with 
SFV vector coding for E6 and E7 proteins (human papilloma virus proteins) provided protection 
from tumour cells expressing these proteins in 40% of animals (Daemen et al, 2000). In that 
study, injection of as few as 104 virus particles was  able to generate CTL response against E6 
and E7 protein expressing cell line, whereas injecting 106 particles led to significantly delayed 
tumour growth and complete protection in 10% mice. A subsequent study from the same group 
demonstrated regression of well established (500 mm3) tumours in the same cervical cancer 
mouse model (Daemen et al., 2004). Although all routes of immunisation were capable of 
generating CTLs in this model, the authors observed intravenous injections to be the most 
effective. In another study, intra-peritoneal injection of 106 SFV viral particles expressing P1A 
gene was sufficient to protect 80% of animals from challenge of tumour cells expressing P1A 
antigen (Ni et al., 2004). Moreover, SFV vaccination was also able to generate therapeutic 
immune response in 50% of mice in the same tumour model.  
 
To confirm these results and investigate whether βgal specific CTL induction would translate 
into protective and therapeutic anti-tumour response in vivo, we used CL-25 cells as a tumour 
model. Intra-peritoneal vaccination of naïve balb/c mice with 1x106 pfu SFV-βgal delayed 
tumour growth in all mice and protected upto 50% of the mice from tumour development. 
Moreover, SFV-βgal administered to mice with well established tumours, significantly delayed 
tumour growth but was noticeably less efficient compared to prophylactic experiments. This is 
not surprising since in therapeutic experiments, the immune system is likely to be manipulated 
and/or suppressed due to the presence of tumour cells and immuno-suppressive factors secreted 
by it. Although, no tumour regression was observed in therapeutic experiments, it is likely to be 
 166
                                                                                                                                                                         Chapter 6 
due to low dose of the virus injected and increasing the virus dose for vaccination would have to 
be evaluated in future therapeutic experiments.  
 
6.3.5 SFV-MTA1 mediated delay in CT-26 tumour progression 
Having established the efficacy of SFV particles in protecting mice from tumour development, 
the SFV-MTA1 vector was tested for the ability to protect mice from MTA1 over-expressing 
tumour. Initial experiments have demonstrated a significant delay in tumour growth in mice 
vaccinated with SFV-hMTA1. Although, delayed tumour growth was observed on vaccination 
with SFV-mMTA1, it did not reach the level of statistical significance. This delay in tumour 
progression in vaccinated animals was reproducible. It should be emphasised that none of the 
vaccinated animals survived the tumour challenge, indicating that the immune response was 
relatively weak. Experiments need to be conducted using higher titre of the virus and its 
combination with other therapeutic interventions such as Treg depletion. It is noteworthy that the 
immunisation protocol and dose of immunisation used in this study were similar to a recently 
published study and was shown to be highly effective in preventive and therapeutic experiments 
(Ni et al., 2004). However, the antigen targeted in that study, P1A, a cancer testis antigen with 
less likelihood of being able to generate immune tolerance. Lack of time did not permit to 
perform these experiments but are necessary to conclusively appraise the therapeutic potential of 
MTA1. 
 
These studies suggest a strong regulatory component against MTA1 making the generation of 
strong immune response difficult. But it would be reasonable to assume that given the optimal 
protocol and strategy of immunisation, immune response can be generated against most antigens, 
albeit at the risk of potential autoimmunity developing. Although, MTA1 boasts of having most 
of the characteristics for an ideal tumour antigen, its expression in several normal tissues is likely 
to play a major role in suppressing the immune response to it. It would be crucial to firstly 
evaluate MTA1 protein expression in thymus during development.  Central tolerance may affect 
MTA1 CTL repertoire and may depend on this thymic expression. However, since MTA1 was 
recognised and cloned by SEREX in our laboratory, it suggests that central tolerance might not 
be very stringent for CD4+ T cells. In the study identifying MTA1 by SEREX, approximately 
10-15% of the prostate cancer patients produced antibody response to MTA1, although the 
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number of serum samples analysed was small (n=13). More samples from cancer patients need to 
be analysed, including other cancers to confirm the immunogenicity of MTA1, not only in 
prostate but other cancers as well. Another potential hurdle in generating immune response to 
MTA1 and other self-antigens is that they are expressed in normal tissues in the absence of co-
stimulatory molecules which would rapidly tolerised any CTLs generated, leading to decreased 
protective and/or therapeutic efficacy of vaccination. It has been showed that CD4+CD25+ cells 
can be generated from naïve CD4+ T cells in vitro depending on antigen stimulation protocol. 
Thus, it is likely that chronic presentation of MTA1 in a non-immunogenic context by normal 
tissues may generate MTA1 specific Tregs and immunising with MTA1 coding vectors would 
actually activate these cells, thereby suppressing the immune system and making clinical 
progress worse. Indeed, Nishikawa et al (2003) have recently shown that DNA immunisation 
using SEREX defined self-antigens (similar as MTA1) leads to activation of antigen specific 
Tregs and enhanced tumour growth in immunised animals compared to control irrelevant gene 
vaccinated mice. Interestingly, this phenomenon could be reversed by IFN-γ either produced by 
CD8+ T cells or externally administered (Nishikawa et al., 2005a; Nishikawa et al., 2005b). 
From the above study, it can be hypothesised that administration of SEREX defined self-antigens 
in a highly immunogenic context (viral vectors) could cause high level IFN-γ secretion and 
reversal of Treg generation. Whether MTA1 immunisation would also generate Tregs is not 
known and needs to be evaluated.  
Thus, caution needs to be exercised in selecting antigens for immunotherapy of cancer. In spite 
of the fact that MTA1 has showed limited potential, as an immunotherapeutic target, it seems 
reasonable to propose that other metastasis associated antigens should be looked at in future, if 
immunotherapy needs to be applied to late stage cancer patients. 
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Chapter 7:- Discussion 
 
Cancer is an intractable disease of varied spectrum and stages and can be defined as 
“uncontrolled cellular proliferation which at its advanced stages spreads to distant organs of the 
body” and is self sufficient for their growth. Normal cell growth and division, which is 
controlled by several key genes called oncogenes and tumour suppressor genes, is deregulated 
owing to genetic events affecting these genes. According to the immunosurveillance theory, 
these transformed cells are constantly eliminated from the body. However, as suggested by 
Robert Schreiber, a state of equilibrium is reached at some point where the rate of elimination of 
cancer cells is balanced by their repopulation (Dunn et al, 2004). During this phase the cancer 
cells are also edited by the immune mechanisms selecting for more aggressive and less 
immunogenic tumour cells (Escape). Taking advantage of the fact the T cells can recognise 
tumour antigens and eliminate cells expressing them, strategies to activate T cells against such 
antigens has gained unprecedented interest over the past few years. But caution must be 
exercised whilst selecting the target antigen as an immune reaction against non-essential antigen 
might actively select for cells which down-regulate specific antigen and thereby hasten the 
immuno-editing and escape stage. This compelled us to investigate the criteria defining the ideal 
tumour antigen for immunotherapy. 
 
7.1 Tumour Antigens and Immunotherapy 
 
Over the past one and a half decades, since the identification of the first tumour antigen (MAGE-
1), immunotherapy has rapidly evolved as the most promising strategy to selectively target 
cancer cells. Moreover, being mediated by our own immune system it is likely to be devoid of 
the distressing and sometimes life threatening side effects of chemotherapy and radiotherapy. 
However, initial enthusiasm generated from the phenomenal success of immunotherapy in 
animal models suffered a set back because of limited clinical benefit in humans.  Whilst 
investigating immunotherapy for potential clinical application in human patients, two key 
parameters have to be considered the tumour antigens targeted and the relevant animal model 
used to investigate it. 
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A number of characteristics should be used to define an ideal tumour antigen and pursuing them 
in animal and human studies. Although a number of groups are advocating personalised vaccines 
based on individual tumour antigens expressed, this is likely to be quite expensive and 
impractical, especially in the developing world. Hence, antigens widely over-expressed in 
tumours are the most suitable targets. For example, bcr-abl is over-expressed in majority of CML 
patients and has been extensively investigated for immunotherapeutic purpose (Clark et al, 
2001). Antigens like bcr-abl and viral antigens are very specific for certain tumours but similar 
antigens for most other cancers have not been identified till date. Cancers are derived from 
normal human tissues and most of them over-express certain essential genes required for growth 
and proliferation. Such antigens are shared between several different tumour types and are the 
most practical targets as they could be applicable to the majority of population. Although, 
targeting over-expressed self-antigens can generate auto-immune response as seen in melanoma 
clinical trials, several other studies have demonstrated no such reactions (Yagi et al., 2006). 
Expression of such genes in normal tissues is unlikely to generate the threshold of MHC-peptide 
complexes capable of activating T cell responses. Another important criterion is the role of the 
antigen in transformation of cells. Targeting a non-essential antigen by therapy could eventually 
lead to de-selection of tumour cells expressing such antigens, thereby immuno-editing and 
selecting of less immunogenic and escape variants from tumours. Thus, antigens essential for 
maintaining the oncogenic phenotype are most promising targets. However, another strategy 
could be to target several non-essential proteins, which would also make generation of escape 
variants less plausible. 
Finally, it is widely agreed that immunotherapy is likely to be more successful if used in 
combination with the conventional modalities of therapies (Lake & Robinson, 2005). Removal of 
the primary tumours by surgery and targeting the metastasis by immunotherapy is likely to be 
highly effective, since removal of the bulk of tumour not only leaves less cancer cells to be dealt 
by the immune cells but also eliminates most of the immuno-suppressive factors released by the 
cancers. Thus, late stage antigens involved in establishing the metastatic phenotype of tumour 
cells seem to be ideal candidates for immunotherapy. 
 
7.2 MTA1 as a potential candidate for cancer 
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Initially identified in 1994 by Toh et al, several studies have since demonstrated over-expression 
of MTA1 in human cancers such as lung, hepatocellular, breast, pancreatic, oesophageal, 
colorectal, gastric, ovarian, laryngeal and prostate cancer (Tang et al., 2003; Sasaki et al., 2002; 
Toh et al., 1999; Nicolson et al., 2003; Moon et al., 2004; Nawa et al., 2000). Independently, 
MTA1 was identified using SEREX expression cloning by Li et al, demonstrating the presence 
of antibody response in cancer patients against MTA1 (Li et al, submitted; Assudani et al, 2005). 
Approximately 40-50% of the cancers over-expresses MTA1 most of which have been correlated 
with metastatic and angiogenesis, and seems like a good target as it would be applicable for 
majority of the population. Moreover, most of the above studies were conducted using primary 
tumours and it is reasonable to assume that MTA1 expression would be even higher in the 
metastatic cells. Moreover, being highly conserved in different species, MTA1 is likely to be 
essential for the growth and survival of tumour cells and indeed normal cells. MTA1 is a part of 
HDAC complex and is involved in transcription repression (Toh et al., 2000). However, its 
structure suggests that it may also have a role as a transcription factor. Contradicting most 
previous studies suggesting MTA1 to be localised in nucleus, a recent study showed that it can 
interact with endophilin 3 in the cytoplasm of brain cells. Several splice variants of MTA1 were 
identified in recently mice and it might be interesting to explore whether different splice variants 
of MTA1 are responsible for its varied functions (Yaguchi et al., 2005).  
 
Three independent studies provided evidence regarding non-redundancy of MTA1 for growth 
and metastatic potential of tumour cells. Over-expression of MTA1 in immortalised 
keratinocytes cell line (HaCaT) led to increased invasive and migratory potential of these cells 
along with increased resistance to apoptosis by up-regulation anti-apoptotic molecule Bcl-xl 
(Mahoney et al., 2002). These results were also confirmed in a pancreatic cancer model as well 
(Hofer et al., 2004). Complementing these studies, down-regulation of MTA1 had the opposite 
effects. Down-regulation of MTA1 expression using antisense phosphorothioate oligonucleotides 
resulted in growth inhibition of human breast cancer cells whereas siRNA mediated MTA1 
inhibition led to decreased malignant phenotype in human oesophageal carcinoma cells (Nawa et 
al., 2000; Qian et al., 2005). All these studies provide strong evidence supporting MTA1’s role 
in late stage cancer progression. However, the mechanism used and the target genes for MTA1 
over-expression were not known until recently. MTA1 expression was significantly correlated 
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with intratumoral microvessel density (MVD) in human breast cancer samples and suggested that 
amongst other function, one of the major role of MTA1 was facilitating angiogenesis which is 
essential for cancer cells to metastasise in the first place and for progressive growth at distant 
organs (Jang et al., 2006). Indeed, a recent study showed MTA1 to be responsible for increased 
stabilisation of hypoxia inducible factor-1 alpha (HIF-1α), thereby up-regulating vascular 
endothelial growth factor (VEGF) and enhancing angiogenesis (Moon et al., 2006). In breast 
cancer cells specifically, breast cancer-amplified sequence 3 (BCAS3) was shown to be a target 
for MTA1, which is responsible for increased tamoxifen resistance in them (Gururaj et al., 
2006).  Considering the expression data and role of MTA1 in cancers, it can be hypothesised that 
not only can MTA1 be targeted in late stage metastatic cancer cells of different backgrounds but 
it can also be used in combination with traditional therapies to improve therapeutic efficacy. 
 
Finally, immunogenicity of an antigen would be the deciding factor in endorsing it with target of 
immunotherapeutic potential. Not all tumour antigens are immunogenic and it would especially 
be so for over-expressed self antigens such as MTA1. Immune cells are educated during 
development to ignore self-antigens; however the number of auto-immune diseases indicates that 
this process is not water tight and in specific priming conditions, these immune cells can be 
activated to react against self antigens. Although MTA1 is an over-expressed self antigen, its 
identification by SEREX in our laboratory (Li et al., submitted; Assudani et al, 2005) provides 
some evidence that MTA1 has been recognised by the CD4+ T cells, which in turn stimulated B 
cells to produce antibodies against it in cancer patients. It was hypothesised that, CD8+ as well 
as CD4+ T cells may exist in patients, whose tumours over-express MTA1. Combined together 
these studies strongly suggested that should MTA1 be immunogenic, it would represent the ideal 
immunotherapeutic target against metastatic cancer and therefore MTA1 immunogenicity was 
investigated. 
 
7.3 Animal models for cancer immunotherapy 
 
Animal models have been used extensively in the past to model human diseases including 
cancer. However, recently reliance on animal models has been seriously questioned due to lack 
of significant clinical benefits of therapies, which showed remarkable benefit in them. 
Nonetheless, animal models have provided great insights into human disease leading to 
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discovery of number of drugs and medical interventions. Although it can be argued that human 
physiological systems is quite different to that of mice, it is more likely that poor animal models 
used in several studies are responsible for the failure of clinical trials in humans. 
Most immunotherapeutic models of cancer use mice as a choice of animal due to obvious 
reasons; short life providing quick answers, relatively inexpensive, easy to handle, ease of 
genetic manipulation and similar physiological systems as humans. A number of therapeutic 
strategies have been investigated on transplantable tumours in mice. These tumours grow quite 
rapidly and are injected at a site (sub-cutaneous) which is not their usual anatomic location. 
Moreover, antigens used in the studies are mostly foreign and highly immunogenic (ovalbumin is 
the most commonly used antigen), whereas most tumour antigens are likely to be self in origin 
and less immunogenic (Dullaers et al., 2006). Other models employ mice producing T cells with 
transgenic TCR for a specific epitope, which is a highly artificial system as antigen specific T 
cells are quite rare in normal circumstances (Marzo et al., 1999). Hence, selection of an animal 
model to investigate a novel therapeutic antigen or any other intervention can be most critical in 
attaining results which can be translated in to humans. Thus it was necessary to first confirm 
expression levels of MTA1, not only in human cancers but also in murine cancers and tissues. 
 
7.4 MTA1 expression in human cancers  
 
MTA1 over-expression was confirmed in several tumours of different histological origin such as 
gastric, colorectal, breast and prostate cancer (data not shown). Levels of MTA1 in cancer 
samples were comparable to those previously published. Approximately 40-60% of cancer 
samples were shown to be over-expressing MTA1 and the rise was generally 2-4 folds. 
Interestingly, other studies have demonstrated similar rise for other metastasis antigens as well. 
This suggests that, although the levels of such metastasis associated genes do not increase a great 
deal, but it is enough to support the migration and metastatic ability of tumour cells. The 
numbers of samples examined in this study were small but some correlation between tumour size 
and node involvement was observed for colorectal cancers but not gastric cancers. A similar 
increase in MTA1 level was observed in breast cancer samples, although several samples could 
not be evaluated accurately due to very low quantities of mRNA available from them. MTA1 has 
been extensively investigated in breast cancer and has been correlated to angiogenesis. 
Interestingly, MTA1s a splice variant of MTA1 has been implicated in binding to oestrogen 
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receptor α (ERα) in the cytoplasm of breast cancer cells (Kumar et al., 2002). Oestrogen receptor 
expression is considered as a good prognostic marker for breast cancers and is down-regulated 
due to binding of MTA1s to ERα. Thus, by inhibiting MTA1s, ERα expression can be restored in 
the nucleus and thereby making breast cancer cells responsive to hormonal therapy. This gives 
an additional strategy to exploit this group of antigens in breast cancer patients. MTA1 over-
expression has also been correlated with prostate cancer progression (Hofer et al., 2004). MTA1 
expression in prostate cancer samples was also studied and only 2 out of 10 patients 
demonstrated significantly elevated MTA1 levels compared to benign prostate tissue (data not 
shown), but could not be correlated with disease progression in these cases. Larger numbers of 
samples need to be examined to draw accurate conclusions, preferably from metastatic samples. 
However, metastatic samples are quite difficult to obtain. LCM samples should be used in future 
studies to accurately evaluate MTA1 expression in cancerous cell without the surrounding 
stroma or normal cells. Moreover, similar to breast cancer MTA1 expression should also be 
correlated with angiogenesis in other cancers. A recent study observed a paradoxical relationship 
between MTA1 and p53 tumour suppressor gene (Qian et al, 2005). Inhibition of MTA1 by 
RNAi also decreased p53 protein levels, although cell proliferation also decreased.  Being a 
tumour suppressor gene, increase in p53 has generally been associated with inhibition of cell 
proliferation and would be expected to correlate with decreased MTA1 levels. This observation 
also needs to be confirmed to explain the complex biological role of MTA1 in cancer cells. 
 
7.5 Validation of MTA1 in a mouse model 
 
As discussed previously, animal models can provide a wealth of information if correctly chosen. 
MTA1 is a highly conserved molecule, being 84% and 96% similar at the DNA and protein 
levels respectively between mouse and human. Also, its expression pattern, localisation and 
functions seem to be identical. Interestingly, several splice variants of MTA1 have been recently 
identified in mice, most of which are yet to be discovered in humans. One of the splice variants 
of mouse MTA1 is similar to the MTA1s antigen identified in human breast cancers. 
Considering these factors, it was hypothesised that results obtained from murine studies targeting 
MTA1 could be directly applicable to humans as well. To verify MTA1 expression at mRNA 
and protein levels in murine tissues and cancer cells, this study evaluated its expression using 
conventional PCR, real-time PCR and western blotting. Both conventional and real-time PCR 
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confirmed that MTA1 was highly over-expressed in all the tumour cells examined compared to 
low level expression in most normal tissues except testis. Interestingly, spermatogenesis is a 
highly active process requiring high motility and proteolytic enzymes, and these properties are 
also shared by metastatic cells.  
These results were further confirmed at the protein level of MTA1 as mRNA and protein levels, 
do not necessarily always correlate. However, in this study western blotting (WB) confirmed the 
results of PCR and high level of MTA1 protein was observed in all cell lines compared to normal 
tissues, where no protein expression could be detected. Previous studies have demonstrated low 
level protein expression of MTA1 using immuno-histochemistry in normal tissues but in this 
study, perhaps the levels of MTA1 were below the detection limit of WB. Increasing the quantity 
of protein loaded by per lane for WB might have enabled MTA1 protein detection. This could be 
highly significant since threshold levels of MHC-peptide expression is required on the cell 
surface for recognition and mediation of CTL activity and very low protein levels of MTA1 may 
not allow that threshold to be reached, thereby preventing auto-immune response of CTLs 
generated against MTA1 by vaccination (Stevanovic & Schild, 1999). 
These results justify investigating MTA1 as a target for immunotherapy against cancer in a 
mouse model, with a potential to being directly relevant to future human studies. 
 
7.6 Peptide vaccines and MTA1 
 
Identification of epitopes presented on the surface of tumour cells in an MHC restricted manner 
can be recognised by CTL leading to tumour lysis. Theoretically, CTLs generated against any 
such single epitope would be able to mediate tumour rejection. Indeed, a minority of patients 
demonstrate significant clinical responses in trials of peptide vaccines (Rosenberg et al., 1998; 
Rosenberg et al., 2004).  Identification of such peptides can prove to be considerably challenging 
but recent technological advances and availability of transgenic mice expressing human HLA 
molecules have expedited this procedure. Several algorithms are available on the World Wide 
Web, which allows prediction of peptides that could bind with higher affinity to a particular 
MHC allele. These peptides can then be synthesised and tested in vitro using human PBMC from 
donors or in vivo in transgenic mice. This study used the widely used software SYFPEITHI to 
predict peptides from MTA1 protein likely to be immunogenic. These peptides were then tested 
in transgenic mice for immunogenicity and natural processing. Three out of seven peptides 
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evaluated in syngeneic balb/c mice were found to be immunogenic. However, CTLs generated 
against these peptides were unable to kill tumour cells naturally over-expressing MTA1 at high 
levels, suggesting that these peptides were not naturally processed and presented by tumour cells. 
Similarly naturally processed peptides could not be identified from human MTA1 in HLA-A2 
transgenic mice.  
Inability to identify naturally processed peptides using the reverse immunology approach can be 
due to several reasons. Firstly, it is now widely believed that high affinity CTLs for self-antigens 
are likely to be deleted in the thymus and CTLs allowed to leave the thymus would be of 
medium to low binding affinity. Activating these CTLs would require highly immunogenic 
strategy and peptide vaccine on their own is not potent enough to do that. Thus, peptides 
identified as non-immunogenic in this study were perhaps less immunogenic and naturally 
processed, but the vaccination protocol used was not able to enhance this response. It should 
however be noted, that different adjuvants were attempted for vaccination, such as IFA, CpG and 
IFA/CpG combination with similar results (data not shown). It is more likely that the peptides 
tested in this study were indeed not naturally processed. Hundreds of peptides can be classified 
as medium/low binding epitopes according to their predicted binding score. But evaluating each 
of them is both expensive and time-consuming. Although prediction softwares have improved in 
recent years to take natural processing into account this is still not very accurate. Moreover, as 
established by a recent study, alternate splicing by the proteasome can produce a completely 
novel peptide from some protein (Vigneron et al., 2004). These peptides would be missed by 
currently available algorithms, but are nonetheless potential therapeutic targets. A more direct 
approach would be to elute peptides from the surface of tumour cells over-expressing MTA1 and 
mass spectrometry mediated identification of MTA1 derived peptides.  However this technique 
is time consuming, laborious, expensive and requires huge numbers of cells. Moreover, eluted 
and identified peptide still does not guarantee their adequate immunogenicity for in vivo killing 
of tumour cells. 
 
Since MTA1 is a self antigen, it is likely to be processed in the thymus by MHC class I 
processing pathway causing central tolerance of CD8+ T cells. CD4+ T cells may escape from 
this mechanism, since; MTA1 identification by SEREX suggests the existence of CD4+ T cells 
against it. Using this argument two class II human MTA1 derived peptides were evaluated in 
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HLA-DR4/DR1 transgenic mouse models. Both peptides were non-immunogenic in HLA-DR1 
mice but were highly immunogenic in HLA-DR4 transgenic mice. However, neither of these 
peptides were naturally processed as tested using two different methods (gene gun & lysate, see 
chapter 5). It is now known that intracellular proteins can also be presented in MHC class II 
restricted context, which if true for MTA1, would affect CD4+ T cell repertoire as well (Bogen 
et al., 1990). More peptides need to be investigated for MHC class II to draw conclusions 
regarding mechanism(s) underlying the existence of T helper cells against MTA1.  
 
7.7 DNA vaccine and MTA1 
 
DNA based vaccine strategies obviate the need to identify specific epitopes from antigens and 
can be used to target whole antigens which might generate immune response against multiple 
epitopes, irrespective of HLA type of the person. To test this, mouse MTA1 cDNA sequence was 
cloned into a mammalian expression vector, which was then used to immunise mice using either 
the gene gun or intramuscular method. Immunised mice were not only tested to reactivity against 
specific peptides but also for their ability to be protected from CT-26 tumour challenge, naturally 
over-expressing MTA1. Immunisation with mouse MTA1 was neither able to generate response 
to any of the peptides previously tested nor provide any protection from fatal tumour challenge. 
The inability of mMTA1 DNA vaccine to generate immune response was not surprising, as 
similar studies targeting self antigens using plasmid vaccine have demonstrated very limited 
potential, even with different methods of vaccination (Naftzger et al., 1996; Curcio et al., 2003). 
It was hypothesised that syngeneic DNA immunisation was not potent enough to be able to break 
tolerance to MTA1 and considering several recent studies, xenogeneic vaccine was employed as 
the next strategy (Bowne et al., 1999; Gold et al., 2003; Naftzger et al., 1996). Immunisation of 
mice with human MTA1 was also unable to provide syngeneic balb/c mice with protection from 
CT-26 tumour cell challenge. Furthermore, it is widely acknowledged that Tregs are responsible 
for suppression of self-antigen specific immune response and their depletion helps to overcome 
this. This led us to try a combination therapy regime consisting of Treg depletion using low dose 
cyclophosphamide and DNA vaccination. Although, this combination regime failed to provide 
significant benefit in immunised animals, further experiments are required with other Treg 
depletion methods to draw definitive conclusions.  
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In spite of a number of advantages of DNA vaccines, this study underlines the problems 
associated with it as well as additional factors that need to be considered. Immune response to 
DNA based vaccines is crucially dependent on antigen delivery and persistence, targeting the 
right cells, adjuvants as well as ensuring the appropriate processing depending on the response 
desired. Although, the presence of unmethylated CpG islands in the plasmid DNA are known to 
be good adjuvants in certain studies, their lack of potency is paradoxically blamed as the 
causative factor for failure of DNA vaccines, which might also be the case in this study. To 
overcome this, strategies such as co-administration of cytokine genes, co-stimulatory molecules, 
xenogeneic vaccine, using gene gun to target skin resident langerhans cells as well as including 
signalling molecules to target antigen to either MHC class I and class II pathway, have all been 
successfully applied in different studies. Moreover, accounting for codon bias also resulted in 
immune response generation to previously non-immunogenic native antigen. Consensus also 
needs to be reached regarding the optimum vaccination strategy for DNA vaccines. Several 
studies advocate intramuscular route as method of choice whereas other propose gene gun 
mediated plasmid delivery. Th2 polarisation of the immune response by gene gun mediated 
vaccination could be a potential problem for cancer immunotherapy and this needs to be properly 
addressed in future studies. Moreover, the intramuscular route is generally accompanied by 
administration of cardiotoxin (muscle degenerating drug) in animal studies, to increase 
inflammatory cell influx at vaccination site leading to superior antigen presentation. Whether this 
strategy would be feasible in humans is still not clear. The failure of DNA based vaccines in 
human clinical trials could be attributed, in part, to poor planning based on conflicting results 
obtained in animal studies and improper optimisation of vaccination strategies. 
Understanding of these factors would be all the more important, for use of ‘self-antigens’ as 
targets for immunotherapy, since most studies have used viral or foreign antigens, and the 
response to these antigens may not apply to ubiquitously expressed ‘self-antigens’.  
 
7.8 Viral Vaccine and MTA1 
 
The aforementioned high vaccination efficacy as well as potent immunogenicity of viral vector 
compelled investigation into this method of vaccination. Several vectors, viral and bacterial, 
have been used in the recent years for cancer immunotherapy. These pathogens are naturally 
capable of infecting a majority of cell types, using the cellular machinery for their propagation 
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leading to high levels of viral antigen production by the cells. These properties have made these 
vectors an attractive choice for cancer immunologists. Vectors such as adenovirus, canarypox 
virus, fowlpox virus and herpes simplex virus have been extensively used for this purpose. 
Although most of these vectors have been highly successful in animal models, their application 
in humans raises certain health and safety, and ethical concerns due to their chance of integration 
into human genome as well as opportunist progressive infection in terminally ill immuno-
suppressed patients. This has dictated researchers to come up with novel vectors, which are 
highly safe without losing their potency. 
 
Semliki forest virus is one of the new generation vectors with multiple bio-safety levels for safe 
application in humans. Genes coding for the virus have been split into two separate vectors, one 
coding for antigens and the other coding for the structural proteins needed for viral particles 
assembly. In order to generate infectious viral particles, both plasmids have to be co-transfected 
in the same cell. This makes the possibility of in vivo recombinant viral particle generation 
negligible. Moreover, the virus generated is inactive and requires activation by α-chymotrypsin 
before use. The original SFV particle system was RNA based and required in vitro transcription 
to generate mRNA from plasmids followed by their transfection into virus producing cells 
(Atkins et al., 1996). Bremner and colleagues (1998) modified this delivery vehicle and 
constructed a DNA based system, where plasmids could be directly transfected into packaging 
cells (DiCiommo et al., 1998). This DNA based SFV vector was evaluated for its capability to 
generate antigen specific immune response. In this study, SFV-Bgal showed good potency in 
generating antigen specific CTL response in immunised mice. At similar titres, SFV was slightly 
better than DISC-HSV and Adenovirus in generating CTLs against immuno-dominant TPH 
peptide from b-gal. Moreover, cytotoxic activity also translated into protective and therapeutic 
effect, since mice immunised with SFV-Bgal were protected from lethal tumour challenge of 
tumour cells expressing B-gal protein and vaccination of mice with established tumours delayed 
their growth. These results confirmed the efficacy of SFV as a potential efficient vector for 
cancer immunotherapy as also seen in other tumour models.  
From this perspective, we evaluated whether tolerance to MTA1 could be overcome using a viral 
vector such as SFV, to enable protective immune response against tumour cells over-expressing 
MTA1. Preliminary studies suggested that SFV-hMTA1/mMTA1 mediated vaccination did 
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indeed delay the growth of tumour in these mice compared to control mice. Although, all the 
mice eventually succumbed to their tumours, significant longer survival and delayed growth was 
observed in vaccinated animals. However, further experiments are required to confirm these 
findings as well as increase the protection observed by combining SFV with other strategies such 
as DNA prime- viral boost, Treg depletion, increase in SFV titre and different routes of 
vaccination (i.v.). Higher titres and intravenous vaccination have been more effective in 
generating anti-tumour immune response and will have to be investigated in future studies.  
 
Construction of DNA based SFV expression systems has come at a cost of low titre generation 
and further study will have to be undertaken to generate higher titres. One of the ways this could 
be achieved is by establishing a packaging cell line, which stably expresses the helper plasmid. 
Transfecting of replicon plasmid (antigen coding) into these cells would be sufficient to produce 
viral particles. Another novel strategy would be the use of a recently developed listeria 
monocytogenes (LM) vector. LM are facultative intracellular bacterium adapted to live in the 
cytosol and can be taken up by the APC, thereby directing antigen to both MHC class I and II 
pathways (Singh & Paterson., 2006).  
 
7.9 Is there a future for MTA1 in cancer therapy? 
 
Although, MTA1 has shown limited potential as an immunotherapeutic target in this study, much 
more work needs to be done in order to confirm its applicability. Its expression in late stage 
tumours needs to be further characterised and its exact role needs to be delineated. A recent 
study suggested MTA1 could be required in the initial stages of metastasis (invasion) but is not 
necessary for later stages (Hofer et al., 2006). Thus, if immunogenic, vaccination against MTA1 
could be used prophylactically in early stage cancer patients to prevent cancer spread and in late 
stage patients to eliminate metastasis, in combination with surgery to remove primary tumours. 
Moreover, MTA1 expression determination in primary tumours, metastatic cells or in the lymph 
nodes might also be useful as a diagnostic or prognostic marker for cancer patients. In a recent 
study by Nishikawa et al (2005), immunisation with SEREX defined self antigens were found to 
induce generation of Tregs instead of CTL or CD4+ T cells (Nishikawa et al., 2005). MTA1 
belongs to a similar category of antigens and can be viewed in a similar manner. It can be 
hypothesised that immunisation with such an antigen can be used for immuno-suppression in 
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auto-immune diseases. Moreover, in the above study, a combination of SEREX defined self 
antigen with a CTL epitope enhanced the potency of the immune response to the MHC class I 
epitopes. Thus, IFN-γ produced from the CTL (against MHC class I peptide) was able to reverse 
the generation of Treg into CD4+ T cells against SEREX antigens. It can therefore be envisioned 
that MTA1 may be applicable for immunisation along with other antigens to enhance the 
immune response against it. 
 
Other members of the MTA1 family have not been extensively investigated and although MTA2 
and MTA3 seem to have similar functions, they could also be potential targets. MTA2, MTA3 
and MTA1s have been implicated in progression of breast cancers but their role in other cancers 
hasn’t been investigated till date. Considering the splice variants of MTA1 identified in murine 
studies, more variants of MTA1 or its family members may exist and need to be identified. 
 
7.10 Self-Antigens and Immunotherapy 
 
Self antigens remain the largest group of tumour antigens identified till date and are rightly being 
investigated as immunotherapeutic targets by several groups. Caution needs to be exercised 
whilst targeting such antigens as auto-immunity is a likely side-effect of strong immune response 
against them. The pros and cons will have to be weighed up for cancer therapy and auto-immune 
side effects that occur following immunisation. Scientists now acknowledge the need to develop 
novel vaccination strategies and vectors for targeting this group of antigens, due to their wide 
spread application. Immune responses have been successfully generated against several ‘self-
antigens’ in animal models and in humans, but further refinements will be needed to translate 
them into objective clinical responses in cancer patients. According to this author, along with the 
antigens, an effective tumour vaccine might have to also include cytokines, chemokines, potent 
adjuvant, combined with an effective strategy for prior depletion of immuno-suppressive cells 
such as Tregs, NKT cells and Gr1+ myeloid cells. 
 
Clearly, a long road lies ahead for cancer immunologists but, remarkable progress has been 
achieved in the past few years and with continued technological advances, cancer patients will be 
identified at a much earlier stage (owing, for example to proteomic biomarker profiling), giving 
immunotherapy the best chance to succeed. Advocates of personalised cancer vaccines argue the 
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unique nature of each individual cancer. The availability of cheaper gene and protein array chips 
in the future might allow us to specifically identify antigens over-expressed by individual cancer 
allowing tailored vaccines to be applied in such patients.  
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